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1 Hintergrund 
1.1 Technische Charackteristika 
Die Biomarker Troponin (Tn) und D-Dimer können mittels Testung im Zen-
trallabor (engl. Central laboratory = CL) oder mittels Point of Care Tests 
(POCTs) gemessen werden. POCTs bieten eine schnelle Rückmeldung der 
Testergebnisse und ermöglichen schnellere Entscheidungen über das Patien-
tInnenmanagement. Sowohl die Probenahme als auch die Datenanalyse wird 
am gleichen Standort durchgeführt, wodurch Transport- und Verarbeitungs-
verzögerungen reduziert werden. 
Tn-POCT und D-Dimer POCT können zur Unterstützung der Diagnose von 
PatientInnen mit Symptomen verwendet werden, die auf ein akutes Koronar-
syndrom (ACS) bzw. eine venöse Thromboembolie (VTE) hinweisen. Theore-
tische Vorteile von POCT sind schnellere Bearbeitungszeiten (engl. Turn-
aroundtime = TAT), kürzere Verweildauer und weniger unnötige Kranken-
hausaufenthalte bzw. weitere Tests. Spezifisch für die einzelnen Biomarker-
Schnelltests werden folgende Szenarien diskutiert: 
 Tn-POCT soll insbesondere dort einen besonderen Stellenwert haben, 
wo Troponin-Tests in einem Zentrallabor nicht vor Ort oder nicht 24 
Stunden am Tag verfügbar sind, da der Zeitfaktor für die Diagnose 
des akuten Koronarsyndroms entscheidend ist. 
 D-Dimer POCT soll beispielsweise bei der Hausärztin/dem Hausarzt 
zum Einsatz kommen, um vorwiegend unnötige Krankenhauseinwei-
sungen/weitere Testungen zu reduzieren. 
Die untersuchten POC-Diagnostika können sowohl in der Notfallmedizin 
(z. B. Notfallambulanz im Krankenhaus) als auch in ambulanter Versorgung 
(z. B. durch AllgemeinmedizinerInnen und FachärztInnen) eingesetzt wer-
den. Tn-POCT kann zudem in anderen präklinischen notfallmedizinischen 
Settings wie z. B. im Krankenwagen verwendet werden. 
Für Tn-POCT wurden 15 Geräte für diesen EUnetHTA-Bericht identifiziert. 
Davon messen 14 Geräte Troponin quantitativ und ein weiteres Gerät quali-
tativ. Für D-Dimer POCT wurden elf Geräte identifiziert, von denen acht 
D-Dimer quantitativ messen. In Anbetracht der Eigenschaften der identifi-
zierten Geräte ist zu konstatieren, dass diese zwischen den Geräten sowohl 
in Bezug auf analytische Charakteristika (z. B. Unterschiede in Probengröße) 
als auch auf weitere technologische Merkmale (z. B. ob sie mit einem ande-
ren Gerät verbunden werden können, auf dem die Diagnosedaten gespeichert 
werden können) heterogen sind. 
Für D-Dimer Tests unterscheiden sich die von der Food and Drug Admi-
nistration (FDA) zugelassenen handelsüblichen Geräte in Bezug auf Refe-
renzwerte und klinische Cut-offs stark. Ähnlich dazu sind Troponin-Test-
verfahren – unabhängig davon, ob sie in einem CL oder am „Point of Care“ 
getestet werden – weder standardisiert noch harmonisiert. Das heißt: Assays 
verwenden oft leicht unterschiedliche Ansätze, wie Troponin im Blut erfasst 
wird. 
Für diesen Bericht dient die übliche Versorgung („usual care“) als Kompara-
tor. Je nach Setting kann dieser einen Versorgungspfad mit oder ohne Mög-
lichkeit einer prompten Zentrallabortestung darstellen. 
Biomarker Tests: 
Tn & D-Dimer  
 
POCT ermöglicht 
schnelle Diagnostik 
Tn-POCT:  
akutes Koronarsyndrom 
 
D-Dimer POCT:  
venöse Thromboembolie 
Settings:  
Notfallmedizin  
(z. B. Notfallambulanz, 
Krankentransport) 
Ambulante Versorgung 
(z. B. niedergelassener 
Bereich) 
 
 
26 POCT Produkte 
identifiziert: 
15 Tn-POCTs 
11 D-Dimer POCTs 
Heterogenität  
der technischen 
Charakteristika 
Komparator:  
übliche Versorgung 
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1.2 Gesundheitsproblem und 
aktuelle Nutzung 
1.2.1 Tn-POCT: Akutes Koronarsyndrom 
Das akute Koronarsyndrom (engl. acute coronary syndrome = ACS) ist ein Ge-
sundheitszustand, welcher mit verschiedenen Symptomen (v. a. Brustschmerz) 
einhergeht und im Wesentlichen von einem verminderten Blutfluss in den 
Koronararterien (Myokardischämie) verursacht wird. Der Begriff ACS wird 
für PatientInnen verwendet, bei denen ein myokardialer Infarkt/eine myokar-
diale Ischämie vermutet oder bestätigt ist. Es gibt verschiedene Arten von 
ACS wie z. B. Nicht-ST-Hebung Myokardinfarkt (NSTEMI), ST-Hebung My-
okardinfarkt (STEMI) oder instabile Angina pectoris.  
Risikofaktoren, die die Wahrscheinlichkeit einer ACS-Entwicklung erhöhen 
könnten, sind hohes Lebensalter, männliches Geschlecht, eine positive Fa-
milienanamnese der koronaren Herzkrankheit, das Vorliegen einer periphe-
ren arteriellen Verschlusskrankheit, Diabetes mellitus, Hyperlipidämie, Hy-
pertonie, Niereninsuffizienz, frühere Myokardinfarkte (MI) und vorherige 
Revaskularisierung. 
Ischämische Herzerkrankungen gehören nach wie vor zu den häufigsten To-
desursachen weltweit. In Europa sterben jährlich etwa 1.800.000 Menschen 
an ischämischen Herzerkrankungen. Das sind 20 Prozent aller Todesfälle, 
wenngleich Unterschiede zwischen den Ländern zu verzeichnen sind. 
Es ist wichtig, die Ursache der Brustschmerzen schnell zu erkennen, um um-
gehend mit einer geeigneten Therapie beginnen zu können, da sich bei einer 
frühzeitigen Intervention bessere Ergebnisse erzielen lassen: Das vorrangige 
Ziel einer frühen Evaluierung/Erstbewertung ist es, die Diagnose von ACS 
zu bestätigen („rule-in“) oder ACS als Ursache der Symptome auszuschließen 
(„rule-out“).  
Die Zielpopulation für die Anwendung von Tn-POCT sind erwachsene Pa-
tientInnen mit Anzeichen und Symptomen von ACS. Bei allen PatientInnen 
mit Verdacht auf kardiale Ischämie sollten im Rahmen der Erstuntersuchung 
kardiale Biomarker getestet werden. Herzspezifisches Troponin ist der am 
weitesten verbreitete diagnostische Biomarker für den Myokardinfarkt (MI). 
Die Standardversorgung von PatientInnen, die mit ACS behandelt werden, 
einschließlich solcher mit wiederkehrenden Symptomen, ischämischen EKG-
Veränderungen oder positiven kardialen Troponinen, ist die Aufnahme ins 
Krankenhaus. Der Schwerpunkt in den ersten 12 Stunden liegt auf der so-
fortigen Linderung der Ischämie und der Prävention des Myokardinfarkts 
und schließlich des Todes. Die PatientInnen werden einer kontinuierlichen 
EKG-Rhythmusüberwachung und Beobachtung bei rezidivierender Ischämie 
unterzogen. PatientInnen mit Verdacht auf ACS in der Ambulanz werden im 
präklinischen Umfeld beurteilt und vor Aufnahme ins Krankenhaus behan-
delt, was unter anderem die Verabreichung einer dualen Thrombozytenthe-
rapie beinhaltet. 
 
akutes Koronarsyndrom 
Myokardinfarkt/ 
Ischämie 
ischämische 
Erkrankungen häufige 
Todesursache 
Brustschmerzen:  
rasche Diagnostik 
notwendig 
Standardversorgung  
bei ACS:  
 
sofortige Linderung der 
Ischämie/Prävention 
eines Myokardinfarkts 
Hintergrund 
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1.2.2 D-Dimer POCT: Venöse Thromboembolien 
Venöse Thromboembolien (VTE) sind Erkrankungen, bei denen sich in einer 
Vene ein Blutgerinnsel (Thrombus) bildet, das sich dann ausdehnt und im 
Blut wandert (ein sog. Embolus). Ein Venenthrombus tritt am häufigsten in 
den tiefen Venen der Beine oder des Beckens auf; dies wird dann als tiefe Ve-
nenthrombose (TVT) bezeichnet. Der Blutfluss durch die betroffene Vene 
kann durch das Gerinnsel begrenzt werden, und es kann zu Schwellungen 
und Schmerzen im Bein führen. Wenn es sich löst und in die Lungenarterien 
gelangt, dann spricht man von einer Lungenembolie (LE), die in einigen Fäl-
len tödlich verlaufen kann. 
Klinische Anzeichen und Symptome von VTE sind unspezifisch und oft asymp-
tomatisch. Folgende Symptome können jedoch auf eine TVT hinweisen: Bein-
schmerzen und/oder Schwellungen, Rötungen und Wärme im Bein. Häufige 
Symptome der LE sind, unter anderem, Dyspnoe, Brustschmerzen, Präsyn-
kope oder Synkope, Fieber, Husten oder einseitige Beinschmerzen. VTE kann 
in der akuten Phase tödlich sein oder zu chronischen Krankheiten und Be-
hinderungen führen, was die langfristige Lebensqualität und Funktionsfähig-
keit der PatientInnen beeinträchtigt.  
VTE ist die dritthäufigste Herz-Kreislauf-Erkrankung. Die jährliche Gesamt-
inzidenz beträgt 100-200 pro 100.000 Einwohner in Europa. PatientInnen, die 
älter als 40 Jahre sind, sind einem erhöhten Risiko ausgesetzt, und das Risi-
ko verdoppelt sich mit jedem Folge-Jahrzehnt.  
Der Diagnosealgorithmus für DVT und LE beginnt mit der ersten Bewer-
tung der Prätestwahrscheinlichkeit. Die Messung des D-Dimers ist der zwei-
te Schritt; dies wird in der Regel mit einem klinischen Vorhersagewert kom-
biniert. Bei positivem D-Dimer Test folgen weitere Untersuchungen, wie z. B. 
Ultraschall zur Diagnose einer TVT, Beatmungs-Perfusions-Scan und Com-
putertomographie-Lungenangiographie zur Diagnose von PE. 
Die Zielpopulation für die Verwendung von D-Dimer POCT sind erwach-
sene PatientInnen mit geringem bis mittlerem Risiko der TVT oder PE. Die 
Standard-Diagnostik für die TVT umfasst die Bildgebung: Vor dem Hinter-
grund der Kosten für bildgebende Verfahren und zunehmender Anzahl ne-
gativer Tests ist eine genaue Überlegung des diagnostischen Pfads wesent-
lich: Bei einigen PatientInnen besteht beispielsweise keine Notwendigkeit 
einer diagnostischen Bildgebung, um die Krankheit auszuschließen. Die di-
agnostische Aufarbeitung stützt sich dann auf die Wahrscheinlichkeitsbewer-
tung vor dem Test, ergänzt durch die Ergebnisse des D-Dimer Tests. 
Die gängige Standardbehandlung von VTE ist die Antikoagulation. Diese Me-
dikamente „verdünnen“ das Blut und verhindern eine weitere Gerinnung. 
  
venöse Thromboembolie 
umfasst Lungenembolie 
und tiefe 
Venenthrombose 
häufig unspezifische 
Anzeichen 
dritthäufigste  
Herz-Kreislauf-
Erkrankung 
Diagnosealgorithmus:  
Einschätzung Prätest-
wahrscheinlichkeit,  
D-Dimer Test,  
etwaige weitere 
Untersuchungen 
Behandlung: 
Antikoagulation 
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2 Forschungsfragen 
Im Zuge dieses Projekts wurden vier Forschungsfragen gewählt: 
 Was empfehlen evidenzbasierte Leitlinien, wie D-Dimer POCT und 
Tn-POCT eingesetzt werden sollen (Stellenwert in diagnostischem 
Pfad, Schwellenwerte in unterschiedlichen PatientInnenpopulationen: 
Notfallmedizin, niedergelassener Bereich)? 
 Welchen klinischen Nutzen im Management von symptomatischen 
PatientInnen (Erwachsene) hat der D-Dimer POCT? 
 Welchen klinischen Nutzen im Management von symptomatischen 
PatientInnen (Erwachsene) hat der Tn-POCT? 
 Kann ein etwaiger theoretischer Nutzen von POCT (D-Dimer und Tn) 
im österreichischen Kontext realisiert werden? 
 
 
 
3 Methodisches Vorgehen 
3.1 Leitliniensynopse 
Für die Leitliniensynopse wurde zunächst eine systematische Literatursuche 
nach relevanten evidenzbasierten Leitlinien in Leitliniendatenbanken („Guide-
line International Network (GIN), Trip Database) durchgeführt. Ergänzend 
dazu wurden ausgewählte Websites internationaler Institutionen (z. B. Nati-
onal Institute for Health and Care Excellence) zur Identifikation relevanter 
Leitlinien manuell durchsucht. 
Die Leitlinienauswahl erfolgte durch zwei unabhängige WissenschafterInnen. 
Die Qualität der eingeschlossenen Leiltinien wurde mittels AGREE-II (Ap-
praisal of Guidelines for Research & Evaluation) durch eine Person bewertet 
und durch eine andere Person kontrolliert. 
Hinsichtlich der relevanten, zu extrahierenden, Daten der Leitlinien wurden 
Empfehlungen zur Anwendung der POCTs nach Stellenwert in diagnosti-
schem Pfad, Schwellenwert und Aussagekraft der Testergebnisse in unter-
schiedlichen PatientInnenpopulationen (Notfallmedizin, Allgemeinmedizin) 
gewählt. Relevante Daten wurden von einer Person extrahiert und von einer 
zweiten verifiziert.  
 
  
Forschungsfragen: 
 
Leitlinienempfehlungen 
 
Evidenz zum  
klinischen Nutzen von  
 
Tn-POCT 
D-Dimer POCT 
Leitliniensynopse: 
Systematische Suche, 
manuelle Suche 
Leitlinienauswahl, 
Qualitätsbewertung  
Fokus auf 
Empfehlungen, wie/ob 
der Einsatz von POCTs 
empfohlen/diskutiert 
wird 
Ergebnisse 
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3.2 Overview of Reviews 
Es wurden zwei systematische Übersichtsarbeiten von systematischen Über-
sichtsarbeiten (Overview of Reviews) zum patientInnenrelevanten Nutzen von 
POC-Diagnostika D-Dimer und Troponin erstellt. Dabei wurden zwei syste-
matische Literatursuchen in folgenden Datenbanken durchgeführt:  
 Cochrane (CENTRAL) 
 Centre for Research and Dissemination (CRD) 
 Embase 
 Ovid MEDLINE 
Zusätzlich wurde jeweils eine Update-Suche der Evidenz für beide Biomar-
ker POCTs auf Basis der bereits vorhandenen Suchstrategien, die von den 
identifizierten systematischen Übersichtsarbeiten zum Einsatz kamen, durch-
geführt. 
Zwei unabhängige WissenschafterInnen führten die Studienselektion und die 
Qualitätsbewertung der Studien durch. Zur Qualitätsbeurteilung der Studi-
en kamen entsprechende Instrumente für systematische Übersichtsarbeiten 
(AMSTAR-2) und für nicht randomisierte Kontrollstudien (ROBINS-I) zum 
Einsatz. Die Datenextraktion wurde von einer Person durchgeführt und von 
einer zweiten Person verifiziert.  
 
 
3.3 ExpertInneninvolvierung 
Zur Beantwortung der Frage hinsichtlich des österreichischen Kontexts wur-
den VetreterInnen der Notfallmedizin, der Allgemeinmedizin und der Fach-
medizin (Kardiologie, etc.) gesucht und hinsichtlich der beiden Diagnostika 
befragt. Die Gespräche wurden protokolliert, gegenübergestellt und narrativ 
beschrieben.  
 
 
 
4 Ergebnisse 
Verfügbare Produkte 
Es wurden im Zuge der manuellen Suche nach relevanten Produkten 26 POC-
Diagnostika identifiziert. Davon messen 15 Geräte Troponin und elf Produk-
te D-Dimer. Die meisten Produkte messen die Biomarker quantitativ (Tn: 
14/15; D-Dimer: 8/11). Es zeigte sich zudem, dass Heterogenität hinsicht-
lich der analytischen Performanz und technologischen Charakteristika be-
steht. Es herrscht Unsicherheit darüber, welche Diagnostika in Österreich 
zum Einsatz kommen. 
 
 
systematische Suchen  
in 4 Datenbanken 
Update Suche nach 
Primärstudien 
Studienselektion & 
Qualitätsbewertung  
ExpertInnen-Befragung 
für österr. Kontext 
26 verfügbare Produkte: 
Heterogenität 
(quantitativ, qualitativ) 
und Ungewissheit, 
welche in Ö zum  
Einsatz kommen 
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4.1 Tn-POCT 
Verfügbare Evidenz 
Für die Bewertung des klinischen Nutzens der Implementierung von Tn-
POCT wurden zwei systematische Übersichtsarbeiten mit moderat bis hoher 
Qualität eingeschlossen; wovon eine ein HTA-Bericht der Canadian Agency 
for Drugs and Technologies in Health (CADTH) mit ähnlicher Fragestellung 
war. Es konnten keine weiteren Primärstudien im Zuge der Update-Suche 
identifiziert werden. 
Die beiden systematischen Übersichtsarbeiten enthielten 42 Primärstudien. 
Der CADTH-Bericht identifizierte 41 Primärstudien. Von diesen untersuch-
ten neun Studien die diagnostische Genauigkeit von Tn-POCT und 30 Stu-
dien den klinischen Nutzen. Weitere zwei Studien wurden vom CADTH-Be-
richt eingeschlossen, die sowohl die diagnostische Testgenauigkeit als auch 
den klinischen Nutzen untersuchten. Die andere eingeschlossene systemati-
sche Übersichtsarbeit identifizierte zwei Studien im Setting der Primärver-
sorgung, wovon eine dieser Studien auch im CADTH-Bericht eingeschlossen 
wurde. Die Gesamtzahl der PatientInnen wurde im CADTH-Bericht nicht 
berichtet und in der anderen systematischen Übersichtsarbeit betrug diese 
545 PatientInnen. 
Darüber hinaus erfüllten acht Leitlinien unsere Einschlusskriterien und wur-
den im Zuge der Leitliniensynopse eingeschlossen. In Bezug auf die Quali-
tät (AGREE-II) waren jeweils drei Leitlinien nachdrücklich zu empfehlen, 
bzw. unter Vorbehalt zu empfehlen. Die beiden verbleibenden Leitlinien sind 
nicht zu empfehlen bzw. als unsicher anzusehen. 
 
Overview of Reviews 
Die Ergebnisse in Bezug auf die diagnostische Testgenauigkeit zeigen, dass 
erhebliche Inkonsistenzen hinsichtlich Aussagen zur diagnostischen Genau-
igkeit bestehen. Diese sind vor allem in den elf, vom CADTH-Bericht einge-
schlossenen, Studien ersichtlich. Des Weiteren gab es bedeutende Einschrän-
kungen bei der Studienqualität der Primärstudien (z. B. ausschließlich nicht-
vergleichende Studien in der anderen systematischen Übersichtsarbeit). Die 
im CADTH-Bericht gefundene Evidenz zeigt, dass Tn-POCT im Vergleich 
zu CL-Tests tendenziell eine geringere Sensitivität, einen niedrigeren nega-
tiven prädiktiven Wert (npW), eine höhere Spezifität und einen höheren po-
sitiven prädiktiven Wert (ppW) aufweist. 
Die beiden inkludierten systematischen Übersichtsarbeiten umfassten 32 Stu-
dien, die den klinischen Nutzen von Tn-POCT untersuchten. Davon waren 
sieben Studien randomisierte Kontrollstudien (RCTs). Im Allgemeinen ist 
die identifizierte Evidenz unzureichend, um eine Nicht-Unterlegenheit der 
Implementierung von Tn-POCT gegenüber CL-Tests nachweisen zu können, 
wenn CL-Tests vor Ort oder rechtzeitig verfügbar sind (z. B. in der Notfall-
ambulanz). Die Evidenz ist ebenfalls unzureichend, um eine deutliche Über-
legenheit gegenüber der Standardversorgung in Settings ohne oder mit ver-
zögerter CL-Testung (z. B. bestimmte ambulante Einrichtungen, präklinische 
Notfallmedizin) zu zeigen. 
 
2 SRs 
moderat bis hohe 
Qualität 
42 Primärstudien 
davon 7 RCTs 
8 Leitlinien: 
3 LL nachdrücklich  
zu empfehlen,  
3 LL unter Vorbehalt  
zu empfehlen,  
2 LL nicht zu 
empfehlen/unsicher 
Overview of Reviews: 
1 CADTH-Bericht, 
11 Studien zu DTA 
(POCT vs CL): 
Niedrigere SEN/npW 
Höhere SPEZ/ppW 
 
1 weiterer SR: 
2 Studien zu DTA (nicht 
komparative Daten) 
Klinischer Nutzen: 
32 Primärstudien 
Ergebnisse 
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Notfallambulanz (Krankenhaus)  
Die im CADTH-Bericht gefundene Evidenz weist darauf hin, dass die Imple-
mentierung von Tn-POCT in der Notfallambulanz die TAT (Reduzierung in 
2 RCTs), die Entlassungszeit (Reduzierung in 2 RCTs & 1 Beobachtungsstu-
die) und die Verweildauer (Reduzierung in 3 RCTs und 2 Beobachtungsstu-
dien, Erhöhung in 1 RCT) reduzieren kann. Darüber hinaus hat die Verwen-
dung von Tn-POCT die Mortalität (2 RCTs, 3 Beobachtungsstudien) oder 
unerwünschte Ereignisse (2 RCTs, 2 Beobachtungsstudien) im Vergleich zu 
CL-Tests bis zu einem Jahr nicht statistisch verändert. Die Lebensqualität 
unterschied sich auch nicht statistisch signifikant bis zu einem Follow-up von 
drei Monaten (1 RCT). Allerdings ist die Evidenz unzureichend, um die Nicht-
Unterlegenheit von Tn-POCT im Vergleich zum CL-Test nachzuweisen – vor 
allem vor dem Hintergrund der schlechteren Sensitivität und des niedrigeren 
negativen prädiktiven Werts, wie vorstehend dargestellt. 
 
Ambulante Versorgung  
(insb. AllgemeinmedizinerInnen und FachärztInnen) 
Es wurde unzureichende Evidenz für die Überlegenheit der Verwendung ei-
nes Pfades mit Tn-POCT im Vergleich zur Standardversorgung (ohne Tn-
POCT) auf der Grundlage der gewählten Endpunkte zum klinischen Nutzen 
gefunden: Die Evidenz aus einer Kohortenstudie, die durch beide der ent-
haltenen systematischen Übersichtsarbeiten identifiziert wurde, deutet da-
rauf hin, dass die Einführung von Tn-POCT die Überweisungsraten reduzie-
ren kann. Es wurden keine Nachweise dafür gefunden, dass die Umsetzung 
von Tn-POCT eine positive oder schädliche Auswirkung auf die Mortalität/ 
Morbidität oder die gesundheitsbezogene Lebensqualität hat. 
 
Präklinische Notfallmedizin (insb. Krankenwagen) 
Derzeit gibt es keine ausreichende Evidenz dafür, dass die Verwendung eines 
Pfades mit Tn-POCT im Vergleich zur Standardversorgung (ohne Tn-POCT) 
etwa im Krankenwagen basierend auf ausgewählten klinischen Endpunkten 
überlegen ist: Der CADTH-Bericht fand jedoch Evidenz (1 RCT), die keinen 
Unterschied in der Krankenhausaufnahme aufweist, und einer nicht statis-
tisch-signifikanten Verkürzung der Zeit vom ersten medizinischen Kontakt 
bis zur Entlassung aus der Notfallambulanz oder der Aufnahme ins Kranken-
haus. Der CADTH-Bericht identifizierte zudem eine Beobachtungsstudie, 
die eine durchschnittliche TAT von 83 Minuten (Range: 46-187) berichtete. 
Hinsichtlich der Mortalität fand der CADTH-Report Evidenz (1 RCT), die 
keinen Unterschied bei der 30-Tages Mortalität zeigte. Die Berichterstattung 
der Ergebnisse ist jedoch stark begrenzt: Es fehlten wichtige weitere Informa-
tionen (z. B. genaue Überlebensraten oder p-Werte). Es wurden keine Hin-
weise auf die möglichen Auswirkungen der Einführung von Tn-POCT auf die 
Lebensqualität gefunden. 
 
Schaden/Nachteile 
Im Hinblick auf die Sicherheit von Tn-POCT hat keine der identifizierten 
Überprüfungen Nebenwirkungen/Nachteile als solche hervorgehoben. Daten 
zur diagnostischen Genauigkeit können jedoch indirekt darauf hinweisen, ob 
Schäden durch falsch positive/falsch negative Befunde zu erwarten sind.  
Notfallambulanz: 
unzureichende Evidenz 
für Nicht-Unterlegenheit  
(POCT vs. CL) 
ambulante Versorgung: 
unzureichende Evidenz 
für Überlegenheit 
(POCT vs. klinische 
Einschätzung + ggf. CL 
zu späterem Zeitpunkt) 
unzureichende Evidenz 
für Überlegenheit 
(POCT vs. klinische 
Einschätzung + ggf. CL 
zu späterem Zeitpunkt)  
Sicherheit: 
keine/unzureichend 
direkte Evidenz,  
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Nur eine einzige Studie, die in beiden systematischen Übersichtsarbeiten iden-
tifiziert wurde, berichtete direkt über den Schaden von entlassenen Patien-
tInnen mit einem ACS: Die Evidenz bestand aus einer Kohortenstudie (Set-
ting: ambulante Versorgung), die einen Rückgang der Überweisungen berich-
tete, der jedoch das Risiko erhöhen kann, PatientInnen mit einem akuten My-
okardinfarkt oder einer instabilen Angina pectoris zu entlassen. Zwei von 178 
PatientInnen in der Tn-POCT-Gruppe erhielten keine Überweisung, obwohl 
sie diese benötigt hätten (Überweisungsrate: 25 % und 43 % der PatientInnen, 
die von Ärzten betreut werden, die Tn-POCT verwenden und nicht verwen-
den). Der p-Wert war jedoch nicht verfügbar. 
 
Leitliniensynopse 
Acht Leitlinien erfüllten die Einschlusskriterien und wurden für die Leitlini-
ensynopse eingeschlossen. Sechs Leitlinien umfassten verschiedene Settings 
(z. B. Notfallambulanz, prähospitale Notfallmedizin, Primärversorgung, etc.), 
eine Leitlinie fokussierte auf Katastrophenmedizin und eine weitere Leitli-
nie definierte keine Settings. 
Keine der enthaltenen Leitlinien gibt eine Empfehlung bezüglich des opti-
malen Zeitpunkts der Tests sowie der diagnostischen Schwellenwerte und Pfa-
de ab, mit der Begründung, dass sich die POCTs kontinuierlich und schnell 
verbessern und ihre Leistungsmerkmale sowohl vom Test als auch vom Kran-
kenhaus abhängig sind. Eine Leitlinie besagt ausdrücklich, dass aufgrund 
fehlender oder schwacher Evidenz keine Empfehlungen zugunsten/gegen die 
Verwendung von Tn-POCT abgegeben werden können. Fünf weitere Leitli-
nien erwähnen nur, dass POCT für die Messung von kardialen Troponinen 
verwendet werden kann. Eine Leitlinie empfiehlt, den qualitativen Troponin-
Test nicht routinemäßig in der hausärztlichen Praxis einzusetzen, um einen 
akuten Myokardinfarkt auszuschließen, und eine weitere Leitlinie empfiehlt 
nur die Verwendung von sensitiver oder hoch-sensitiver Tests.  
Drei Leitlinien betonen, dass die TAT für die Prüfung von Herzmarkern ma-
ximal eine Stunde betragen sollte. Zwei Leitlinien kommen zu dem Schluss, 
dass eine Implementierung dann sinnvoll ist, wenn eine TAT von einer Stun-
de nicht eingehalten werden kann. 
Des Weiteren wurde eine Leitlinienempfehlung hinsichtlich der technischen 
Charakteristika der Tests abgegeben: Die Leitlinie empfiehlt, dass Troponin-
tests nicht nur qualitative, sondern auch quantitative Informationen liefern 
sollten. 
Die Sensitivität ist Bestandteil der Diskussion in den identifizierten Leitli-
nien: 2 Leitlinien sagen aus, dass die Sensitivität von Tn-POCT unter der 
von CL-Tests liegt und daher nicht als sensitiv oder hoch sensitiv angesehen 
werden kann. Eine andere Leitlinie besagt dagegen, dass Tn-POCT (lizen-
siert in UK) in seiner Sensitivität den 12-stündigen laborbasierten Standard-
Tn-Assays entspricht. Nach Angaben einer weiteren Leitlinie können Tn-
POCT-Werte erste diagnostische Informationen liefern, aber der Vorteil ei-
ner kürzeren TAT steht einer geringeren Sensitivität, einer geringeren diag-
nostischen Genauigkeit und einem niedrigeren negativen prädiktiven Wert 
gegenüber. Darüber hinaus begünstigt die strenge quantitative Assay-Stan-
dardisierung, die für die Routinediagnose erforderlich ist, die CL-Tests.  
Eine wesentliche Einschränkung der identifizierten Leitlinien besteht darin, 
dass in den letzten drei Jahren (vor 2016) keine Leitlinien veröffentlicht wur-
den, wodurch ein Mangel rezenter Leitlinien besteht. 
1 Kohortenstudie: 
Verweis, dass Rückgang 
der Überweisung  
durch POCT negative 
Konsequenzen haben 
könnte  
(2/178 pts mit UA/MI 
wurden entlassen)  
8 Leitlinien 
 
unterschiedliche 
Settings 
keine spezifischen 
Empfehlungen zu 
optimaler Zeitpunkt/ 
Schwellenwerte etc. 
konsistente Empfehlung 
für Tn-POCT bei  
TAT < 1 Std von 2 LL 
Empfehlung für 
quantitative Messung 
von 1 LL 
Senitivität von Tn-POCT 
kontroversiell: 
2 LL: geringer als CL, 
1 LL: in UK lizenzierte 
Tn-POCTs vergleichbar 
mit CL (12 stündig) 
Einschränkung: 
Publikationsdatum aller 
LL vor 2016, Aktualität? 
Ergebnisse 
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ExpertInnenbefragung 
Im Hinblick auf die österreichische Situation waren die von uns konsultier-
ten ExpertInnen der Ansicht, dass es ein theoretisches Potenzial von Tn-
POCT in Situationen gibt, in denen ein CL-Test nicht verfügbar wäre oder 
zu lange dauern würde, bis die Ergebnisse vorliegen. Es besteht jedoch Zwei-
fel, ob solche Szenarien in Österreich tatsächlich existieren. 
 
 
4.2 D-Dimer POCT 
Verfügbare Evidenz 
Insgesamt wurden sechs systematische Übersichtsarbeiten mit moderat bis 
hoher Qualität in diesem Bericht eingeschlossen. Im Zuge der Update-Suche 
wurden zusätzlich zwei Primärstudien eingeschlossen, welche auf die TVT 
fokussierten und in den systematischen Übersichtsarbeiten unzureichend be-
rücksichtigt wurden. 
Die systematischen Übersichtsarbeiten erzielten eine moderat bis hohe Qua-
lität nach AMSTAR-2. Das Verzerrungspotenzial der eingeschlossenen nicht 
randomisierten kontrollierten Studien (NRCTs) war moderat bis schwerwie-
gend nach Robins-I. 
In den sechs systematischen Übersichtsarbeiten wurden zwischen vier und 
52 Studien eingeschlossen (199-55.268 PatientInnen). 
Darüber hinaus erfüllten zehn Leitlinien die Einschlusskriterien. Hinsicht-
lich der Qualität (AGREE-II) ist zu konstatieren, dass fünf Leitlinien nach-
drücklich, und die verbleibenden fünf Leitlinien nur unter Vorbehalt zu emp-
fehlen sind.  
 
Overview of Reviews 
Im Zuge dieser Übersichtsarbeit wurde relevante Evidenz in der ambulanten 
Versorgung (3 systematische Übersichtsarbeiten), der Notfallambulanz im 
Krankenhaus (2 systematische Übersichtsarbeiten) gefunden. Eine weitere 
identifizierte systematische Übersichtsarbeit berichtete nicht von den jewei-
ligen Settings der gefundenen Evidenz. Die zwei identifizierten Primärstu-
dien fokussierten auf den Einsatz von D-Dimer POCT in der Primärversor-
gung. 
Insgesamt mangelt es an zuverlässigen und qualitativ hochwertigen Nach-
weisen für die Nicht-Unterlegenheit gegenüber CL-Tests und für die Über-
legenheit gegenüber der üblichen Versorgung (ohne sofortige CL-Tests) in 
der Notfallversorgung oder ambulanten Versorgung (insb. Allgemeinmedizi-
nerInnen und FachärztInnen). 
 
Input von ExpertInnen: 
theoretischer Vorteil in 
Settings ohne CL-Tests, 
Zweifel, ob es diese  
in Ö gibt 
6 SRs:  
moderat bis  
hohe Qualität 
2 NRCTs:  
moderat-
schwerwiegendes 
Verzerrungspotenzial 
4-52 eingeschlossene 
Studien (199-55.268 pts) 
10 Leitlinien: 
5 LL nachdrücklich  
zu empfehlen &  
5 LL empfehlenswert 
unter Vorbehalt 
Settings:  
ambulante Versorgung 
(3 SRs + 2 Primärstudien) 
Krankenhaus-Setting:  
2 SRs 
NR in 1 SR 
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Ambulante Versorgung  
(insb. AllgemeinmedizinerInnen und FachärztInnen) 
Im Setting der ambulanten Versorgung deutet die Evidenz darauf hin, dass 
die Kombination von D-Dimer POCT (insbesondere der quantitativen Tes-
tungen) mit einer klinischen Entscheidungsregel (z. B. durch die Hausärz-
tin/den Hausarzt) bei Verwendung bei oligosymptomatischen PatientInnen 
mit geringer Wahrscheinlichkeit für VTE zu einer genaueren Diagnose von 
VTE führt als ohne POCT. Der negative prädiktive Wert des kombinierten 
D-Dimer POCT und der klinischen Entscheidungsregel ist hoch (>95 %), 
was bedeutet, dass unnötige Bildgebung in einem Krankenhaus vermieden 
werden könnte. Der effiziente Einsatz eines D-Dimer POCT in Kombination 
mit einer klinischen Entscheidungsregel erfordert jedoch Training, Experti-
se und Praxis.  
Es wurde jedoch keine Evidenz gefunden, die die Auswirkungen der Einfüh-
rung von D-Dimer-POCT auf Mortalität/Morbidität, Lebensqualität oder Pa-
tientInnenmanagement in der ambulanten Versorgung direkt untersucht.  
Zwei identifizierte Primärstudien, die die Evidenz aus systematischen Über-
sichtsarbeiten aktualisierten, berichteten von Daten in Bezug auf Turnaround-
Zeit (1 Studie: <5 min-34 min) und Überweisungsraten (1 Studie: kein s. s. 
Unterschied zwischen Intervention und üblicher Versorgung). Aufgrund des 
erhöhten Verzerrungspotenzials der Studien konnte der Evidenzkörper je-
doch nicht maßgeblich verändert werden. 
 
Notfallambulanz (Krankenhaus)  
Hinsichtlich der möglichen Auswirkungen der Implementierung von D-Dimer 
POCT in der Notfallambulanz berichtete eine identifizierte systematische 
Übersichtsarbeit von Evidenz zur Auswirkung der Implementierung von D-
Dimer POCT auf das PatientInnenmanagement. Die Qualität des Berichts 
war jedoch moderat. Basierend auf Beobachtungsstudien konnte festgestellt 
werden, dass die Implementierung von D-Dimer POCT womöglich mit einer 
Reduzierung der TAT, der Anzahl der Krankenhauseinweisungen und der 
Aufenthaltsdauer einhergehen könnte. Eine weitere systematische Übersichts-
arbeit identifizierte Evidenz in der Notaufnahme berichtete aber ausschließ-
lich über nicht-vergleichende Daten in Bezug auf „failure rates“ und Effizi-
enz. Keine der in diesen Settings identifizierten Übersichtsarbeiten berich-
tete über die diagnostische Testgenauigkeit für D-Dimer POCT.  
Allgemein war daher die Evidenz unzureichend, um einen positiven Einfluss 
auf das PatientInnenmanagement nachweisen zu können. Es wurde zudem 
keine Evidenz gefunden, die eine mögliche Auswirkung der Implementierung 
auf die patientInnenrelevanten Endpunkte Mortalität/Morbidität sowie Le-
bensqualität überprüft.  
 
Schaden/Nachteile 
Im Hinblick auf die Sicherheit hat keine der identifizierten systematischen 
Übersichtsarbeiten Nebeneffekte/Nachteile als solche hervorgehoben. Die in 
diesem Bericht dargestellten Daten zur diagnostischen Genauigkeit können 
jedoch indirekt darauf hinweisen, ob Schäden durch falsch positive/falsch 
negative Befunde zu erwarten sind. 
ambulante Versorgung: 
POCT + klinische 
Entscheidungsregel 
führt zu genauerer 
Diagnose bei 
Verwendung von 
oligosymptomatischen 
Pts  
keine direkte Evidenz 
aus SRs 
2 NRCTs 
TAT: <5 min-34 min 
Überweisungsraten: 
keine s. s. Unterschiede 
zwischen IG und CG 
Notfallmedizin: 
unzureichende Evidenz 
in Notfallambulanz: 
1 SR  
 
Reduktion TAT & 
Krankenhauseinweisung
en, Aufenthaltsdauer  
 
Evidenzbasis: 
Beobachtungsstudien 
Sicherheit:  
nicht direkt gemessen 
Eruieren der Vor- und 
Nachteile auf Basis 
indirekter Evidenz 
(DTA) 
Ergebnisse 
LBI-HTA | 2019 15 
Die Evidenz bestätigt, dass D-Dimer POCT einen hohen negativen prädik-
tiven Wert hat, sehr sensitiv, aber nicht sehr spezifisch ist. Die Sensitivität 
des D-Dimer POCTs wird verbessert, wenn er mit einem klinischen Wahr-
scheinlichkeitswert vor dem Test kombiniert wird. Die systematischen Über-
sichtsarbeiten und Leitlinien stimmen überein, dass D-Dimer POCT ohne 
diesen nicht verwendet werden sollte. Die Spezifität von D-Dimer nimmt mit 
zunehmendem Alter stetig ab, so dass bei älteren Menschen altersgerechte 
Cut-offs erforderlich sind. 
 
Leitliniensynopse 
Die Empfehlungen der zehn eingeschlossenen Leitlinien sind hinsichtlich 
der Verwendung von D-Dimer Tests konsistent: Acht von zehn Leitlinien 
kommen zu dem Schluss, dass D-Dimer POCT verwendet werden kann, um 
eine vermutete Lungenembolie oder eine tiefe Venenthrombose auszuschlie-
ßen. Nur eine Leitlinie gibt aufgrund fehlender oder schwacher Evidenz gar 
keine Empfehlung ab und eine Leitlinie empfiehlt indirekt, dass kein Ultra-
schall erforderlich ist, wenn der D-Dimer Wert mit POCT gemessen werden 
kann.  
Die empfohlenen Settings für die Verwendung von D-Dimer POCT sind da-
gegen in den Leitlinien weniger konsistent erwähnt: Drei Leitlinien haben 
relevante Settings nicht definiert, drei Leitlinien definierten Allgemeinme-
dizin/Primärversorgung als mögliches Setting und eine weitere Leitlinie be-
schreibt, dass D-Dimer POCT in vielen Settings zur Anwendung kommen 
kann (Primär-, Sekundär-, Tertiärversorgung). Zwei weitere Leitlinien be-
schreiben, dass der Test in der Notfallambulanz und in weiteren ambulan-
ten Settings zum Einsatz kommen kann. Eine weitere Leitlinie beschreibt so-
wohl ambulante als auch stationären Settings als mögliche Einsatzgebiete.  
Zwei Leitlinienempfehlungen sind in Bezug auf die empfohlene Sensitivität 
des D-Dimer Tests inkonsistent. Eine Leitlinie besagt, dass der einfache qua-
litative D-Dimer POCT in Kombination mit der klinischen Wahrscheinlich-
keit im Vergleich zum quantitativen ELISA-Test bei PatientInnen mit ge-
ringem Risiko in seinem Wert vergleichbar sein kann, während eine andere 
Leitlinie sich gegen die Verwendung von qualitativer oder semi-quantitativer 
Tests in der Primärversorgung ausspricht. 
 
ExpertInnenbefragung 
Im Hinblick auf die österreichische Situation gab es keinen klaren Konsens 
zum potentiellen Nutzen von D-Dimer POCT. Es ist festzuhalten, dass ent-
sprechende Ausbildung und Fachwissen notwendig ist, um die Ergebnisse 
von POC-Diagnostika neben den Ergebnissen der Vortestwahrscheinlichkeit 
korrekt interpretieren zu können. Darüber hinaus ist die Kenntnis klinischer 
Entscheidungsregeln Voraussetzung für die Anwendung des Tests. Während 
zwei der ExpertInnen deshalb eher kritisch zum D-Dimer POCT im nieder-
gelassenen Bereich in Österreich stehen, war eine Expertin der Ansicht, dass 
D-Dimer POCT eine unentbehrliche Rolle spielt und HausärztInnen die ent-
sprechende Expertise mitbringen, um D-Dimer POCT richtig anwenden zu 
können.  
 
 
 
D-Dimer POCT sehr 
sensitiv, aber nicht  
sehr spezifisch 
 
zum Ausschluss von  
VTE geeignet 
10 Leitlinien  
 
konsistente 
Leitlinienempfehlungen: 
8/10 Leitlinien:  
D-Dimer POCT als 
Ausschlussdiagnostik  
inkonsistente 
Empfehlungen 
hinsichtlich relevanter 
Settings 
inkonsistente 
Empfehlungen 
hinsichtlich  
des Einsatzes 
qualitativer Tests 
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5 Diskussion 
Ziel dieses Berichts war es, den klinischen Nutzen und die Sicherheit von 
Tn-POCT und D-Dimer POCT in der ambulanten Versorgung und der Not-
fallmedizin bei symptomatischen PatientInnen zu bewerten. Sowohl für Tn-
POCT als auch für D-Dimer POCT gibt es keine ausreichenden Beweise, 
um eine Nicht-Unterlegenheit gegenüber CL-Tests und eine Überlegenheit 
gegenüber der aktuellen Situation (ohne sofortige CL-Tests) in der Notfall-
versorgung oder ambulanten Versorgung (insb. AllgemeinmedizinerInnen und 
FachärztInnen) nachzuweisen. 
Obwohl der Schwerpunkt dieses HTA-Berichts auf dem klinischen Nutzen 
liegt, wurde auch Evidenz für die diagnostische Genauigkeit, die in den ein-
geschlossenen systematischen Übersichtsarbeiten identifiziert wurde, berich-
tet. Diese Evidenz ist möglicherweise nicht aktuell, da neuere Tests nicht in-
kludiert waren. Verbesserungen im Bereich der diagnostischen Genauigkeit 
zeigen jedoch nur indirekt, ob der Einsatz der POCTs auch zu patientIn-
nenrelevanten Vorteilen – wie dem Vermeiden unnötiger Interventionen und 
Krankenhausaufenthalte – führt.  
Des Weiteren wurden in den – diesem Bericht zugrundeliegenden – Über-
sichtsarbeiten sehr viele, oft heterogene, Produkte als Intervention definiert: 
Es wurden im Zuge der manuellen Suche nach relevanten Produkten 26 POC-
Diagnostika identifiziert. Davon messen 15 Geräte Troponin und elf Produk-
te D-Dimer. Die meisten Produkte messen die Biomarker quantitativ (Tn: 
14/15; D-Dimer: 8/11). Diese Heterogenität der Produkte – gepaart mit ei-
ner Unwissenheit darüber, welche dieser Tests nun in Österreich eigentlich 
zum Einsatz kommen – stellt eine wesentliche Limitation für die Validität 
der Aussage dieser Evaluierung dar. 
Die Suche nach laufenden Studien ergab, dass es derzeit fünf laufende Stu-
dien zur Evaluierung der Verwendung von Tn-POCT in der Notfallambu-
lanz gibt. Zwei davon sind RCTs und weitere drei identifizierte Studien sind 
NRCTs. Ergebnisse zum PatientInnenmanagement (z. B. LOS, TTD) werden 
in drei Studien gemessen, und zwei weitere Studien bewerten ausschließlich 
die diagnostische Performanz dieser Diagnostika. Für D-Dimer POCT wur-
den keine laufenden NRCTs oder RCTs identifiziert. 
Darüber hinaus ist zu erwähnen, dass alle Vorteile, die sich aus der Imple-
mentierung von Tn-POCT und D-Dimer POCT ergeben, stark vom Setting 
und dem Gesundheitssystem abhängig sind. Aus diesem Grund könnten Eva-
luierungsstudien im Bereich der Versorgungsforschung, im Vergleich zu tra-
ditionellen randomisierten Kontrollstudien, besser geeignet sein, um den kli-
nischen Nutzen in bestimmten Settings vollständig zu eruieren. 
 
  
Evidenz unzureichend, 
um Nicht-
Unterlegenheit im 
Vergleich zu CL-Tests 
und Überlegenheit  
im Vergleich zur 
Standardversorgung 
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Limitationen: 
Evidenz zu DTA stammt 
aus systematischen 
Übersichtsarbeiten 
(mit ev. älteren POCTs) 
Heterogenität der 
Produkte 
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laufende Studien: 
5 Studien zu Tn-POCT 
 
keine Studien zu  
D-Dimer POCT 
Übertragbarkeit der 
Ergebnisse, 
settingabhängigkeit,  
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6 Schlussfolgerungen 
Weitere konkrete Anwendungsforschung zu spezifischen Tests (quantitativ 
mit prä-definierten weiteren technologischen Charakteristika) ist jedenfalls 
notwendig: Die Versorgungsforschung kann hier gezielt eingesetzt werden, 
um den klinischen Nutzen in unterschiedlichen österreichischen Settings zu 
überprüfen.  
 
konkrete  
Versorgungsforschung 
spezifischer Tests in 
spezifischen Settings 
erforderlich 
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1 SUMMARY OF RELATIVE EFFECTIVENESS  
OF TN-POCT AND D-DIMER POCT 
Scope 
This rapid assessment addresses the research question whether using the Point of Care Tests 
(POCT) for D-dimer and troponin (Tn) in symptomatic patients presenting at ambulatory (primary 
or community care) settings or emergency care settings is more effective and/or safer than current 
diagnostic practice. Subsequently, the following research questions can be formulated:  
• How do evidence-based guidelines recommend the use of Tn-POCT (position in the diag-
nostic path, threshold values in different patient populations, settings)? (guideline synopsis) 
• How do evidence-based guidelines recommend the use of D-dimer-POCT (position in the di-
agnostic path, threshold values in different patient populations, settings)? (guideline synopsis) 
• What are the clinical benefits of Tn-POCT in the management of symptomatic patients 
(adults)? (overview of reviews) 
• What are the clinical benefits of D-dimer POCT in the management of symptomatic patients 
(adults)? (overview of reviews) 
• Can a theoretical benefit of POCT (D-dimer and Tn) be realized in the Austrian and  
Romanian context? (expert consultation) 
 
Introduction 
Description of technology and comparators 
The biomarkers Tn and D-dimer can be measured using a central laboratory (CL, either in the 
hospital or non-hospital centred medical laboratories) or by using point of care tests. Point of care 
tests (POCTs), also known as near patient or bedside testing, are diagnostic tests that are per-
formed near patients rather than in central laboratories [1]. POCTs provide rapid feedback of test 
results, potentially enabling faster decisions about patient management. Both sampling and data 
analysis are performed at the same site, reducing transport and processing delays [2, 3]. [B0001] 
For Tn-POCT, 15 devices were identified for this assessment. Of these, 14 devices measure tro-
ponin quantitatively and one further device measures it qualitatively. For D-dimer POCT, eleven 
devices were identified, eight of which measure D-dimer quantitatively. When reviewing the char-
acteristics of the identified devices, it is notable that these are heterogeneous between devices 
when it comes to both analytic performance (e.g., differences in analytical range and sample size) 
and further technological characteristics (e.g., as to whether it can be connected to another device 
on which the diagnostic data can be stored). [A0020] 
Tn-POCT and D-dimer POCT can be used to aid the diagnosis of patients with symptoms sugges-
tive of suspected acute coronary syndrome and venous thromboembolism respectively. Theorec-
tical advantages of POCT include faster turnaround time, reduced length of stay and reduced un-
necessary hospitalisation/further testing. Tn-POCT is especially sought to be beneficial in this con-
text; in settings where CL testing is not onsite or not available 24 hours per/every day, because 
time is critical in the diagnosis of acute coronary syndrome. Furthermore it may, especially in the 
context of implementing D-dimer POCT, reduce hospital admissions [4]. [B0002] 
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Both of the technologies under evaluation are used by healthcare professionals. Tn-POCT and D-
dimer POCT may be used in emergency care settings such as EDs as well as in primary care set-
tings [5-7]. Tn-POCT may further be used in other pre-hospital emergency medicine settings such 
as in ambulance vehicles [5]. [B0004] 
For D-dimer assays, the commercially available devices approved by the Food and Drug Admin-
istration vary greatly when it comes to reference values and clinical cut-offs [7]. Similarly, Tn as-
says are – regardless of whether tested in a CL or at the point of care – neither standardised nor 
are they harmonised. That is to say; every assay uses a distinct set of antibodies for capturing 
and detecting Tn in the blood [8]. [B0018] 
Test kits and/or analysers and adequate know-how are required to use the POCT devices. How-
ever, the required equipment and supplies strongly depend on the type of POCT being implement-
ed. If fixed devices (benchtop-instruments) are implemented, one has to further think of where the 
analysers are to be positioned because these tests technically cannot be moved but have a spe-
cific location, e.g., in doctor’s office or ambulance [9]. [B0008] [B0009] 
 
Health problem and current use 
Tn-POCT: Acute coronary syndrome 
The target population for the use of Tn-POCT is adult patients presenting with signs and symp-
toms of acute coronary syndrome. Acute coronary syndrome is a health condition encompassing 
means and spectrum of signs and symptoms caused by a decreased blood flow in the coronary 
arteries (myocardial ischemia). The term acute coronary syndrome is used for patients that present 
with suspected or confirmed acute myocardial ischemia or infarction. There are different types of 
acute coronary syndrome such as non-ST elevation myocardial infarction, ST-elevation myocardi-
al infarction or unstable angina [10, 11]. [A0002] 
Ischemic heart disease is one of the leading causes of mortality globally. In Europe, approximate-
ly 1,800,000 persons die due to ischemic heart disease yearly. This is 20 per cent of all deaths in 
Europe, although the variation among countries is substantial [12, 13]. [A0005] [A0006] 
The treatment of myocardial ischemia is time-critical as the condition can lead to death. It is, there-
fore, crucial to rapidly identify the cause of the chest discomfort, which is the main symptom of 
suspected acute coronary syndrome, to be able to start appropriate therapy promptly. The primary 
goal of early evaluation, within 15 minutes after presentation, is to confirm the diagnosis of acute 
coronary syndrome (“rule-in”) or exclude acute coronary syndrome as the cause of the symptoms 
(“rule-out”) [11]. This involves the following steps [14]: initial physical examination and obtaining 
the medical history of the patient, resting 12 lead electrocardiography, and finally cardiac troponin 
measurement. [A0004] [A0024] 
The target population for the use of Tn-POCT is adult patients presenting with signs and symp-
toms of acute coronary syndrome. Tn-POCT can spare the referral of patients to an inpatient unit 
in cases where there are no ischemic electrocardiography changes, if there is clinical ambiguity, 
and if symptoms last for more than 12 hours [15]. All patients who present to the emergency de-
partment with symptoms suggestive of cardiac ischaemia should be evaluated with cardiac bio-
markers as part of the initial evaluation. Cardiac specific troponin is the most widely utilized diag-
nostic biomarker for myocardial infarction and is the preferred laboratory test [16]. [A0007] [A0023] 
[A0011] 
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The standard of care for patients who present with acute coronary syndrome, including those with 
recurrent symptoms, ischemic electrocardiography changes, or positive cardiac troponins, is ad-
mission to hospital. The primary focus in the first 12 hours is the immediate relief of ischemia and 
the prevention of myocardial infarction and eventually death. [A0025] 
 
D-dimer: Vyenous Thromboembolism 
Venous thromboembolism is a condition in which a blood clot (a thrombus) forms in a vein and 
then dislocates to travel in the blood (an embolus). A venous thrombus most commonly occurs in 
the deep veins of the legs or pelvis; this is then called a deep vein thrombosis. The clot can limit 
blood flow through the affected vein, and it can cause swelling and pain in the leg. If it dislodges 
and travels to the lungs, to the pulmonary arteries, it is called a pulmonary embolism, which in 
some cases may be fatal. [A0002] 
Clinical signs and symptoms of venous thromboembolism are non-specific and often asymptomatic. 
If deep vein thrombosis is symptomatic, the most common symptoms are leg pain and/or swelling, 
redness and warmth in the leg. If pulmonary embolism is symptomatic, symptoms include, but are 
not limited to, dyspnoea, chest pain, pre-syncope or syncope, fever, cough, unilateral leg pain [17, 
18]. Venous thromboembolism may be fatal in the acute phase or lead to chronic disease and dis-
ability, which affects the patients’ long-term quality of life and functional capacity. [A0004] [A0005]  
Venous thromboembolism is the third most frequent cardiovascular disease. The overall annual 
incidence is 100-200 per 100.000 inhabitants in Europe [17]. Venous thromboembolism is likely to 
be an escalating public health problem due to the prominence of age as a risk factor and the in-
creasing age of the population [19]. Patients older than 40 years are at increased risk and risk 
doubles with each decade. Hence an increasing number of patients are expected to be diagnosed 
and treated to avoid fatal pulmonary embolism [17]. [A0006] 
The diagnostic algorithm for both deep vein thrombosis and pulmonary embolism starts with the 
initial assessment of the pre-test probability. Measurement of d-dimer is the second step; this is 
usually combined with a clinical prediction score. If the d-dimer test is positive further testing fol-
lows, such as ultrasound for the diagnosis of deep vein thrombosis, ventilation-perfusion scan and 
computed tomography pulmonary angiography for the diagnosis of pulmonary embolism [18] [17]. 
[A0024] 
The target population for the use of D-dimer POCT is adult patients at low to moderate risk for pre-
senting with deep vein thrombosis or pulmonary embolism [18]. The standard diagnostic workup 
for deep vein thrombosis includes imaging: the costs of imaging modalities and the increasing 
number of negative tests lead to a reconsideration of the diagnostic strategies. In some patients, 
there is no need for diagnostic imaging to exclude the disease, the diagnostic workup relies then 
only on the pre-test probability assessment, complemented by the D-dimer test results [18]. [A0007] 
[A0023] [A0011] 
The current standard practice for the treatment of venous thromboembolism is anticoagulation. 
These drugs “thin” the blood and prevent further clotting. There is a wide variation in practice, but 
patients are usually given a brief course of heparin treatment initially while they start on a 3–6-
months course of warfarin. [A0025] 
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Methods 
The EUnetHTA Core Model® was used as a reporting standard. Assessment elements from the 
Rapid Relative Effectiveness Assessments Version 4.2 were utilised. Where applicable, further as-
sessment elements from the HTA Core Model® Application for Diagnostic Technologies version 3.0. 
were used. 
Search 
To identify potentially relevant systematic reviews and meta-analyses, systematic searches in four 
databases were performed (The Cochrane Library, Centre for Reviews and Dissemination, Embase 
via Elsevier, Medline via Ovid). To identify primary studies updating or extending the evidence de-
rived from available systematic reviews, two further searches were conducted in four databases 
(Medline via Ovid, Embase via Elsevier, The Cochrane Library, Cumulative Index to Nursing and 
Allied Health Literature). To identify relevant clinical practice guidelines, systematic searches were 
carried out in the following databases: Trip database and the Guidelines International Network (G-
I-N) database. Also, manual searches were carried out on the websites of the HTA institutes and 
professional organisations. 
Study selection 
Searching and study selection occurred separately for each POCT. Two independent researchers 
for each POCT undertook study selection in accordance with the PRISMA statement [20, 21]. For 
both POCTs, we identified the most recent and high quality systematic review from all those identi-
fied which we updated either for publication year (Tn) or by widening the subject of the review (D-
dimer). 
Selected outcomes 
We focused on assessing the effectiveness/clinical utility of these POCT devices. Consequently, 
we chose mortality/morbidity, quality of life and patient management as outcomes of interest. The 
latter was split into nine further outcomes: number of hospital admission, treatment initiation, refer-
ral rates, door-to-needle time, turnaround time, time to discharge, length of stay, further diagnostic 
testing, and time to clinical decision. Safety outcomes included side effects/disbenefits. 
Data extraction and analyses 
One researcher from LBI-HTA extracted the data and another researcher from NSPHMPDB checked 
the extracted data. The evidence was qualitatively synthesised. 
Quality rating 
The quality of the eligible studies was assessed using the following tools: For systematic reviews, 
the AMSTAR-2 checklist [22] was utilised, whilst for non-randomised controlled trials (NRCTs) the 
quality was assessed using the Robins-I tool [23]. To assess the quality of the included guidelines, 
the Appraisal of Guidelines, Research and Evaluation (AGREE II) reporting checklist [24] was used. 
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Results  
For Tn-POCT, we identified 15 devices for this rapid relative effectiveness assessment, 14 of which 
measure troponin quantitatively. For D-dimer POCT, eleven devices were identified, eight of which 
measure D-dimer quantitatively. It was not possible to identify which type of POCT product is ac-
tually used in the Austrian or Romanian health care system. 
 
Tn-POCT 
Available evidence 
For the evaluation of the effectiveness of implementing Tn-POCT, two systematic reviews were 
included [25, 26] of which one was a report [25] from the Canadian Agency for Drugs and Tech-
nologies in Health (CADTH). These two systematic reviews included a total of 42 primary studies. 
An update search was conducted on one of the reviews [25], but no further eligible primary stud-
ies were identified. The included systematic reviews reached a moderate [26] to high [25] certain-
ty according to AMSTAR-2.  
In addition, eight clinical practice guidelines met our inclusion criteria and were included in the 
guideline synopsis [11, 14-16, 27-30]. Concerning quality (AGREE-II), three guidelines are recom-
mendable [11, 14, 28], and recommendable with modification [15, 29, 30] respectively. The remain-
ing two guidelines [16, 27] are not fully recommendable. 
 
Clinical Effectiveness and safety 
Results relating to diagnostic test accuracy shows that there are significant inconsistencies in esti-
mates measured across setting as evident in the comparison of DTA estimates of the eleven stud-
ies included in the CADTH report [25] and significant limitations with study quality (e.g., solely non 
comparative studies in the other review [26]). Evidence found by the CADTH report [25] relating to 
11 studies on diagnostic test accuracy shows, that compared with CL testing, Tn-POCT tended to 
have a lower sensitivity, lower negative predictive value, higher specificity and higher positive pre-
dictive value. 
The included systematic reviews [25, 26] included 32 studies investigating the clinical utility of Tn-
POCT, of which seven were randomised controlled trials. Broadly, the identified evidence was in-
sufficient to show non-inferiority in comparison to CL testing when implementing Tn-POCT if CL 
testing is onsite or timely available (e.g., in emergency departments). The evidence is also insuffi-
cient to clearly show superiority when compared to usual care in settings without or delayed CL 
testing (e.g., certain ambulatory settings, pre-hospital emergency medicine). 
In the emergency department, evidence from the CADTH report [25] showed limited evidence 
that implementing Tn-POCT in the emergency department may reduce turnaround time (reduction 
in 2 RCTs), time to discharge (reduction in 2 RCTs & 1 observational study), and length of stay 
(reduction in 3 RCTs and 2 observational studies, increase in 1 RCT). However, the use of Tn-
POCT did not statistically change mortality (2 RCTs, 3 observational studies) or adverse events (2 
RCTs, 2 observational studies) compared with CL testing up to one year follow-up. Quality of life 
was also not statistically significantly different up to three months of follow-up (1 RCT). Thus the 
evidence is insufficient to clearly show non-inferiority of Tn-POCT in comparison to CL testing 
also in light of the poorer sensitivity and lower negative predictive value as shown above [25].  
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In ambulatory (primary and community) care, insufficient evidence was found indicating supe-
riority of using a pathway with Tn-POCT compared to usual care (without Tn-POCT) based on the 
selected clinical utility outcomes: evidence based on one cohort study that was identified by both 
of the included systematic reviews [25, 26] suggests that implementing Tn-POCT may reduce the 
referral rates but potentially with an increased risk of missing out on acute myocardial infarction or 
unstable angina. No evidence was found to conclude that implementing Tn-POCT has a beneficial 
or harmful effect on mortality/morbidity or health-related quality of life. 
In pre-hospital emergency medicine, there is also insufficient evidence indicating superiority of 
using a pathway with Tn-POCT compared to usual care (without Tn-POCT) in the ambulance based 
on the selected clinical utility outcomes: The CADTH report [25] found evidence consisting of one 
RCT showing no difference in hospital admissions and a non-statistical reduction of time from first 
medical contact to discharge from emergency department or admission to hospital. The same re-
view found evidence consisting of one non-comparative observational study showing a median turn-
around time of 83 minutes (range: 46-187). Concerning the outcome mortality, the CADTH report 
[25] found evidence consisting of one RCT showing no difference in death in the next 30 days, but 
no further information was reported (e.g., exact survival rates or p-values). No evidence was found 
with regard to the potential effect of implementing Tn-POCT on quality of life. 
Concerning safety, none of the identified reviews highlighted side effects/disbenefits as such. How-
ever, data on diagnostic accuracy can indirectly indicate as to whether harms of false-positives 
and false negatives can be expected. Only one study identified in both systematic reviews [25, 26] 
directly reported on the harm of discharged patients with an acute coronary syndrome: The evi-
dence consisted of one cohort study in the primary care setting that reported a decrease in refer-
rals that, however, may increase the risk of missing out patients with an acute MI or UA. Two out 
of 178 patients in the Tn-POCT group needed but did not receive a referral (referral rate: 25% and 
43% of patients managed by physicians using and not using Tn-POCT respectively). However, 
the p-value was not reported/available. 
 
Guideline synopsis 
Eight clinical practice guidelines met our inclusion criteria and were included in the guideline syn-
opsis [11, 14-16, 27-30]. Six guidelines [11, 14-16, 28, 30] were developed for the outpatient set-
ting (emergency department, pre-hospital, primary care, ambulance), one guideline was developed 
for disaster medicine [29], one guideline did not specifically define the setting but states the guide-
line is applicable for all cardiac caregivers [27].  
None of the included guidelines makes a recommendation regarding the optimal timing of testing, 
and the diagnostic thresholds and pathways with the reasoning that POCTs continuously and rap-
idly improve and their performance characteristics are both assay and hospital dependent. One 
guideline [15] specifically states that no recommendations can be made due to lack of or weak 
evidence. Five guidelines only mention that POCT can be used for the measurement of cardiac 
troponins [11, 19, 27, 29, 30]. One guideline [15] recommends not to use qualitative troponin test 
routinely in primary care to exclude an acute myocardial infarction and one guideline recommends 
the use of sensitive or high-sensitivity assays only [14]. Three guidelines stress that the cardiac 
marker testing turnaround time (TAT) should be a maximum of one hour [14, 27, 30]. Two guide-
lines come to the (consistent) conclusion that if institutions cannot comply with this requirement, 
POCT should be implemented [27, 30]. One guideline [30] suggest that troponin tests should pro-
vide not only qualitative but also quantitative information. According to two guidelines, the sensi-
tivity of Tn-POCT is considered to be below that of CL assays and they cannot be considered sen-
sitive or high-sensitivity [11, 14]. On the other hand, one guideline states that Tn-POCT licensed 
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in the United Kingdom are equivalent in sensitivity to the 12 hour laboratory-based standard Tn 
assays [28]. Also, one guideline [14] states that Tn-POCT values may provide initial diagnostic 
information, but the advantage of shorter turnaround time is counterbalanced by lower sensitivity, 
lower diagnostic accuracy and lower negative predictive value. Furthermore, the rigorous quanti-
tative assay standardisation that is needed for routine diagnosis favours CL testing [11]. A major 
limitation of the guideline synopsis is that recent guidelines, published in the last three years, could 
not be identified. 
 
Expert consultation 
In terms of the Austrian situation, the experts we consulted believed that there is a theoretical 
potential value of Tn-POCT in settings where a CL would not be available or would take too long 
to supply results. However, there is a doubt as to whether such scenarios actually exist in Austria. 
In the Romanian context, the potential value of Tn-POCT was considered positive by all consulted 
experts. Rural areas with no access to CL testing were highlighted as particularly relevant set-
tings, as it was thought that use of these tests would change referral practices and release the 
burden on very crowded highly specialised hospitals. If this occurs, the experts expect that it 
would allow for better spending of funds and better health outcomes. 
 
Upcoming evidence 
The search for ongoing studies revealed that there are currently five ongoing studies evaluating 
the use of Tn-POCT in the emergency department. Two of these are RCTs, and further three iden-
tified studies are NRCTs. Patient management outcomes (e.g., LOS, TTD) are measured in three 
studies and a further two studies solely evaluate the clinical performance of these diagnostics. 
 
D-dimer POCT 
Overall, six systematic reviews [26, 31-35] were identified. The reviews identified between four 
and 52 primary studies and the total number of patients from individual studies included in the 
reviews ranged from 199 [32] to 55,268 [34]. Two primary studies [36, 37] were additionally in-
cluded that specifically considered deep vein thrombosis, that had not been adequately ad-
dressed in the reviews. 
The included systematic reviews reached a moderate [26, 32, 35] to high [31, 33, 34] quality ac-
cording to the AMSTAR-2 assessment. In terms of risk of bias of the primary studies (assessed 
with the ROBINS-I tool), one study [37] was considered to have a moderate risk of bias for the 
patient management outcomes while the risk of bias of the other study [36] was rated as severe.  
Ten guidelines [15, 17-19, 29, 38-42] met our inclusion criteria and included some form of recom-
mendation or mentioning of D-dimer POCT. With regard to quality (AGREE-II), five guidelines were 
fully recommendable [18, 38, 39, 42, 43] and the remaining guidelines were recommendable with 
modifications [15, 19, 29, 40, 41].  
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Clinical effectiveness & Safety 
Evidence was identified in ambulatory (primary and community) care and emergency care. Three 
systematic reviews [26, 31, 33] reported on evidence in ambulatory care (primary and community 
care), whilst two reviews [34, 35] restricted their review to the emergency department or hospital 
emergency care settings. One further review [32] did not specify the setting and only mentioned 
the outpatient setting (without further description). Two primary studies [36, 37] were further iden-
tified that focused on primary care. 
In ambulatory care settings (primary and community care), the evidence identified suggests 
that, when used among patients with a low probability of venous thromboembolism, the combina-
tion of D-dimer POCT (especially the quantitative type) with a sensitive clinical decision rule (e.g. 
when general practitioners use a D-dimer POCT in combination with the more sensitive Wells clini-
cal decision rule) leads to a more accurate diagnosis of venous thromboembolism than without 
POCT. The negative predictive value of the combined D-dimer POCT and clinical decision rule 
can be quite high (>95%) which means some patients may avoid referrals to imaging within a hos-
pital setting. However, efficient use of a D-dimer POCT combined with a clinical decision rule re-
quires training, expertise and practice. No direct comparative evidence was found elaborating the 
effect of implementing D-dimer POCT on mortality/morbidity, quality of life, or patient management 
in ambulatory care settings. Two primary studies [36, 37] updating the evidence from systematic 
reviews reported on data with regard to turnaround time (1 study: <5min-34 min) and referral rates 
(1 study: no statistically significant. difference between intervention and usual care) but did not 
change the available body of evidence identified within the overview of reviews. 
Concerning the potential effect of implementing D-dimer POCT in emergency care, one system-
atic review [35] reported evidence on the effect of implementing D-dimer POCT on patient man-
agement, although this was a purely narrative review with only moderate quality at most, consid-
ering the emergency department setting. Based on observational studies, this review found a re-
duction of turnaround time, number of hospital admissions and length of stay. Another review [34] 
included evidence in the emergency department, but reported solely on non-comparative data in 
relation to failure rates and efficiency. None of the reviews identified in the emergency department 
setting reported on diagnostic test accuracy for D-dimer POCT. However, the evidence is insuffi-
cient to show a beneficial effect on patient management, and no evidence was found to evaluate 
the effect on mortality/morbidity and quality of life in the emergency department.  
As a consequence, there is a lack of reliable, good quality evidence to show non-inferiority com-
pared to CL testing and superiority compared to the current situation (with no immediate CL test-
ing) in emergency care or ambulatory (primary and community care) settings. 
With regard to safety, none of the identified reviews highlighted side effects/disbenefits as such. 
However, data on diagnostic accuracy can indirectly indicate as to whether harms of false-posi-
tives and false negatives can be expected. 
Broadly, the reviews [26, 31-35] confirm that D-dimer testing is very sensitive with a high negative 
predictive value, but it is not very specific. The sensitivity of the D-dimer test is improved when it is 
combined with a pre-test clinical probability score and reviews concur that D-dimer POCT should 
not be used without this. The specificity of D-dimer decreases steadily with age so age-adjusted 
cut-offs are needed among the elderly. 
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Guideline synopsis 
Ten guidelines [15, 18, 19, 29, 38-43] met our inclusion criteria and included some form of rec-
ommendation or mentioning of D-dimer POCT.  
The guideline recommendations are consistent in terms of the use of D-dimer tests more broadly. 
Eight out of ten guidelines conclude that POCT can be used to exclude suspected pulmonary 
embolism or deep vein thrombosis [18, 19, 29, 38, 39, 41-43]. Only one guideline [40] does not 
make a recommendation due to lack of or weak evidence and one guideline makes an indirect re-
commendation saying that there is no need for an ultrasound if D-dimer level can be measured 
with POCT [29]. The recommended settings are somewhat inconsistent in the included guidelines: 
three guidelines did not define the setting [29, 39, 42], three guidelines are applicable only in the 
community or primary care setting [15, 19, 43], one guideline is applicable in numerous settings 
(primary, secondary, tertiary care) [18], two guidelines only in the emergency department [40] or 
in emergency department and outpatient settings [41], and one guideline both in the ambulatory 
and inpatient setting [38]. Two guidelines are inconsistent in terms of the recommended sensitivity 
of the D-dimer test. One guideline [38] states that the simple qualitative D-dimer POCT in combi-
nation with clinical probability may be comparable in its value when compared to the quantitative 
ELISA test in low-risk patients, while another guideline [15] recommends not to use qualitative or 
semi-quantitative tests in primary care. 
 
Expert consultation 
In terms of the Austrian situation, some experts believed that D-dimer POCT could only have a 
limited role outside the hospital setting at present, because of the shortage in the training and ex-
pertise required to correctly interpret the results alongside the pre-test probability. In addition, a 
prerequisite for the use of the test is familiarity with and routine use of clinical decision rules, which 
may not be the case in ambulatory care settings in Austria, unlike other healthcare systems with a 
strong primary care sector. However, one of the consulted experts believes that Austrian family 
doctors do have (must have) the needed expertise to use D-dimer POCT. This expert mentions 
that the goal is hereby to avoid unnecessary hospitalisations, and the test would be able to do that 
to a certain extent. The time element is not considered to be as crucial for D-dimer as there is less 
danger in the patient waiting to attend hospital and have further tests there. 
In the Romanian context, the potential value of these D-dimer POCT was considered positive by 
all consulted experts. Rural areas with no access to CL testing were highlighted as particularly 
relevant settings, as it was thought that use of these tests would change referral practices and 
release the burden on very crowded highly specialised hospitals. If this occurs, the experts expect 
that it would allow for better spending of funds and better health outcomes. 
 
Upcoming evidence 
For D-dimer POCT, no ongoing NRCTs or RCTs were identified. 
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Discussion 
The aim of this report was to evaluate the clinical utility/effectiveness and safety of Tn-POCT and 
D-dimer POCT in symptomatic patients presenting to ambulatory (primary or community care) or 
emergency care with symptoms that could be related to acute coronary syndrome and suspected 
deep vein thrombosis or pulmonary embolism respectively. For both Tn-POCT and D-dimer POCT, 
there is insufficient evidence to show non-inferiority compared to CL testing and superiority com-
pared to the current situation (with no immediate CL testing) in emergency care or ambulatory 
(primary and community care) settings. 
Although the focus of this health technology assessment is on clinical utility, we did include the 
evidence related to diagnostic accuracy as reported in the identified systematic reviews. This evi-
dence may not be up-to-date. However, improvements in diagnostic test accuracy only indirectly 
show whether implementation would result in patient-relevant benefits. The aim of this review is 
evaluating clinical utility as a final endpoint, as recommended in diverse methodological guidelines 
[44]. 
Furthermore, this assessment included a variety of – often somewhat heterogeneous – products: 
26 POCT diagnostics were identified through manually searching for relevant POCT devices. Of 
these, 15 devices measure troponin and eleven D-dimer products. Most products measure the bio-
markers quantitatively (Tn: 14/15; D-dimer: 8/11). Further differences in technological characteris-
tics are present. This heterogeneity of the products is further paired with not knowing about which 
tests are actually used in Austria and Romania – an essential limitation for a meaningful evalua-
tion. 
In addition, it should also be mentioned that any benefits found from implementing Tn-POCT and 
D-dimer POCT are strongly dependent on the setting and health care system. For this reason, 
evaluation studies in the field of health service research might be better suited to fully determine 
the clinical benefit in specific settings than traditional randomised controlled trials.  
 
Conclusion 
Should such tests be considered for implementation or their use extended, prior further research 
on specific point of care tests (quantitative, with certain pre-defined analytical characteristics) in 
specific settings in Austria and Romania would be needed. Here a health services research ap-
proach might be more appropriate than traditional evidence-based medicine to assess potential 
benefits in different settings from a systems approach. 
 
POCT/point of care tests: D-dimer and troponin 
Version 1.4, 26.11.2019 EUnetHTA Joint Action 3 WP4 20 
Table 1: Summary table of the results on the use of Tn-POCT 
Effectiveness and diagnostic accuracy of Tn-POCT: Summary of the evidence 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ 
Conclusion 
CADTH, 
2016 
[25] 
SR 41/NR Diverse 
(incl. ED 
and 
primary 
care 
settings) 
High DTA results (at admission: range of POCT vs. range of CL): 
SEN: 26%-88% vs. 68%-100%  
SPEC: 84. %-98. % vs. 75%-94% 
PPV: 31. %-85. % vs. 10%-82% 
NPV: 90%-99% vs. 95%-100% 
Clinical utility: 
“In Settings Where a Central Laboratory is Available  
[Tn-POCT] tended to shorten  
turnaround time (TAT),  
length of hospital stay, and  
time to discharge.  
The use of [Tn-POCT] did not statistically change  
mortality rates or severe adverse events compared with a central laboratory in most 
studies, in up to one year of follow-up.  
There was no difference in quality of life among patients who were tested using POC or central 
laboratory within up to three months’ follow-up. Subgroup analyses of clinical-utility studies 
based on study design, setting, the level of sensitivity of the central laboratory methods, the 
types of cTn (I or T), and funding status did not show any differences in findings. (…). 
In Settings Where No Central Laboratory is Available  
In pre-hospital or ambulance settings, limited evidence points to the potential use  
of [Tn-POCT] for the diagnosis and management of patients. [Tn-POCT] may  
reduce the percentage of patients referred to the emergency department from  
a primary health care centre.  
[Tn-POCT] testing was shown to be feasible and reliable for patients transported by 
ambulance, and can shorten the time from first medical contact to patient disposition (…).” 
“Overall, given  
the limitations with 
the data and the 
inconsistency in 
DTA estimates,  
the usefulness of 
[Tn-POCT1] in 
settings with  
access to central 
laboratories may  
be limited.”  
“In settings with no 
access to a central 
laboratory, such as 
in rural health care 
centres or remote 
settings, [Tn-POCT] 
may be useful due 
to the potential to 
help reduce 
unnecessary 
transfer of patients 
to larger centres.” 
                                                     
1 Note: The synonymous term “POC cTn testing” was used instead of the term Tn-POCT in the report. 
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Effectiveness and diagnostic accuracy of Tn-POCT: Summary of the evidence 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ 
Conclusion 
Schols, 
2018 
[26]  
SR 2/545 Primary 
Care 
Moderate DTA results (range of 2 studies, results of MI/MI+unstable angina): 
SEN: 67%-83%/21%-29% 
SPEC: 98-100%/98-100% 
PPV: 40%-100%/40%-100% 
NPV: 99%-99.7%/94%-96% 
Clinical utility: 
Limited evidence (1 comparative cohort study) was found that Tn-POCT would reduce the 
referral rate, but the identified cohort study noted that it may be on offset of potentially 
missing out on patients with an acute myocardial infarction or unstable angina. 
No conclusion  
on Tn-POCT, 
highlighting the 
inconclusive 
available evidence. 
Abbreviations: CADTH – Canadian Agency for Drugs and Technologies in Health; CL – central laboratory; cTn – cardiac troponin; DTA – diagnostic test accuracy; MI – myocardial infarction;  
NPV – negative predictive value; NR – not reported; POC – point of care; POCT – point of care test; PPV – positive predictive value; pts – patients; SEN – sensitivity; SPEC – specificity;  
SR – systematic review. 
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Table 2: Summary table of the results on the use of Tn-POCT in the emergency department 
The use of Tn-POCT in the emergency department: Summary of the evidence 
Effect on patient management   
1 SR [25] High No. of hospital admission: N/A 
Treatment initiation: N/A 
RR: N/A 
DNT: N/A 
TAT (evidence base: 2 RCTs, 11 observational studies using a variety of different definitions of TAT2): 
RCTs (2 studies, cTnI or cTnT testing, 2,134 and 833 enrolled patients respectively): 
• Reduction in 2/2 studies: 43 min (median; p value not available) in one study, and 71 and 147 min in the other study3  
(median; s. s., with p<0.001) 
Observational studies (5 prospective, 1 retrospective and 5 pre-post studies respectively, cTnI or cTnT testing, 31 to 2,386 enrolled pts) 
• Reduction in 11/11 studies: 18-93 min (p values available for 5/11 studies, with s. s. differences in these studies) 
TTD (evidence base: 2 RCTs, 1 observational study): 
RCTs (2 studies, cTnT or cTnI testing, 487 and 2,134 enrolled pts respectively): 
• Reduction in 2/2 studies: 5 and 7 min (mean and median respectively; s. s. with p=0.04 and p value not available respectively) 
Observational studies (1 pre-post study, multiple biomarkers 4,886 enrolled pts): 
• Reduction in 1/1 study: 26 min (p value not available) 
LOS: 
Emergency room stay (evidence base: 3 RCTs, 2 observational studies):  
RCTs (3 studies, cTnI or cTnT testing, 487-912 enrolled pts): 
• Reduction in 2/3 studies: 0.2 and 0.8 h (mean and median; diff. n. s. in individual studies) 
• Increase in 1/3 studies: 0.1 h (median; diff. n. s.) 
Observational studies (2 pre-post studies, cTnI testing, 366 and 671 enrolled pts respectively):  
• Reduction in 2/2 studies: 1.9 h (mean; p value NR) and 2-2.7 h respectively (mean; diff. s. s.) 
Hospital stay in ED (evidence base: 1 RCT) 
RCTs (1 study, cTnI testing, 2,243 enrolled pts) 
• Reduction in 1/1 study: 2.2 h (mean; diff. n. s.) 
Currently,  
the evidence  
is insufficient 
indicating non-
inferiority of 
using a pathway 
with Tn-POCT 
compared to 
usual care if CL 
testing is timely 
available. 
                                                     
2 E.g., time from blood draw to result. 
3 When using the definitions “time from collection to physician notification” and “time from presentation to anti-ischemic therapy” respectively. 
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The use of Tn-POCT in the emergency department: Summary of the evidence 
1 SR [25] 
(continuation) 
 Further testing: N/A 
TCD (evidence base: 1 RCT, 1 pre-post study): 
RCTs (1 study, cTnI testing, 2,134 enrolled pts) 
• Reduction in 1/1 study: 9 min (median; p value not available) 
Observational studies (1 pre-post study, multiple biomarker testing, 4,886 enrolled pts): 
• Reduction in 1/1 study (multiple biomarkers): 26 min (mean; p value not available) 
Effect on mortality/morbidity 
1 SR [25] High Mortality (evidence base: 2 RCTs and 3 observational studies) 
RCTs (2 studies; cTnT or cTnI testing, 487 and 2,243 enrolled pts respectively) 
• POC vs. CL: 0.5 vs. 0% in one study (p value NR) and 1% vs.0.2% in another study (n. s., with p=0.142) 
Observational studies (3 prospective studies; cTnI or cTnT testing; 508-1,410 enrolled pts) 
• None of the studies compared Tn-POCT with CL head-to-head (using statistical testing) 
Cardiac events (evidence base: 2 prospective studies, cTnI or cTnT testing) 
30 day cardiac event rate (1 prospective study, 704 enrolled pts; POCT vs. CL):  
• Low risk pts: 0% (95%CI: 0-25.9) vs. 0% (95%CI: 0-21.5), p value NR 
• High risk pts: 24.8% (95%CI: 20.1-30.1) vs. 28.6% (95%CI: 23.4-34.4), p value NR 
Cardiac events after 1 year (1 prospective study, 1,410 enrolled pts; POCT vs CL): 
• 2.1% (95%CI: 1.5-3) vs. 2.2% (95%CI: 1.6-3.1), p value NR 
Other Adverse events (AE) and composite end points in ED (evidence base: 2 RCTs, cTnT or cTnI testing) 
Major AE after 3 m FU (1 RCT, 2,243 enrolled pts; POCT vs CL): 3% vs. 2%, diff. n. s., with p=0.313 
CEP events4 at 6 m (1 RCT, 487 enrolled pts; cTnT testing, POCT vs. CL): 10.4% vs. 5.4%, p value NR 
Effect on QoL 
1 SR [25]  QoL (evidence base: 1 RCT, cTnI testing, 2,243 enrolled pts using the EQ-5D questionnaire): 
POC vs. CL:  
• After 1 m: 0.742 vs. 0.759 (n. s., with p=0.614) 
• After 3 m: 0.752 vs. 0.759 (n. s., with p=0.638) 
Abbreviations: CL – central laboratory; DNT – door-to-needle-time; LOS – length of stay; m – month(s); n. s. – not statistically significant; N/A – no evidence available; pts – patients; QoL – quality of life; 
RCT – randomised controlled trial; RR – referral rates; SR – systematic review; s. s. – statistically significant; TAT – turnaround time; TCD – time to clinical decision;TTD – time to discharge. 
                                                     
4 AMI, coronary revascularization, cardiac arrest, or mortality in patients with a negative first cTn test at 3 m FU 
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Table 3: Summary table of the results on the use of Tn-POCT in ambulatory (primary or community care) 
The use of Tn-POCT in primary care settings: Summary of the evidence 
Evidence base  Quality Results Conclusion 
Effect on patient management 
2 SRs [25, 26] Moderate  
to High 
No. of hospital admission: N/A 
Treatment initiation: N/A 
RR (evidence base: 1 comparative cohort study identified by both SRs):  
• Reduction in 1/1 study (TnT testing, 196 enrolled pts): 32/128 pts (25%) vs.  
29/68 pts (43%), p value not reported5 
DNT: N/A 
TAT: N/A 
TTD: N/A 
LOS: N/A 
Further testing: N/A 
TCD: N/A 
Currently, the evidence is insufficient 
indicating superiority of using a pathway 
with Tn-POCT compared to usual care in 
ambulatory care (primary or community 
care) if CL testing is not timely available. 
Effect on mortality/morbidity 
No evidence identified  N/A - 
Effect on QoL 
No evidence identified N/A - 
Abbreviations: CL – central laboratory; DNT – door-to-needle-time; LOS – length of stay; N/A – no evidence available; pts – patients; QoL – quality of life; RR – referral rates; SR – systematic review; 
TAT – turnaround time; TCD – time to clinical decision; TTD – time to discharge. 
 
  
                                                     
5 Yet, it is mentioned in the review that the authors of the primary study noted that there were some two patients that were not referred and missed cases (one AMI and one unstable angina respectively). 
It is therefore concluded that the use of Tn-POCT in pts with chest pain “may reduce emergency referrals, but probably at the cost of an increased risk to miss patients with an acute myocardial infarction 
or unstable angina”. 
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Table 4: Summary table of the results on the use of Tn-POCT in pre-hospital emergency medicine (PHEM)  
Effectiveness of implementing Tn-POCT in pre-hospital emergency medicine: Summary of the evidence 
Evidence base  Quality Results Conclusion 
Effect on patient management 
1 SR [25] High No. of hospital admissions (ambulance; evidence base: 1 RCT with 601 enrolled pts):  
No difference between Tn-POCT and usual care (no further information provided) 
Treatment initiation: N/A 
RR: N/A 
DNT: N/A 
TAT (ambulance; evidence base: 1 observational study; 928 pts): 83 min (median, range: 46-167) 
TTD (ambulance; evidence base: 1 RCT):  
• Reduction in 1/1 study (median time Tn-POCT vs CL): 8.8 hours (range: 6.2 h to 10.8 h) vs.  
9.1 h (range 6.7 hours to 11.2 hours), P = 0.05. 
LOS: N/A 
Further testing: N/A 
TCD: N/A 
Currently, the evidence is 
insufficient indicating superiority  
of using a pathway with Tn-POCT 
compared to usual care in pre-
hospital emergency medicine if  
CL testing is not timely available. 
Effect on mortality/morbidity 
1 SR [25] High Mortality: (ambulance; 1 RCT, 601 enrolled pts) 
• Death in the next 30 days: no difference between groups (no further information provided) 
Effect on QoL  
No evidence identified N/A N/A 
Abbreviations: CL – central laboratory; DNT – door-to-needle-time; LOS – length of stay; N/A – no evidence available; pts – patients; QoL – quality of life; RR – referral rates; SR – systematic review; 
TAT – turnaround time; TCD – time to clinical decision; TTD – time to discharge; RCT – randomised controlled trial. 
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Table 5: Summary table of the results on the use of D-dimer POCT 
Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ Conclusion 
Schols, 
2018 [26] 
SR 2/892 Primary 
care 
Moderate DTA:  
SEN: stand alone D-dimer 84%; Wells ≤4 + D-dimer 94-95%;  
Wells ≤2 + D-dimer 97%. 
SPEC: stand-alone D-dimer 62%; Wells ≤4 + D-dimer 38-51%;  
Wells ≤2 + D-dimer 32%. 
PPV: stand alone D-dimer 24%; Wells ≤4 + D-dimer 21-37%;  
Wells ≤2 + D-dimer 20%. 
NPV: stand alone D-dimer 96%; Wells ≤4 + D-dimer 94-99%;  
Wells ≤2 + D-dimer 99%. 
Effectiveness: NR 
No studies assessed the effects of D-dimer 
on treatment initiation or referral rates.  
All studies were considered at high risk of 
bias. Evidence suggests combining D-dimer 
with a clinical decision rule (e.g. when GP 
use of a D-dimer POCT is combined with 
the Wells clinical decision rule) leads to 
more accurate diagnosis. Further research 
on clinical effectiveness is necessary. 
Geersing, 
2009 [31] 
SR & 
meta 
alanysis 
23/13,959 Primary or 
secondary 
care 
High DTA: 
SEN:  
0.85 (95%CI 0.78-0.90) for SimpliRED D-dimer;  
0.87 (0.81-0.91) for Clearview Simplify D-dimer; 
0.93 (0.88-0.97) for Triage D-dimer;  
0.96 (0.91-0.98) for Cardiac D-dimer. 
SPEC:  
0.48 (95% CI 0.33-0.62) for Triage D-dimer;  
0.57 (0.52-0.62) for Cardiac D-dimer;  
0.62 (0.54-0.69) for Clearview Simplify D-dimer;  
0.74 (95%CI 0.69-0.78) for SimpliRED 
Likelihood ratio of a negative test result:  
0.07 (95%CI 0.04-0.16) for Cardiac D-dimer;  
0.18 (95%CI 0.08-0.43) for Triage D-dimer;  
0.21 (0.15-0.29) for SimpliRED D-dimer;  
0.22 (95% CI 0.15 to 0.29) for Clearview Simplify D-dimer. 
Effectiveness: NR 
The two quantitative tests (Cardiac  
D-dimer and Triage D-dimer) scored most 
favourably. 
In outpatients suspected of VE, D-dimer 
POCT can contribute important information 
and guide patient management, especially 
in low-risk patients (i.e. with low score on  
a clinical decision rule). 
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Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ Conclusion 
Pasha, 
2010 [32] 
SR 4/199 Not 
specified6 
Moderate DTA: 
Incidence of VTE despite negative testing and  
unlikely clinical probability: 2% (95% CI: 0.1-10.1%)? 
Effectiveness: 
In 49/199 (25%) patients with unlikely clinical probability  
and normal D-dimer CT scans could be withheld. 
Mortality/Morbidtidy: 1 person (2%) 
Overall (across POCT and lab tests) pooled 
incidence of morbidity was 0.34% (95%CI 
0.036-0.96%) and combined incidence of 
death (across POCT and lab tests) was 0.1% 
(95% CI 0.0-0.5%). Combined 3-month 
mortality risk of PE (across POCT and lab 
tests) was 0.10% (95%CI 0.002-0.46%). 
1 death occurred across all studies  
(this was in the POCT study). 
Ruling our PE on basis of unlikely clinical 
probability and normal D-dimer is very safe. 
Hendriksen, 
2015 [33] 
SR 10/598 Primary 
care 
High Sensitivity*: (* Data are ordered by values of the test accuracy rate) 
88% (78%-94%) for simplified revised Geneva ≤2 model 
90% (81-96%) for original revised Geneva ≤5 
95% (87%-98%) for original Wells ≤4; 95% (87-98%)  
for modified Wells ≤2 
96% (88%-99%) for simplified Wells ≤1 
Specificity*: 48% (44%-53%) for original revised Geneva ≤5; 
49% (45-53%) for the simplified Wells ≤1; 50% (46-55%) for 
the modified Wells ≤2; 51% (47-55%) for the original Wells 
≤4; 53% (49%-57%) for simplified revised Geneva ≤2. 
PPV*: 20% (15%-24%) for original revised Geneva ≤5; 21% 
(17-26%) for original Wells ≤4; 21% (17-26%) for modified 
Wells ≤2; 21% (17-25%) for simplified Wells ≤1; 21% (16-26%) 
for simplified revised Geneva ≤2. 
NPV*: 97% (95-99%) original revised Geneva ≤5; 97%  
(94-99%) simplified revised Geneva ≤2; 99% (96-100%) 
original Wells ≤4; 99% (96-100%) modified Wells ≤2; 99% 
(97-100%) simplified Wells ≤1.  
Efficiency was comparable across all 
models but the Wells rules combined with 
D-dimer POCT gave the best performance 
in terms of lower failure rates 
                                                     
6 Only "outpatients" stated in one study in this review that used a POCT but not defined further (i.e. if primary care or ED) 
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Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ Conclusion 
Effectiveness: 
Failure rates across all models:  
1.2% (95%CI 0.2%-3.3%) for simplified Wells ≤1 
1.5% (95%CI 0.4-3.7%) for original Wells ≤4 
1.5% (95%CI 0.4-3.8%) for modified Wells ≤2 
2.7% (95%CI 1.1-5.4%) for original revised Geneva ≤5  
3.1% (95%CI 1.4%-5.9%) for simplified revised Geneva ≤2 
Efficiency across all models:  
43% (95%CI 39%-48%) for simplified Wells ≤1 
44% (95%CI 40-48%) for original revised Geneva ≤5 
45% (95%CI 41-49%) for modified Wells ≤2 
46% (95%CI 41-50%) for original Wells ≤4 
48% (95%CI 44%-52%) for simplified revised Geneva ≤2 
Lucassen, 
2011 [34] 
SR 52/55,268 Hospital 
setting 
(emergency 
department, 
outpatients 
or 
inpatients) 
High DTA: NR for D-dimer POCT 
Effectiveness: 
Failure rate (across all studies with qualitative d-dimer 
testing): 1.0% (95%CI 0.8-1.3%) 
combined with gestalt 0.7% (95%CI 0.4-1.2%) 
combined with Wells cutoff value ≤4: 1.7% (95%CI 1.0-2.8%) 
combined with Wells cutoff value <2: 0.9% (95%CI 0.6-1.5%) 
Efficiency (across all studies with qualitative d-dimer testing): 
45% 95%CI 39-52%);  
Combined with gestalt: 52% (95%CI 40-64%) 
Combined with Wells cutoff value ≤4: 42% (95%CI 32-52%) 
Combined with Wells cutoff value <2: 40% (95%CI 33-48%) 
Combining a decision rule and gestalt7  
can safely exclude PE when combined with 
sensitive D-dimer testing except when the 
less sensitive Wells rule (cutoff value ≤4) is 
combined with qualitative D-dimer POCT 
                                                     
7 Note: Physician’s unstructured estimate (“gestalt”). 
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Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies/ 
included pts 
Setting Quality Summary of the results Authors’ Conclusion 
Marquardt, 
2015 [35] 
SR 7/3,279 ED  Moderate DTA: NR 
Effectiveness: 
No. of hospital admissions (1 before-after study, 462 pts) 
decreased by 13.8% 
TAT in ED (evidence base: 7 observational studies8, 3,279 pts): 
• Reduction in 5 studies (comparative; prospective and 
retrospective): 10-101.5 min (using different measures  
of central tendency; p-values and information on stat. 
testing not reported) 
• No comparative data shown from 2 studies9  
D-dimer POCT can safely improve patient 
journey times 
Abbreviations: ED – emergency department; NPV – negative predictive value; NR – not reported; pts – patients; POCT – point of care test; PPV – positive predictive value; SEN – sensitivity;  
SPEC – specificity; SR – systematic review; TAT – turnaround time. 
  
                                                     
8 While the review reported initially on seven included studies on TAT, data are only presented for six studies. 
9 Non-comparative data was shown in one study (time to result: 10-38 min) and not reported at all in another study that the review described.  
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Table 6: Summary table of the results on the use of D-dimer POCT derived from primary studies updating the overview of reviews 
Effectiveness of implementing D-dimer-POCT: identified studies updating the evidence from SRs 
Evidence base  Study 
design 
Included 
pts 
Setting Risk of 
Bias 
Summary of the results Conclusion 
Effect on patient management  
2 studies 
[36, 37] 
NRCT 971 Primary 
care 
Moderate 
to severe 
TAT (1 study): <5min to 34 min  
RR (1 study): no statistically significant difference in patients referred, 
not referred between intervention and usual care group 
The identified evidence  
updating the overview of reviews 
is insufficient to suggest that 
implementing D-dimer POCT  
is non-inferior in comparison  
to CL testing and superior in 
comparison to usual care if  
CL is not (timely) available. 
Effect on mortality/morbidity 
No studies identified - - - - - 
Effect on QoL 
No studies identified - - - - - 
Abbreviations: CL – central laboratory; NRCT – non randomised controlled trial; pts – patients; RR – referral rate; SRs – systematic reviews; TAT – turnaround time. 
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2 SCOPE 
This rapid assessment addresses the research question whether using the point of care tests 
(POCT) for D-dimer and troponin in symptomatic populations presenting at ambulatory care (pri-
mary or community care settings) or emergency care settings is more effective and/or safer than 
current diagnostic practice. This topic was chosen based on a request from the representatives of 
the federal states in Austria who commissioned our agency to do a health technology assessment 
(HTA) on two POCTs, D-dimer and troponin (Tn), in symptomatic patients. POCT is expected to 
enable testing during a consultation and to enable triage of patients in need of further examination 
and a transfer to a hospital, while sparing other unnecessary tests or hospital admissions 
In order to assess the evidence on the POCTs under evaluation, we conducted an overview of re-
views on the clinical utility of Tn-POCT and D-dimer POCT. We also extracted information on the 
surrogate endpoints related to diagnostic test accuracy (DTA) if these were also included in the 
reviews on clinical utility.  
In addition, the scope of this assessment was limited to two broad categories: ambulatory care 
(primary and community care) and emergency medicine.  
Table 7: Inclusion criteria (PICO) for Tn-POCT 
Population  Adult patients ≥18 years with signs and or symptoms of acute coronary syndrome (ACS) 
and/or other symptoms such as chest pain or breathlessness that are potentially indicative 
of acute myocardial infarction which is suspected and has not been ruled out. Specific 
high-risk groups of patients will be excluded. 
The intended use of the biomarker cardiac troponin is for use in patients who present with 
chest pain and/or suspected myocardial infarction (MI). 
MeSH-terms: acute coronary syndrome, myocardial infarction, unstable angina pectoris, 
cardiac troponin.  
ICD-10: I20-I24 
Intervention  Point of care cardiac troponin products that are available on the market are as follows:  
i-STAT cTnI (Abbott Point of Care), Roche CARDIAC Troponin T, Cobas h232 (Roche), 
Stratus® CS Analyzer (Siemens), Minicare I-20 Troponin-I (cTnI) assay (Philips), 
LABGEOIB TnI analyser (Samsung), ADEXUSDx® Troponin I Test (NowDiagnostics), 
RAMP® Cardiac Troponin I test (Response Biomedical), Troponin I Test (Eurolyser), 
mLabs Troponin I (Micropoint), PATHFASTTM (LSI Medience Corporation; former Mitsubishi), 
Triage Troponin I Test (Quidel), AQT90 FLEX cTnI and AQT90 FLEX cTnT (Radiometer), 
troponin I test (PBM), i-CHROMA Diagnostics (Sycomed) 
Comparison All comparators will be included.  
For the impact of POCT on patient management, usual care (incl. central laboratory 
methods) will be used. 
In the diagnostic performance testing, reference standard tests are likely to include 
echocardiography, angiography and laboratory testing (as opposed to the near-patient 
testing devices).  
Outcomes Evidence-based clinical recommendations regarding the use of Tn-POCT 
Effectiveness/clinical utility:  
• Patient management: Number of hospital admissions, treatment initiation, referral 
rates (RR), door-to-needle time (DNT), turnaround time (TAT), time to discharge 
(TTD), length of stay (LOS), further diagnostic testing, time to clinical decision (TCD) 
• Mortality and morbidity  
• patient quality of life (QoL) 
Safety: side effects/disbenefits 
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Study design At the first stage, systematic reviews and meta-analyses as well as HTA reports and 
evidence-based guidelines will be included.  
Publications published from 2009 onwards will be included (to identify recently published 
systematic reviews). For the search to identify relevant guidelines, no filter with regard to 
publication date applied. 
In a second stage, primary studies (controlled trials ≥ 10 participants) may be included  
in order to update the results of available systematic reviews or expand the scope of 
available systematic reviews. 
 
Table 8: Inclusion criteria (PICO) for D-dimer POCT 
Population  Adult patients ≥18 years with symptoms such as leg swelling, chest pain or trouble 
breathing that are potentially indicative of deep vein thrombosis or pulmonary embolism. 
Specific high-risk groups of patients (e.g. those with a previous VTE or those with cancer) 
will be excluded.  
Pulmonary embolism ICD 10: 0882, I269, I260; Deep vein thrombosis ICD 10: I801, I828, 
I829, O223, I822, I820, I802, I81, O082, I823, O871; Thrombophlebitis ICD 10: I809, I821, 
I808, I803.10 
The intended use of the technology is for use as a diagnostic tool to rule out the presence 
of venous thromboembolism often in conjunction with use of a clinical prediction rule 
(such as Wells or Geneva).  
MeSH-terms: Pulmonary Embolism, venous thrombosis, thromboembolism,  
“fibrin fibrinogen degradation products” 
Intervention  D-dimer POCTs included the following products: SimpliRED D-dimer (Agen Biomedical), 
NycoCard™ D-dimer Single Test (Abbott), Triage D-dimer (Alere), Clearview Simplify  
D-dimer (Alere), Roche Cardiac D-dimer (Roche), Dade Dimertest (Siemens) Stratus  
CS Acute Care D-dimer (Siemens), mLabs D-dimer (Micropoint Bioscience), PATHFAST  
D-dimer (Pathfast), i-CHROMA D-dimer (Boditech), AQT90 FLEX D-dimer (Radiometer) 
Comparison All comparators will be included.  
For the impact of POCT on patient management, usual care (incl. central laboratory 
methods) will be used. 
In the diagnostic performance testing, reference standard tests are likely to include 
computerized tomography pulmonary angiography (CTPA), ultrasound, venography/ 
angiography and laboratory testing (as opposed to the near-patient testing devices).  
Outcomes Evidence-based clinical recommendations regarding the use of D-dimer POCT  
Effectiveness/clinical utility:  
• Patient management: Number of hospital admissions, treatment initiation, referral 
rates (RR), door-to-needle time (DNT), turnaround time (TAT), time to discharge 
(TTD), length of stay (LOS), further diagnostic testing, time to clinical decision (TCD) 
• Mortality and morbidity 
• patient quality of life (QoL) 
Safety: side effects/disbenefits  
Study design At the first stage, systematic reviews and meta-analyses as well as HTA reports and 
evidence-based guidelines will be included.  
Publications published from 2009 onwards will be included (to identify recently published 
systematic reviews). For the search to identify relevant guidelines, no filter with regard to 
publication date applied. 
In a second stage, primary studies (controlled trials ≥ 10 participants) may be included  
in order to update the results of available systematic reviews or expand the scope of 
available systematic reviews. 
 
                                                     
10 https://bmjopen.bmj.com/content/suppl/2015/11/11/bmjopen-2015-008864.DC1/bmjopen-2015-008864supp_tables.pdf 
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3 METHODS AND EVIDENCE INCLUDED 
3.1 Assessment Team 
LBI-HTA (lead authors): 
• Developed first draft of EUnetHTA project plan  
• Identified and contacted manufacturers 
• Performed the literature search, literature selection, data extraction and risk of bias  
assessment (in agreement with co-author).  
• Performed interviews with stakeholders in AT to ascertain context factors. 
• Carried out the assessment: answered assessment elements, filled in checklist regarding 
potential “ethical, organisational, patient and social and legal aspects” of the HTA Core Mod-
el® for rapid REA.  
• Sent “draft versions” to reviewers, compiled feedback from reviewers and performed 
changes according to reviewer’s comments.  
• Prepared final assessment and wrote the executive summary of the assessment 
NSPHMPDB (co-authors): 
• Contributed to the development of the EUnetHTA project plan 
• Reviewed the project plan draft. 
Supported the production of all domains and quality checked all steps  
(relating to data, information, sources). 
• Co-authored the report (e.g, collaboration in the literature selection, independent  
quality assessment, and verification of the data extraction) 
• Performed interviews with stakeholders in RO to ascertain context factors. 
• Approved/endorsed conclusions drawn as well as all draft versions and  
the final assessment including the executive summary. 
• Made substantial contributions to the conception, and revision of the report  
(especially Romanian context) 
• Gave final approval of the version to be published 
Dedicated reviewers: 
• Guaranteed quality assurance by thoroughly reviewing the project plan and  
the assessment drafts. 
• Reviewed methods, results, and conclusions based on the original studies included. 
• Provided constructive comments in all the project phases 
External expert: 
• Guaranteed quality assurance by thoroughly reviewing the project plan and  
the assessment drafts. 
• Reviewed methods, results, and conclusions based on the original studies included 
• Provided constructive comments in all project phases 
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The project was split into two parts: D-dimer POCT and Tn-POCT. One researcher from the LBI-
HTA was in charge of these projects respectively (LS, GG). From the co-authors, there were four 
researchers involved: two researchers for D-dimer (SF, MC) and troponin (SGS, CS) respectively. 
One further researcher from LBI-HTA (JE) was in charge of the guideline synopsis on the use of 
these biomarker tests and was assisted by all other researchers. 
Co-authors were involved for all decisions and discrepancies were resolved by consensus. 
 
3.2 Source of assessment elements 
Assessment elements were taken from the latest version of the EUnetHTA Core Model ® (Version 
4.2) [45]. Due to the fact that safety was not reported by most of the included studies, we com-
bined presentation of the results of both of these domains in one chapter. 
 
3.3 Search 
To identify relevant clinical practice guidelines (CPGs), systematic searches were carried out in 
the following databases: 
• Trip database 
• Guidelines International Network (G-I-N) database 
In addition, manual searches were carried out on the websites of the following HTA institutes and 
professional organizations: 
• National Institute for Health and Care Excellence (NICE) 
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. 
(AWMF, Association of the Scientific Medical Societies in Germany) 
• Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V.  
(DGK, German Cardiac Society) 
• European Society of Cardiology (ESC) 
• American Heart Association/American College of Cardiology (AHA/ACC) 
• Canadian Agency for Drugs and Technologies in Health (CADTH) 
• Scottish Intercollegiate Guidelines Network (SIGN) 
• New Zealand Guidelines Group (NZGG) 
• Australian National Health and Medical Research Council (NHMRC) 
• Belgian Healthcare Knowledge Centre (KCE) 
• Royal Australasian College of Surgeons (ASERNIP-S) 
• UpToDate database: https://www.uptodate.com/home 
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To identify potentially relevant systematic reviews and meta-analyses, systematic searches in the 
following four databases were performed: 
• The Cochrane Library 
• Centre for Reviews and Dissemination (CRD) 
• Embase via Elsevier 
• Medline via Ovid 
To identify primary studies updating or extending the evidence derived from available systematic 
reviews, a further search was conducted in the following databases: 
• Medline via Ovid 
• Embase via Elsevier 
• The Cochrane Library 
• Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
Detailed tables on search strategy are included in Appendix 1. 
Table 9 gives a broad overview of the research questions and the methods used to answer these. 
Table 9: Research questions and the related method used  
Research questions Method 
How do evidence-based guidelines recommend Tn-POCT 
be used (position in the diagnostic path, threshold values 
in different patient populations, settings)? 
Synopsis of recommendations 
from CPGs (included in health 
problem and current use) 
How do evidence-based guidelines recommend D-dimer-
POCT be used (position in the diagnostic path, threshold 
values in different patient populations, settings)? 
Synopsis of recommendations 
from CPGs (included in health 
problem and current use) 
What are the clinical benefits of Tn-POCT in the 
management of symptomatic patients (adults)? 
A systematic review of 
effectiveness and safety 
What are the clinical benefits of D-dimer POCT in  
the management of symptomatic patients (adults)? 
A systematic review of 
effectiveness and safety 
Can a theoretical benefit of POCT (D-dimer and Tn)  
be realized in the Austrian and Romanian context? 
Consultation with experts in AT 
and RO to reflect on context 
factors (expert input) 
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3.4 Study selection 
Searching and study selection occurred separately for each POCT. Study selection was under-
taken by two independent researchers for each POCT in accordance with the PRISMA statement 
[20, 21]. 
For both POCTs, we identified the most recent and high quality systematic review from all those 
identified which we updated either for publication year (Tn) or by widening the subject of the review 
(D-dimer). 
For guidelines, no limitation was applied for the year of publication and systematic reviews were 
only included if published after 2009. Relevant guidelines/systematic reviews and primary studies 
published in English and German language were included.  
Given the broad variety of definitions, we classified the device according to POCT or laboratory 
method following assignment by the study authors (whether they classified it as a POCT or not). If 
the study authors did not mention whether or not it is a POCT and we were familiar with the test, 
which was classified as a POCT elsewhere, we also classified it as POCT. If uncertainty persisted, 
we asked a clinical expert for his/her view for the final judgement. We used several sources guid-
ing our decision as to whether a test was POCT or not [4, 8, 46, 47]. 
 
Tn-POCT 
For the guideline synopsis, we searched for potentially eligible guidelines on the use of Tn-POCT 
in clinical practice. A total of 231 references were identified through database searching and man-
ual searching. After title and abstract screening, 43 were identified as being potentially relevant. 
Of these, 35 were subsequently excluded based on the full-text review. We included eight guide-
lines in the synopsis. The study selection process is depicted in Figure 1. 
For synthesising the evidence on the clinical utility of Tn-POCT, we firstly searched for systematic 
reviews of high quality that could be used for the qualitative synthesis of the evidence. The data-
base search yielded 178 unique entries. After the abstract screening phase, 134 records were ex-
cluded and one further eligible publication was identified through a web-based hand-search, re-
sulting in 45 publications eligible for full-text screening. Five studies met the inclusion criteria, of 
which only two had a sufficient (moderate or high) methodological quality according to the Assess-
ing the Methodological Quality of Systematic Reviews-2 (AMSTAR-2) assessment and, hence was 
included for the synthesis of the evidence. The study selection for systematic reviews and meta-
analyses is depicted in Figure 2.  
In a second step, we searched for primary studies to update the evidence derived from systematic 
reviews and meta-analyses. The time period was chosen based on the last systematic search 
conducted within the identified systematic reviews (2016-2019). The database search yielded 983 
unique entries that we screened on a title and abstract level. Of these, 890 articles were excluded 
and 93 records were eligible for the full-text screening. However, the full-text review revealed that 
none of these studies fulfilled our inclusion criteria. The study selection process is depicted in 
Figure 3. 
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Figure 1: Flow chart to identify clinical practice guidelines on the use of Tn-POCT  
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Figure 2: Flow chart to identify systematic reviews and meta-analyses for Tn-POCT 
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Figure 3: Flow chart to identify primary studies for Tn-POCT (publication period: 2016-2019) 
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For deep vein thrombosis in ambulatory care (primary and community care), the database search 
yielded 259 unique entries that we screened on a title and abstract level. Of these, 254 articles 
were excluded and five records were eligible for the full-text screening. The full-text review revealed 
that two of these studies fulfilled our inclusion criteria. The study selection process is depicted in 
Figure 6. 
For emergency care settings, the database search yielded 696 unique entries that we screened 
on a title and abstract level. Of these, 675 articles were excluded and 21 records were eligible for 
the full-text screening. The full-text review revealed that none of these studies fulfilled our inclu-
sion criteria. The study selection process is depicted in Figure 7. 
 
 
Figure 4: Flow chart to identify clinical practice guidelines on the use of D-dimer POCT 
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Figure 5: Flow chart to identify systematic reviews and meta-analyses for D-dimer POCT 
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Figure 6: Flow chart to identify primary studies for D-dimer POCT in ambulatory care 
(primary and community care) settings  
 
 
Figure 7: Flow chart to identify primary studies for D-dimer POCT in emergency care settings 
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3.5 Data extraction and analyses 
One researcher from LBI-HTA extracted the data and another researcher from NSPHMPDB 
checked the extracted data. The evidence was qualitatively synthesised. 
 
3.6 Quality rating  
The quality of the eligible studies was assessed using the following tools: For systematic reviews, 
the AMSTAR-2 checklist [22] was utilised, whilst for randomised controlled studies and non ran-
domised controlled trials (NRCTs) the quality was assessed using the Cochrane risk of bias tool 
[48] and the Robins-I tool [23] respectively. 
To assess the quality of the included guidelines, the Appraisal of Guidelines, Research and Eval-
uation (AGREE II) reporting checklist [24] was used. 
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3.7 Description of the evidence used 
Table 10: Main characteristics of reviews included for Tn-POCT 
Author and year  
or study name 
Study  
type 
Quality  
(AMSTAR-2) 
Number of included 
studies (Tn)/Number of 
included pts 
Intervention (s) Main  
endpoints 
Included in clinical 
effectiveness and/or 
safety domain 
CADTH, 2016 [25] SR High 41/NR Tn-POCT DTA and Clinical utility  EFF 
Schols, 2018 [26] SR Moderate 2/545 Various POCT (including Tn-POCT) DTA and clinical utility EFF 
Abbreviations: DTA – diagnostic test accuracy; EFF – effectiveness; NR – not reported; POCT – Point of Care; SAF – safety; SR – systematic review; Tn – Troponin; Tn-POCT – Troponin Point of Care. 
 
Table 11: Main characteristics of reviews included for D-dimer POCT 
Author and year 
or study name 
Study  
type 
Quality 
(AMSTAR-2) 
Number of included 
studies (D-dimer)/ 
Number of included pts 
Intervention (s) Main  
endpoints 
Included in clinical 
effectiveness and/or 
safety domain 
Schols, 2018 [26] SR Moderate 2/892  Various POCT  
(including D-dimer) 
Clinical effectiveness, DTA 
and/or effect on treatment and 
referral rates to secondary care 
EFF 
Geersing 2009 [31] SR & meta-
analysis 
High 23/13,959 D-dimer POCT DTA (sensitivity and specificity) EFF 
Pasha, 2010 [32] SR & meta-
analysis 
Moderate 1/199 Lab & D-dimer POCT Incidence of PE or DVT and  
its attributable mortality 
EFF 
Hendriksen, 2015 
[33] 
SR and 
validation of 
prediction 
models in 
primary care 
High 10/598 11 Diagnostic (Pulmonary 
embolism) prediction models 
with D-dimer POCT 
Discriminative ability of models, 
efficiency (proportion of patients 
in the whole cohort stratified to 
the group with low predicted 
probability of PE) and failure rate  
EFF 
                                                     
11 Total number of patients of the database used to test various models identified. 
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Author and year 
or study name 
Study  
type 
Quality 
(AMSTAR-2) 
Number of included 
studies (D-dimer)/ 
Number of included pts 
Intervention (s) Main  
endpoints 
Included in clinical 
effectiveness and/or 
safety domain 
Lucassen, 2011 
[34] 
Meta-
analysis 
High 52/55,268 Physician’s unstructured 
estimate (“gestalt”) and clinical 
decision rules in combination 
with quantitative and qualitative 
D-dimer testing  
DTA, failure rates, successful 
avoidance of imaging 
EFF 
Marquardt, 2015 
[35] 
SR Moderate 7/3,27912 POCT in emergency 
departments 
Turnaround time, time to 
diagnosis, referral or discharge 
EFF 
Abbreviations: SR – systematic review; POCT – Point of Care Test; DTA – diagnostic test accuracy; EFF – effectiveness, PE – pulmonary embolism. 
 
Table 12: Main characteristics of primary studies included for D-dimer POCT & DVT 
Author and year or study 
name 
Study  
type 
Risk of Bias Number of 
included pts 
Intervention (s) Main  
endpoints 
Included in clinical 
effectiveness and/ 
or safety domain 
Oude Elferink, 2015 [37] NRCT Moderate 290 8 different D-dimer 
tests, one of which was 
POCT (Simplify) 
DTA and clinical utility 
(turnaround time) 
EFF 
Kingma, 2017 [36] NRCT Severe 681 Implementation of a 
guideline consisting of 
clinical decision rule 
combined with negative 
D-dimer test 
Proportion of non-referred 
pts, proportion of missed 
DVT cases, proportion of 
pts in whom guideline 
incorrectly applied  
EFF 
Abbreviations: DTA – diagnostic test accuracy; DVT – deep vein thrombosis; EFF – effectiveness; NRCT – non randomised controlled trial, POC – point of care. 
 
 
                                                     
12 Total number of d-dimer patients on which data on turnaround time is available.  
POCT/point of care tests: D-dimer and troponin 
Version 1.4, 26.11.2019 EUnetHTA Joint Action 3 WP4 46 
3.8 Deviations from project plan 
Due to the fact that an overview of reviews was primarily conducted, Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) [49] was not used within this assess-
ment. Also, the included systematic reviews did not use GRADE, hence as a consequence and 
for consistency reasons, neither did we use GRADE when updating the evidence of these reviews. 
Additional assessment elements from the HTA Core Model® for the full assessment of Diagnostic 
Technologies [50] were added to the effectiveness assessment elements. 
There were slight adaptations of the PICO table based on the input from the clinical experts and 
dedicated reviewers. 
Outcomes: Effectiveness and safety outcomes were changed: Harms from false positives and 
false negatives were initially considered as a safety outcome but is now considered as an effec-
tiveness outcome. Safety outcomes were revised to focus on side effects/disbenefits. 
 
 
POCT/point of care tests: D-dimer and troponin 
Version 1.4, 26.11.2019 EUnetHTA Joint Action 3 WP4 47 
4 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC) 
4.1 Research questions  
Element ID Research question 
B0001 What are the technology and the comparator(s)? 
A0020 For which indications have the technology received marketing authorisation  
or CE marking? 
B0002 What is the claimed benefit of the technology in relation to the comparator(s)? 
B0003 What is the phase of development and implementation of the technology  
and the comparator(s)? 
A0021 What is the reimbursement status of the technology? 
B0004 Who administers the technology and the comparator(s) and in what context  
and level of care are they provided? 
B0018 Are reference values or cut- off points clearly established?  
B0008 What kind of special premises are needed to use the technology  
and the comparator(s)?  
B0009 What equipment and supplies are needed to use the technology? 
 
4.2 Results 
Features of the technology and comparators 
[B0001] – What are Tn-POCT and D-dimer POCT and usual care? 
The biomarkers troponin (Tn) and D-dimer can be measured using a central laboratory (CL; e.g., 
in the hospital or non hospital centered medical loboratories) or by using POCT. The term usual 
care or standard care describes pathways that may or may not include CL. By contrast, a care 
pathway with Tn-POCT or D-dimer POCT is the intervention in this assessment. 
POCTs, near the patient or bedside testing are diagnostic tests that are performed near patients 
rather than in central laboratories [1]. POCTs provide rapid feedback of test results, potentially en-
abling faster decisions about patient management. Both sampling and data analysis are performed 
at the same site, reducing transport and processing delays [2, 3]. 
Yet, it appears that there is no standardised robust definition of POCT within medical literature and 
in clinical practice. The International Organisation for Standardisation (ISO) defines POCT as “(...) 
testing that is performed near or at the site of a patient with the result leading to possible change 
in the care of the patient” [51]. 
While the ISO definition of POCT primarily refers to the geographical point (near the patient), there 
are further aspects that characterise POCT such as the time point (e.g., fast results). The follow-
ing typical characteristics are central for a POCT device [1]. 
• Conducting the testing in the immediate vicinity of the patients 
• Conducting the testing outside of the CL or satellite laboratory 
• No sample preparation and use of full-blood instead 
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• No pipetting steps 
• “Ready to use” reagents 
• Special measuring devices that are specifically designed or used  
for single sample measurement 
• No need for extensive medical-technical training to use the devices 
• Short turnaround time (TAT) 
• Possibility to immediately derive a diagnosis and draw therapeutical consequences  
from the results. 
There are numerous different distinctions of devices in the context of POCT. There are four nota-
ble characteristics when it comes to the available devices in the context of POCT [9]: 
• Hand-held devices [9]: These devices can be qualitative (discrimination against plus/minus 
results) or quantitative (usually this test needs a further analyser; see description of other 
unit-use systems below). 
• Other unit-use or multi-use systems [9]: For each testing, there is a packed strip to be 
used for single-use; whole blood is hereby used. These systems can be designed only for 
one parameter or for different multiple parameters by using different test strips [9]. An ex-
ample of aunit-use POCT systems is the i-STAT manufactured by Abbott [9]. 
• Fixed devices (benchtop-instruments): These devices are complex analytical systems 
that usually need more space than unit-use systems. These analytical systems may be de-
scribed as highly optimised, more compact and user-friendly systems that still use the same 
technology as is used in central laboratories [9]. Examples of small bench-top analysers in-
clude, for instance, the PathfastTM, AQT90 FLEX, and the Stratus® CS 200 Acute Cardiac 
Care device [52]. 
• Lab-on-a-chip systems: This new instrument is aimed to have the whole laboratory testing 
within one chip, but is insufficiently developed and evaluated to be used in clinical practice 
[9]. 
The intervention (implementing Tn-POCT or D-dimer POCT) covers not only the test per se, but 
also, for instance, the training of personnel. The comparator of this assessment (usual care) also 
consists of the same biomarker testing but in a medical laboratory, not at the point of care.The 
reader is referred to chapter 5 for a nuanced description of the potential comparators currently 
used in clinical practice. 
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Table 13: Overview of available Tn-POCT and D-Dimer POCT systems 
 Technologies 
Name Tn-POCT D-dimer POCT 
Proprietary 
name 
(Manufacturer) 
i-STAT cTnI (Abbott Point of Care)  
CARDIAC Troponin T, cobas h 232 (Roche) 
Stratus® CS Analyzer (Siemens) 
Minicare I-20 Troponin I (cTnI) assay (Philips) 
LABGEOIB TnI analyser (Samsung) 
ADEXUSDx® Troponin I Test (NowDiagnostics),  
RAMP® Cardiac Troponin I test (Response 
Biomedical),  
mLabs Troponin I (Micropoint) 
PATHFASTTM (LSI Medience Corporation; 
former Mitsubishi), 
Triage Troponin I Test (Quidel) 
AQT90 FLEX cTnI and AQT90 FLEX cTnT 
(Radiometer),  
Troponin I Test (Eurolyser),  
LifeSign MI TnI (PBM/Lifesign) 
i-CHROMA Diagnostics (Sycomed) 
SimpliRED D-dimer  
(Agen Biomedical) 
NycoCard™ D-dimer Single Test 
(Abbott) 
Triage D-dimer (Quidel) 
Clearview Simplify D-dimer (Alere) 
Roche Cardiac D-dimer (Roche) 
Dade Dimertest (Siemens) 
CS Acute Care D-dimer (Siemens) 
mLabs D-dimer (Micropoint 
Bioscience) 
PATHFAST D-dimer (LSI Medience 
Corporation; former Mitsubishi),  
i-CHROMA D-dimer (SYCOmed) 
AQT90 FLEX D-dimer (Radiometer) 
Note: products were identified using a web-based search. The list of these devices is not exhaustive. 
Abbreviations: Tn-POCT – Troponin point of care testing; D-dimer POCT – D-dimer point of care testing. 
Sources: [53-74]  
 
For Tn-POCT, 15 devices were identified for this assessment. Of these, 14 devices measure tro-
ponin quantitatively and one further device measures it qualitatively. For D-dimer POCT, eleven 
devices were identified, eight of which measure D-dimer quantitatively. When reviewing the char-
acteristics of the identified devices, it is notable that these are heterogeneous between devices 
when it comes to both analytic performance (see differences in analytical range and sample size) 
and further technological characteristics (e.g., as to whether they can be connected to another de-
vice on which diagnostic data can be stored). For a nuanced description of the available devices 
according to information from the manufacturers and online resources, the reader is referred to 
Table 14 and Table 15 for Tn-POCTs and to Table 16 and Table 17 for D-dimer POCTs. 
The identification of all available POCT devices was challenging due to a number of factors: first, 
the vague definition of POCT, which was particularly problematic when the author or manufacturer 
did not use the term POCT as such; second, there are numerous POCT devices on the market 
(as a result, the reader is reminded that the tables are not exhaustive); and third, there are some 
products that measure multiple biomarkers13 in one test. These POCT systems were deemed to 
be beyond the scope of this assessment. 
 
                                                     
13 Products are among others: Samsung LABGEO IB SOB Cardiac 3 Panel Test (Troponin I/NT-proBNP/D-dimer), Samsung 
LABGEO IB CHF Plus Test Troponin I/NT-proBNP, Samsung LABGEO IB Cardiac 3-in-1 Panel Test Troponin I/CK-MB/ 
Myoglobin, ADEXUSDx® Troponin I/Myoglobin Test, Quidel Triage® Cardio 2 Panel (Trop, BNP), Quidel Triage® Cardio 3 
Panel (CK-MB, Trop, BNP), Quidel Triage Meter Pro (Troponin I, CK-MB, Myoglobin, BNP and D-dimer), Quidel Triage 
Cardiac Panel (Myoglobin, CK-MB und Troponin) 
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Table 14: Features of Tn-POCT systems 
Product name 
(manufacturer) 
i-STAT cTnI (Abbott 
Point of Care) 
CARDIAC Troponin T, 
cobas h 232 (Roche) 
Stratus® CS 
Analyzer Tropo-
nin-I (Siemens) 
Minicare I-20 
Troponin-I (cTnI) 
assay (Philips) 
LABGEOIB  
TnI analyser 
(Samsung) 
ADEXUSDx® 
Troponin I Test 
(NowDiagnostics)  
RAMP® Cardiac 
Troponin I test 
(Response Biomedical)  
Source(s) [53] and information 
from manufacturer, [75] 
Information from 
manufacturer, [75] 
[54, 75] [55, 75] [56, 75] [57, 75] [58, 75] 
Qualitative/ 
quantitative or 
semi-quantitative 
Quantitative Quantitative Quantitative Quantitative Quantitative Qualitative Quantitative 
Sample size 17 μL 150 μL N/A N/A N/A N/A 75μL 
Analytical range 
(expected) 
Reportable: 0.00 to 
50.00 ng/mL (µg/L). 
Reference range: 
0.00-0.08 ng/mL 
40-2,000 ng/L 0.03-50 ng/mL N/A 0,05-30 ng/mL N/A N/A 
Cut-off value (ng/l)  80 50 70 N/A 100 N/A N/A 
Coefficient  
of Variation 
10-20% (99th 
percentile) 
N/A <10%  
(99th percentile) 
N/A 10-20%  
(99th percentile) 
N/A N/A 
Storage 
requirements 
Refrigerated at 2 to  
8 ºC until expiration 
date. 
Up to 14 days at 
room temperature 
(20 to 25ºC). 
Individual cartridges 
may be used after 
standing five minutes 
at room temperature. 
All cartridges should 
be used immediately 
after opening pouch. 
Until the printed expi-
ration date at 2-8 °C. 
Up to 1 week at  
room temperature  
(15-25 °C). 
The test can be used 
immediately after 
removal from the 
refrigerator. 
The test must be used 
within 15 minutes once 
the pouch has been 
opened. 
N/A N/A N/A 4-30 °C N/A 
Performance time  10 min <12 min 14 min 10 min 20 min 15 min 19 min 
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Product name 
(manufacturer) 
i-STAT cTnI (Abbott 
Point of Care) 
CARDIAC Troponin T, 
cobas h 232 (Roche) 
Stratus® CS 
Analyzer Tropo-
nin-I (Siemens) 
Minicare I-20 
Troponin-I (cTnI) 
assay (Philips) 
LABGEOIB  
TnI analyser 
(Samsung) 
ADEXUSDx® 
Troponin I Test 
(NowDiagnostics)  
RAMP® Cardiac 
Troponin I test 
(Response Biomedical)  
Connectivity Wireless or wired 
data transfer 
(pending on i-STAT 
analyzer used) with 
flexible connectivity 
and interfacing 
software solutions, 
e.g. Abbott Info HQ. 
Wireless technology 
(COBAS ®Technology 
required) 
N/A Minicare's built-in 
connectivity auto-
matically updates 
the information in a 
patient's electronic 
file as soon as the 
reading has been 
obtained. 
N/A N/A N/A 
Print function Yes (via separate  
i-STAT printer) 
N/A N/A N/A Yes N/A N/A 
Data storage on 
device 
Up to 1,000  
test records 
2,000 patient test results  
500 QC test results  
200 IQC test results 
N/A N/A N/A N/A N/A 
Note: All cut-off values and coefficient of variation values were used from a recent publication [75] that tried to standardise these using ng/l instead of μg/l; NA – not applicable or not available. 
Abbreviations: IQC – internal quality control; QC – quality control. 
 
Table 15: Features of Tn-POCT systems (continued) 
Product name 
(manufacturer) 
mLabs 
Troponin I 
(Micropoint) 
PATHFASTTM High 
Sensitivity POC Troponin I 
(LSI Medience Corporation; 
former Mitsubishi),  
Triage 
Troponin I 
Test (Quidel) 
AQT90 FLEX cTnI 
(Radiometer),  
AQT90 FLEX  
cTnT (Radiometer) 
Troponin I 
test 
(Eurolyser) 
LifeSign MI 
TnI (PBM/ 
Lifesign) 
i-CHROMA 
Tn-I 
Diagnostics 
(Sycomed)14 
Source(s) [59, 75] [60, 75] [61, 62, 75] [63, 75] [63, 75], information 
from manufacturer 
[64, 75] [65, 75] [66, 75] 
Qualitative/ 
quantitative or 
semi-quantitative 
Quantitative Quantitative Quantitative Quantitative Quantitative Quantitative Qualitative Quantitative 
                                                     
14 The only identified information was retrieved from a company called KIN Diagnostics. In the medical literature, the test is referred to be considered as belonging to Sycomed.  
It was unclear to the review authors which company lastly sells this device. 
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Product name 
(manufacturer) 
mLabs 
Troponin I 
(Micropoint) 
PATHFASTTM High 
Sensitivity POC Troponin I 
(LSI Medience Corporation; 
former Mitsubishi),  
Triage 
Troponin I 
Test (Quidel) 
AQT90 FLEX cTnI 
(Radiometer),  
AQT90 FLEX  
cTnT (Radiometer) 
Troponin I 
test 
(Eurolyser) 
LifeSign MI 
TnI (PBM/ 
Lifesign) 
i-CHROMA 
Tn-I 
Diagnostics 
(Sycomed)14 
Sample size 250 μl 100 μl N/A 2 mL whole blood  
(for up to 5 tests) 
2 mL whole blood  
(for up to 5 tests) 
N/A 120 μL N/A 
Analytical range 
(expected) 
0.02 to  
50 ng/ml 
2.33-50,000 ng/L N/A Reportable range: 
0.01-25 µg/L (ng/mL) 
Reportable range: 
0.01-25 µg/L 
1,00- 
10.00 ng/ml 
N/A 0.01- 
15.00 ng/mL 
Cut-off value 
(ng/l) 
N/A 20 N/A 99th percentile: 23 ng/L 99th percentile: 17 ng/L 1,500 N/A N/A 
Coefficient of 
Variation 
N/A < 10% (99th percentile) N/A 0.021 μg/L: CV = 12.9 % 
0.035 μg/L: CV = 7.7 % 
9.2 μg/L: CV = 4.4 % 
0.027 µg/L: CV = 9.6 % 
0.21 µg/L: CV = 5.6 % 
12.0 µg/L: CV = 5.4 % 
N/A N/A N/A 
Storage 
requirements 
2-8 oC N/A N/A Whole blood:  
2 hours at 18-25 °C 
Plasma:  
2 hours at 18-25 °C 
Plasma:  
24 hours at 2-8 °C 
Plasma:  
>24 hours at -18 °C 
Whole blood:  
3 hours at 18-25 °C 
Plasma:  
3 hours at 18-25 °C 
Plasma:  
24 hours at 2-8 °C 
Plasma:  
>24 hours at -18 °C 
2-8 °C. 2-30 °C. 4-30 °C. 
Performance time  < 8 min < 17 min 20 min < 19 min < 13 Min 10 min 15 min N/A 
Connectivity N/A N/A Quidel Triage 
Census®-
Software 
Yes Yes N/A N/A N/A 
Print function N/A Yes Yes Yes Yes N/A N/A N/A 
Data storage on 
device 
N/A Patient data: 1,000, QC 
data: 1800, CAL data: 300 
Yes Yes Yes N/A N/A N/A 
Notes: All cut-off values and coefficient of variation values were used from a recent publication [75] that standardised these using ng/l instead of μg/l; 
N/A – information was not available or not found within the online search 
Abbreviations: IQC – internal quality control; QC – quality control. 
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Table 16: Features of D-dimer POCT systems 
Product name 
(manufacturer) 
SimpliRED D-dimer 
(Agen Biomedical) 
NycoCard™ D-dimer Single Test  
(Abbott) 
Triage D-dimer 
(Quidel) 
Clearview Simplify D-dimer 
(Sekisui) 
Roche CARDIAC D-DIMER 
(Roche) 
Source No source identified Information from manufacturer, [76] [67] [77] [68] and information from 
manufacturer 
Qualitative/ 
quantitative or 
semi-quantitative 
Qualitative 15 Quantitative Quantitative Qualitative Quantitative 
Sample size N/A 50 μL N/A N/A 150 μL 
Analytical range 
(expected) 
N/A 0.1-20.0 mg/L 100-5,000 ng/mL N/A 0.1-4 μg/mL 
Cut-off value N/A 0.3 mg/L N/A N/A 0.5 µg/mL 
Coefficient of 
Variation 
N/A ≤ 15% in the measuring range below 10 mg/L  
> 15% in the measuring range above 10 mg/L 
N/A N/A NA 
Storage 
requirements 
N/A 2-8 °C 2-8 °C 2-25 °C 2-8 °C. 
Performance time  N/A <3 min Appr. 20 min 10 min 8 min 
Connectivity N/A N/A N/A N/A Wireless technology 
(COBAS® Technology 
required) 
Print function N/A N/A Yes N/A N/A 
Data storage on 
device 
N/A N/A Yes N/A 2,000 patient test results  
500 QC test results  
200 IQC test results 
Notes: N/A – information was not available or not found within the online search 
 
                                                     
15 Information was retrieved from a secondary literature [47]. 
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Table 17: Features of D-dimer POCT systems (continued) 
Product name 
(manufacturer) 
Dade Dimertest Latex 
assay (Siemens) 
Stratus CS Acute 
Care D-dimer 
(Siemens) 
mLabs D-dimer 
(Micropoint 
Bioscience) 
PATHFAST D-dimer 
(LSI Medience 
Corporation; former 
Mitsubishi) 
i-CHROMA D-dimer 
(Boditech ) 
AQT90 FLEX D-dimer 
(Radiometer) 
Source [78] [71, 72] [69] [70] [79, 80] Information from 
manufacturer, [73] 
Qualitative/ 
quantitative or 
semi-quantitative 
Qualitative/ 
semi-quantitative 
Quantitative Quantitative Quantitative Quantitative Quantitative 
Sample size N/A N/A 250 μL 100 μl N/A 2 mL whole blood  
(for up to 5 tests) 
Analytical range 
(expected) 
N/A 6 – 5,000 ng/mL 100-10,000 ng/ml 
 
0.005-5 μg/mL 50~10,000 ng/mL 80-100,000 μg/L. 
Cut-off value NA NA NA NA 500 µg/L 500 µg/L 
Coefficient of 
Variation 
NA 4.1 % at 412 ng/mL NA NA NA 194 µg/L: CV = 15.3 % 
572 µg/L: CV = 12.8 % 
61,614 µg/L: CV = 7.4 % 
Storage 
requirements 
2-8°C N/A 2-8°C N/A 4-30°C. Whole blood: 3 hours at 
18-25 °C 
Performance time N/A 14 min 4-10 min 15 min 12 min 20 min 
Connectivity N/A N/A N/A NR N/A Yes 
Print function N/A N/A N/A Yes N/A Yes 
Data storage on 
device 
N/A N/A N/A Patient data: 1,000 
QC data: 1,800 
CAL data: 300 
N/A Yes 
Notes: N/A – information was not available or not found within the online search 
Abbreviations: IQC – internal quality control; QC – quality control. 
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[A0020] – For which indications have the Tn-POCT and D-dimer POCT  
received marketing authorisation or CE marking? 
Tn-POCT and D-dimer POCTs are in vitro diagnostic tests that are used in the diagnosis and treat-
ment of myocardial infarction and pulmonary embolism (PE)/deep vein thrombosis (DVT) respec-
tively [53-74]. The reader is referred to chapter 5 for the current use of, and indications for, the use 
of the diagnostics under evaluation. 
Both of the POCTs are subject to in-vitro diagnostic regulation (IVDR) from the European Union 
(EU) 2017/746 [81]. The IVDR replaced the former directive on in-vitro diagnostics (IVD) directive 
98/79/ec [82]. Currently, there is a transition period, making the regulation fully applicable in May 
2022 [83]. The aim of the new regulation is to harmonise and strengthen the regulation within the 
EU. Substantial changes are notable such as the rule-based classification system as opposed to 
the list-based approach that was previously in place. Also, new concepts of both performance eval-
uation and the role of clinical evidence are being introduced [84]. 
 
[B0002] – What is the claimed benefit  
of a pathway with Tn-POCT and D-dimer POCT in relation to usual care? 
Tn-POCT has the advantage to decrease the TAT when compared to a pathway with clinical ad-
judication and CL. POCT usually does not replace the CL but it may be described as having an 
“oversight” role. As a result, the timely results (due to shorter TAT) may leverage a clinically im-
portant advantage with regard to adequate decision making in comparison to CL testing/no imme-
diate testing [4]. This can also lead to an optimisation of resource use [85]. 
For Tn-POCT and D-dimer POCT, it is expected that the decreased TAT also translates into a de-
crease of length of stay (LOS). In some settings (such as rural or remote areas), POCT devices are 
also expected to avoid expensive, unnecessary transportation costs, especially in the context of 
Tn-POCT, if timely testing leads to triage referrals to the main centres [4]. Tn-POCT is especially 
sought to be beneficial in settings where CL testing is not onsite or not available 24 hours per/ 
every day, because time is critical in the diagnosis of acute coronary syndrome (ACS). Furthermore, 
POCT may, especially in the context of implementing D-dimer POCT, further reduce hospital im-
aging [4]. 
On the other hand, the claimed benefit of CL testing is that it usually has better diagnostic perfor-
mance: Tn-POCT is, for instance, expected to have lower sensitivity, a lower diagnostic accuracy 
and a lower negative predictive value (NPV) in comparison to CL testing [4]. 
POCT devices may also be further harmful when compared to CL testing, if quality standards are 
not upheld. Incorrect results may lead to undesirable effects that could have otherwise been pre-
vented [86]. Therefore, analytical and diagnostic performance is of great importance in the context 
of POCT devices. These may suffer from increased risk of error in the pre-, intra-, and post-analyt-
ical period. In the pre-analytical period, for instance, one problem may be that further parameters 
are measured that are beyond the scope of the actual clinical question. For instance, the biomarkers 
myoglobin and Creatin-Kinase Muscle-Brain (CK-MB) are often used with Tn-POCT devices even 
though there is proof that they do not exhibit valuable additional information [86]. In the intra-ana-
lytical period, some POCT devices’ measurements may be more inconclusive [86]; e.g., POCT de-
vices measuring cardiac Tn have been critiqued to not meeting recommended quality standards 
[87]. In the post-analytical period, risks of error may include the poorer documentation (that is often 
handwritten), and, in combination with the fast accessibility of the results, can lead directly to harms 
to the patients [86]. As a result, it is mandatory to reflect on strategies with regard to quality assur-
ance when implementing these devices [88].  
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[B0003] – What is the phase of development and implementation 
of Tn-POCT and D-dimer POCT and the comparators? 
[A0021] – What is the reimbursement status of Tn-POCT and D-dimer POCT? 
The manufacturers were asked for information on the reimbursement status of the POCT devices 
under evaluation. However, we only received some information on the reimbursement status. For 
products of the company radiometer, Tn-POCT and D-dimer POCT are currently reimbursed in Italy, 
Belgium, Netherlands, Czech Republic, Germany, France, Hungary, Switzerland and Turkey (see 
Table 18). 
Table 18: Overview of countries providing reimbursement for the AQT90 Flex analyser 
Country cTnI cTnT D-dimer 
Austria    
Italy Y Y Y 
Lithuania    
Belgium Y Y Y 
Netherlands Y Y Y 
Czech Rep. Y Y Y 
Denmark    
Germany Y Y Y 
Spain    
France Y Y Y 
Hungary Y Y Y 
United Kingdom    
Schwitzerland Y Y Y 
Turkey Y Y Y 
Finland    
Norway    
Sweden    
Note: Radiometer kindly provided us with this information. “Y” means that it is currently reimbursed. 
Abbreviations: cTnI – cardiac troponin I; cTnT – cardiac Troponin T; Y – yes. 
 
[B0004] – Who administers Tn-POCT and D-dimer POCT and the comparator(s)  
and in what context and level of care are they provided? 
Both of the technologies under evaluation are used by healthcare professionals. Tn-POCT16 and 
D-dimer POCT may be used in emergency care settings such as emergency departments (ED) as 
well as primary care settings [5-7]. Tn-POCT may further be used in other pre-hospital emergency 
medicine (PHEM) settings such as in ambulance cars [5]. 
                                                     
16 For Tn-POCT, certain in-hospital settings such as intensive care units may also be a setting where Tn-POCT may be used, 
but these settings were beyond the scope of this assessment [4].  
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[B0018] – Are reference values or cut- off points clearly established?  
Ideally, devices measuring cardiac Tn should meet a 10% coefficient of variation (CV) at the 99th 
percentile upper reference limit. However, for POCT devices in the context of Tn, a CV of ≤ 20% 
at the 99th percentile upper reference limit (URL) is regarded as being acceptable in the medical 
literature [46]. Tn assays are – regardless of whether tested in a CL or at the point of care – nei-
ther standardised nor are they harmonised. That is to say; every assay uses a distinct set of anti-
bodies for capturing and detecting Tn in the blood [8]. In addition, most of the data on analytical 
characteristics stem from the manufacturers, as opposed to solid data from studies that have been 
published in peer-reviewed academic journals. This data often does not correspond to data in clini-
cal laboratories in clinical practice [46].  
For D-dimer assays, the commercially available devices approved by the Food and Drug Admin-
istration (FDA) vary greatly when it comes to reference values and clinical cut-offs [7]. When using 
CL testing, a normal range of D-dimer is considered to be less than 500 ng/ml [3, 89, 90]. Ideally, 
the clinical laboratory should establish the reference range and cut-off value. In case a cut-off value 
from the literature is used, it is mandatory that the methodology of measurement is identical – pre-
ferably also coming from the same manufacturer. Some POCT devices also test D-dimer semi-
quantitatively based on latex agglutination. This testing, however, is less clinically valuable due to 
a high inter-observer variability [91]. 
 
[B0008] – What kind of special premises are needed  
to use the technology and the comparator(s)? Overlaps with: B0009 
[B0009] – What equipment and supplies are needed to use POCT devices? 
Test kits and/or analysers and adequate know-how are required to use the POCT devices. How-
ever, the required equipment and supplies strongly depend on the type of POCT being implement-
ed. If fixed devices (benchtop-instruments) are implemented, one has to further think of where the 
analysers are to be positioned because these tests technically cannot be moved but have a spe-
cific location, e.g., in doctor’s office or ambulance [9].  
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5 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
5.1 Research questions 
Element ID Research question 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What are the symptoms and the burden of disease or health condition  
for the patient? 
A0006 What are the consequences of the disease or health condition for society?  
A0024 How is the disease or health condition currently diagnosed according  
to published guidelines and in practice? 
A0025 How is the disease or health condition currently managed according  
to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much are the technologies utilised? 
 
5.2 Results Tn-POCT 
Overview of the disease or health condition 
[A0002] – What is acute coronary syndrome (ACS) in the scope of this assessment? 
ACS is a health condition encompassing means and spectrum of signs and symptoms caused by 
a decreased blood flow in the coronary arteries (myocardial ischemia). The term ACS is used for 
patients that present with suspected or confirmed acute myocardial ischemia or infarction (MI). 
There are different types of ACS such as non-ST elevation myocardial infarction (NSTEMI), ST-
elevation myocardial infarction (STEMI) or unstable angina (UA) [10, 11].  
ACS can be categorized in terms of the ST-segment elevation into two groups: 
• Persistent (>20 min) ST-segment elevation with acute chest pain. The persistent ST-eleva-
tion is indicative of immediate coronary angiography because patients normally have an 
acute total coronary occlusion and most of them develop an STEMI [14]. 
• No persistent ST-elevation with acute chest pain. This condition is suggestive of non-ST 
segment elevation ACS (NSTE-ACS) [14]. These patients present a broad clinical spectrum 
and can further be divided on the basis of cardiac biomarkers of necrosis to NSTEMI or UA. 
UA is characterised by myocardial ischemia without elevated biomarkers and means a po-
tentially reversible phase [11, 14, 19]. 
 
[A0003] – What are the known risk factors for ACS? 
Factors that could increase the probability of developing ACS are older age, male sex, positive 
family history of coronary artery disease (CAD), the presence of peripheral arterial disease, diabe-
tes mellitus, hyperlipidaemia, hypertension, renal insufficiency, prior MI, and prior revascularization 
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[11, 14]. ACS occurs three to four times more often in men than in women below the age of 60 
years, but after the age of 75, women represent the majority of patients. Women tend to present 
more often with atypical symptoms [12].  
 
[A0004] – What is the natural course of ACS? 
Most patients presenting with NSTE-ACS will develop NSTEMI, and most patients presenting with 
ST-elevation ACS will ultimately develop STEMI [14]. MI, whether STEMI or NSTEMI, is defined 
as the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting 
of evidence of acute myocardial ischemia [92]. The treatment of MI is time-critical as the condition 
can lead to death. Overall, NSTEMI patients appear to have lower short-term mortality compared 
with STEMI individuals [11, 14], while at 1- or 2-years follow up the mortality rates become com-
parable (likely due to differences in baseline characteristics, including older age and a greater pre-
valence of co-morbidities in the NSTEMI population) [14]. Patients with UA do not develop myo-
cardial necrosis and have a considerably lower risk of death [14].  
 
Effects of the disease or health condition 
[A0005] – What are the symptoms and the burden of ACS? 
The main symptom of suspected ACS is chest pain. The clinical spectrum of NSTE-ACS may range 
from patients free of symptoms at presentation to individuals with ongoing ischemia, electrical or 
haemodynamic instability or cardiac arrest [14]. NSTE-ACS most commonly presents as a pres-
sure-type chest pain (angina) that typically occurs at rest or with minimal exertion lasting at least 
10 minutes [11], or according to the ESC definition [14] over 20 minutes, radiating to the left arm 
(or both arms or the right arm), neck or jaw [11, 14]. Patients with NSTE-ACS may also present 
with diaphoresis, sweating, dyspnoea, nausea, abdominal pain, or syncope [11, 14]. Atypical symp-
toms include epigastric pain, indigestion-like symptoms, stabbing or pleuritic pain and isolated dys-
pnoea. Atypical symptoms appear more frequently in women, older patients over 75 years, pa-
tients with diabetes mellitus and chronic renal disease or patients with dementia [11, 14]. 
Likewise, the main symptom of STEMI is chest pain, including various combinations of chest, up-
per extremity, mandibular, or epigastric discomfort during exertion or at rest, or an ischaemic equiv-
alent such as dyspnoea or fatigue. Often, the discomfort is diffuse; not localized, nor positional, 
nor affected by movement of the region. However, these symptoms are not specific for myocardial 
ischaemia and can be observed in other conditions such as gastrointestinal, neurological, pulmo-
nary, or musculoskeletal complaints. MI may occur with atypical symptoms such as palpitations or 
cardiac arrest, or even without symptoms [92]. 
 
[A0006] – What are the consequences of ACS for society? 
Ischemic heart disease (IHD) remains among the leading causes of mortality globally. In Europe, 
approximately 1,800,000 persons die due to IHD yearly. This is 20 percent of all deaths in Europe, 
although the variation among countries is substantial [12, 13]. 
While the incidence of STEMI has decreased considerably over the last decade; the rate of NSTEMI 
has slightly increased [14]. The incidence rate of STEMI ranges from 43 to 144 per 100,000 per 
year in the various European countries [12].  
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STEMI mortality remains substantial; the inhospital mortality in the national registries in the ESC 
countries varies between 4 and 12 percent, while 1-year mortality among STEMI patients in angi-
ography registries is approximately 10 percent [12]. 
The 28-day case mortality rate for ACS among patients in developed nations is approximately 10 
percent, but varies with the severity of the disease and the treatment provided. Less than 15 to 30 
percent of patients who present to the ED with nontraumatic chest pain have ACS (including MI 
and UA) [93].  
 
Current clinical management of the disease or health condition 
[A0024] – How is ACS currently diagnosed according  
to published guidelines and in practice? 
The most common symptom suggestive of ACS is chest pain. It is important to rapidly identify the 
cause of the chest complaint to be able to promptly start appropriate therapy, as early intervention 
has shown to have better outcomes [11]. The causes of chest pain can be distinguished into two 
main categories: non-ischemic cardiovascular causes (aortic dissection, expanding aortic aneurysm, 
pulmonary embolism etc.) and non-cardiovascular causes (pulmonary, gastrointestinal, musculo-
skeletal, psychiatric disorders, other) [11].  
The primary goal of early evaluation/initial assessment (within 15 minutes after presentation) is to 
confirm the diagnosis of ACS (“rule-in”) or exclude ACS as the cause of the symptoms (“rule-out”). 
In the course of the risk assessment, the likelihood that the symptoms represent ACS and the like-
lihood of adverse outcomes is evaluated and patients are assigned to low, intermediate, or high 
risk for ACS, based on information obtained from the patients’ medical history, physical examina-
tion, electrocardiogram (ECG) and cardiac troponins. The determination of the level of risk on ini-
tial evaluation is vital to guide patient management, including the need for additional diagnostic 
testing and treatment [11]. 
Several scoring systems and clinical prediction algorithms have been developed for risk assess-
ment, and different guidelines have endorsed different systems. The AHA/ACC recommends for 
the assessment of patients presenting to the ED with undifferentiated chest pain the TIMI risk 
score, PURSUIT risk score, GRACE risk score, and the National Cardiovascular Data Registry’s 
Action Registry (NCDR-ACTION registry). The Sanchis score, Vancouver rule, Heart score and 
HEARTS3 score, and Hess prediction rule were developed specifically for the assessment of pa-
tients presenting with chest pain at the ED [11]. The ESC recommends the GRACE risk score or 
GRACE 2.0, and the TIMI risk score [14].  
Steps of the initial assessment of patients with suspected ACS 
Evaluation consists of an initial physical examination and medical history, which considers factors 
related to the likelihood of ACS such as age, sex, symptoms, prior history of coronary artery dis-
ease (CAD) and the number of traditional risk factors [11]. The initial physical examination focus-
es on findings that permit rapid triage and immediate diagnosis. Comorbid conditions and non-
coronary causes of chest pain or extracardiac pathologies are identified [11, 14].  
The resting 12 lead ECG is an important diagnostic tool in the initial assessment of patients with 
suspected ACS. Based on the ECG, the ST-segment elevation can be examined and the type of 
ACS decided on: STEMI in case of persistent ST-segment elevation or NSTE-ACS in case of non-
ST-segment elevation. ECG should be done within 10 minutes of arrival to the ED or at first con-
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tact with emergency medical services in the pre-hospital setting and must be interpreted by a 
qualified physician [11, 14, 15, 19, 27]. Outpatient facilities should have the capacity for ECG and 
cardiac troponin measurements with immediate ED referral because STEMI, as well as NSTEMI 
is a serious emergency and should be treated immediately [11]. ACS can often fail to be diag-
nosed with an initial ECG; the ECG results might be normal even when the patient has ACS. It is 
therefore recommended to obtain additional 12-lead ECGs in case of persistent or recurrent symp-
toms or diagnostic uncertainty [11, 19].  
Biomarkers complement the clinical assessment and 12-lead ECG in the diagnosis, risk stratifica-
tion and treatment of patients with suspected NSTE-ACS. Measurement of a biomarker, prefera-
bly high-sensitivity cardiac troponin I/T ((cTnI/cTnT) is mandatory in all patients with suspected 
NSTE-ACS to help to distinguish between UA and NSTEMI. Troponin should be measured at 
presentation and also later to identify a rising and/or falling pattern [14].  
 
Figure 8: Initial assessment of patients with suspected ACS 
Source: ESC [14] 
 
Diagnostic algorithms (rule-in and rule-out algorithms) 
Different guidelines recommend using different rule-in and rule-out algorithms for the diagnosis of 
ACS based on the initial risk stratification and the type of available troponin assay. Early rule-out 
protocols typically involve cardiac troponin measurements on presentation and 3 to 6 hours later 
with a high-sensitivity assay [11, 15, 19]. Moreover, the ESC recommends that the 0h/3h algorithm 
can be shortened to 0h/1h. The cut-off levels within the 0h/1h algorithm are assay dependent and 
always have to be accompanied by a detailed clinical assessment and ECG and repeat blood 
sampling if the chest pain is recurrent or ongoing [14]. 
The AHA/ACC recommends that additional troponin levels should be obtained beyond 6 hours 
after symptom onset in patients with normal troponins on serial examination when ECG changes 
and/or clinical presentation confer an intermediate or high index of suspicion for ACS. Patients with 
suspected ACS and high-risk features should be referred to the ED immediately. Patients with less 
severe symptoms may be considered for referral to the ED, a chest pain unit, or a facility capable 
of performing adequate evaluation [11]. In patients with possible ACS and a normal ECG, normal 
High LikelihoodLow Likelihood
1. Presentation
2. ECG
3. Troponin
4. Diagnosis Non-cardiac UA OtherCardiac NSTEMI STEMI
STEMI = ST-elevation myocardial infarction; NSTEMI = non-ST-elevation myocardial infarction; UA = unstable angina.
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cardiac troponins, and no history of CAD, it is reasonable to initially perform (without serial ECGs 
and troponins) coronary computerized tomography (CT) angiography to assess coronary artery 
anatomy (or rest myocardial perfusion imaging with a technetium-99m radiopharmaceutical to ex-
clude myocardial ischemia) [11]. The ESC recommends that coronary angiography should be con-
sidered in high-risk patients, while in patients with low to intermediate likelihood of NSTE-ACS, CT 
coronary angiography should be considered [14]. Other life-threatening conditions presenting with 
chest pain, such as aortic dissection and pulmonary embolism, may also result in elevated tropo-
nin levels and should be considered as differential diagnoses [14, 19].  
Guidelines on the use of Troponin POCT 
Eight CPGs met our inclusion criteria and were included in the guideline synopsis [11, 14-16, 27-
30]. Six guidelines [11, 14-16, 28, 30] were developed for the outpatient setting (ED, pre-hospital, 
primary care, ambulance), one guideline was developed for disaster medicine [29], one guideline 
did not specifically define the setting but states the guideline is applicable for all cardiac caregiv-
ers [27]. Two guidelines [15, 29] contain recommendations on the diagnosis of several health con-
ditions including ACS. Therefore we included this guideline in the guideline synopsis on both tro-
ponin and D-dimer POCT. One of these guidelines was developed to make recommendations if 
the patients present with chest pain and this included the diagnosis of both pulmonary embolism 
(PE) and ACS [15]. The other guideline was developed for disaster medicine and includes rec-
ommendations on the diagnosis of both DVT and ACS [29]. The overview of the included guide-
lines including the issuing society, the date of issue, and the summary of the recommendation and 
the level of evidence/class of recommendation can be found in Table A2 in the appendix. 
None of the included guidelines makes a recommendation regarding the optimal timing of testing, 
and the diagnostic thresholds and pathways with the reasoning that POCTs continuously and rap-
idly improve and their performance characteristics are both assay and hospital dependent. One 
guideline [16] specifically states that no recommendations can be made due to lack of or weak evi-
dence. Five guidelines only mention that POCT can be used for the measurement of cardiac tropo-
nins [11, 19, 27, 29, 30]. The German Society of General Practice and Family Medicine (DEGAM 
[15] recommends not to use qualitative troponin test routinely in primary care to exclude an acute 
MI and one guideline recommends the use of sensitive or high-sensitivity assays only [14]. Three 
guidelines stress that the cardiac maker testing TAT should be maximum one hour [14, 27, 30]. 
Two guidelines come to the conclusion that if institutions cannot comply with this requirement, 
POCT should be implemented [27, 30]. The National Academy of Clinical Biochemistry (NACB) [30] 
suggests that troponin tests should provide not only qualitative but also quantitative information. 
According to the ESC and AHA guidelines, the sensitivity of Tn-POCT is considered to be below 
that of CL assays and they cannot be considered sensitive or highly-sensitive [11, 14]. On the 
other hand, SIGN states that Tn-POCT licensed in the UK are equivalent in sensitivity to the 12 
hour laboratory-based standard Tn assays [28]. The ESC recommends high-sensitivity assays 
over less sensitive ones [14]. According to the ESC, Tn-POCT values may provide initial diagnos-
tic information, but the advantage of shorter TAT is counterbalanced by lower sensitivity, lower 
diagnostic accuracy and lower NPV. Furthermore, the rigorous quantitative assay standardization 
that is needed for routine diagnosis favours CL testing [11]. 
Primarily, clinicians should be aware of the sensitivity of the tests used for troponin evaluation in 
their hospitals and cut-off point concentrations for clinical decisions [11]. The diagnostic thresholds 
depend not only on the type of the assay but also on the characteristics of the reference popula-
tion (e.g. sex) [28]. 
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The quality appraisal of the guidelines can be found in Table A11 in the Appendix. A major limita-
tion of the guideline synopsis is that recent guidelines, published in the last three years, could not 
be identified. This must be taken into consideration when relying on the conclusions of the guide-
lines as there might be a need for update especially with the rapid technological developments in 
the field. Other limitations include a lack of clarity whether patients’ views and preferences were 
sought, whether the guidelines were piloted among target users, missing procedures or plans for 
updating the guidelines, missing monitoring/auditing criteria, and potential cost implications of ap-
plying the recommendations was often not considered. There are some methodological weakness-
es in terms of the rigour of development and missing information on editorial independence espe-
cially in two guidelines [15, 27]. 
 
[A0025] – How is ACS currently managed according to published guidelines and in practice? 
The standard of care for patients who present with ACS, including those with recurrent symptoms, 
ischemic ECG changes, or positive cardiac troponins, is admission to hospital. The primary focus 
in the first 12 hours is the immediate relief of ischemia and the prevention of MI and eventually 
death. Patients undergo continuous ECG rhythm monitoring and observation for recurrent ische-
mia [11]. Patients with suspected ACS in the ambulance are assessed in the pre-hospital envi-
ronment and receive treatment prior to admission to hospital, which may include administration of 
dual antiplatelet therapy [28].  
Two treatment pathways are available for patients with NSTE-ACS: the invasive strategy triages 
patients to an invasive diagnostic evaluation (i.e., coronary angiography). The initial ischemia-
guided strategy requires an invasive evaluation of only those who fail to respond to medical ther-
apy, have objective evidence of ischemia, or have clinical indicators of very high prognostic risk. 
In both strategies, patients should receive anti-ischemic and antithrombotic medical therapy [11].  
STEMI is a serious emergency and should be treated with immediate reperfusion. Primary PCI is 
the preferred reperfusion strategy within 12 hours of symptom onset, provided it can be performed 
120min from STEMI diagnosis by an experienced team [12]. 
 
Target population 
[A0007] – What is the target population of this assessment? 
The target population for the use of Tn-POCT is adult patients presenting with signs and symp-
toms of MI. Troponin tests can spare the referral of patients to an inpatient unit in cases where 
there are no ischemic ECG changes, if there is clinical ambiguity, and if symptoms last for more 
than 12 hours [15]. 
 
[A0023] – How many people belong to the target population? 
ACS is estimated to have an annual incidence rate of over 780,000 cases in the United States. 
Approximately 70% of these have NSTE-ACS [11]. While the incidence of STEMI has decreased 
appreciably over the last decade, the rate of NSTEMI has slightly increased [14].  
In Europe, approximately 1,800,000 persons die due to IHD yearly. The incidence cases of IHD 
accounted for around 5,5 million in 2015 in Europe [13].  
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[A0011] – How much are the technologies utilized?  
All patients who present to the ED with symptoms suspicious of cardiac ischaemia should be eval-
uated with cardiac biomarkers as part of the initial evaluation [16]. Cardiac specific troponin is the 
most widely utilized diagnostic biomarker for myocardial infarction and is the preferred laboratory 
test. (LOE I) [16]. In the general practitioner (GP) praxis (according to the DEGAM guideline), the 
measurement of the cardiac troponin is only useful in clinically ambiguous cases when the symp-
tom onset exceeds 12 hours [15].  
 
5.3 Results D-dimer POCT 
Overview of the disease or health condition 
[A0002] – What is venous thromboembolism (VTE) in the scope of this assessment?  
Venous thromboembolism (VTE) is a condition in which a blood clot (a thrombus) forms in a vein 
and then dislocates to travel in the blood (an embolus). A venous thrombus most commonly occurs 
in the deep veins of the legs or pelvis; this is then called a DVT. Blood flow through the affected 
vein can be limited by the clot, and it can cause swelling and pain in the leg. If it dislodges and 
travels to the lungs (to the pulmonary arteries), it is called a pulmonary embolism (PE), which in 
some cases may be fatal. VTE as a term includes both DVT and PE [18]. 
 
[A0003] – What are the known risk factors for VTE? 
There are a number of environmental (also known as temporary or setting-related) as well as genet-
ic (also called as permanent or patient-related) risk factors for VTE. These can also be grouped 
into strong, moderate and weak categories. Strong predisposing risk factors are (odds ratio >10): 
fracture of the lower limb, hospitalisation for atrial fibrillation or heart failure within the last 3 months, 
hip or knee replacement, major trauma, myocardial infarction within the last 3 months, previous 
VTE, spinal cord injury. Moderate risk factors (odds ratio 2-9): arthroscopic knee surgery, auto-
immune diseases, blood transfusion, central venous illness, chemotherapy, congestive heart or 
respiratory failure, erythropoiesis-stimulating agents, hormone replacement therapy, in vitro fertili-
zation, infection (especially pneumonia, HIV, urinary tract infection), inflammatory bowel disease, 
cancer, oral contraceptive therapy, paralytic stroke, postpartum period, superficial vein thrombosis, 
thrombophilia. Weak risk factors (odds ratio <2): bed rest longer than three days, diabetes mellitus, 
hypertension, immobility due to sitting e.g. due to prolonged air or car travel, increasing age, obe-
sity, pregnancy, laparoscopic surgery and varicose veins [17].  
 
[A0004] – What is the natural course of VTE? 
VTE may be fatal in the acute phase or lead to chronic disease and disability. Acute PE is the 
most serious clinical presentation of VTE and is often the consequence of undiagnosed and/or un-
treated DVT [17]. Non-fatal VTE can cause serious longer-term conditions such as post-thrombotic 
syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH). PTS is a chronic 
condition that may develop after DVT due to damage to the deep veins and their valves. It affects 
20%-40% of patients after DVT of the lower limb, can be debilitating to patients, and have a signif-
icant impact on quality of life (QoL). CTEPH is less common and is caused by obstruction of the 
pulmonary arteries due to PE. This puts excessive pressure on the heart which can be harmful to 
some patients, causing heart failure [18]. The incidence of CTEPH after PE is currently estimated at 
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approximately 1.5% (with a wide range reported by mostly small-cohort studies), with most cases 
appearing within 24 months of the index event [17].  
VTE can be recurrent. The rate of recurrence is highest during the first two weeks and declines 
thereafter. The risk of recurrence is predicted to be higher in the early period if the patient has 
active cancer or fails to rapidly achieve therapeutic levels of anticoagulation. The frequency of 
recurrence does not appear to depend on the clinical presentation (DVT or PE) of the first event, 
but recurrent VTE is likely to occur in the same clinical form as the index episode. Recurrence is 
more frequent after multiple VTE episodes as opposed to a single event, and after unprovoked 
VTE as opposed to if the patient is exposed to temporary (setting-related) risk factors, particularly 
surgery. It is also more frequent in women who continue hormone intake after a VTE episode and 
in patients who have had PE or proximal vein thrombosis compared to calf vein thrombosis. Ele-
vated D-dimer levels also indicate an increased risk of recurrence [17].  
 
Effects of the disease or health condition 
[A0005] – What are the symptoms and the burden of VTE for the patient? 
Clinical signs and symptoms of VTE are non-specific and often asymptomatic.  
• DVT: if it is symptomatic, the most common symptoms are leg pain and/or swelling, redness 
and warmth in the leg.  
• PE: it may be completely asymptomatic and may be discovered incidentally during diagnos-
tic work-up for another disease or at autopsy. If PE is symptomatic, it is suspected in case 
of the following symptoms and signs: dyspnoea, chest pain, pre-syncope or syncope, fever, 
cough, unilateral leg pain, signs of DVT, tachypnoea, tachycardia, hypoxia, pyrexia, elevated 
jugular venous pressure, gallop rhythm, systemic hypotension, cardiogenic shock, widely split 
second heart sound, tricuspid regurgitant murmur, pleural rub and haemoptysis [17, 18]. 
Fatal PE is very often underdiagnosed, because of the non-specificity of symptoms and 
signs prior to death, which may be attributed to myocardial infarction, pneumonia, or other 
pathology [19].  
VTE may be fatal. Non-fatal VTE may affect the patients’ long-term QoL and functional capacity 
[42]. VTE has high mortality when untreated but the treatment also carries risks, principally haem-
orrhage [19]. 
 
[A0006] – What are the consequences of VTE for society? 
VTE is likely to be an escalating public health problem due to the prominence of age as a risk 
factor and the increasing age of the population [19]. Patients older than 40 years are at increased 
risk and risk doubles with each decade. Hence an increasing number of patients are expected to 
be diagnosed and treated to avoid fatal PE [17]. In six European countries with a total population 
of 454,4 million, more than 370,000 deaths were related to VTE in 2004. Of these patients, 34% 
died suddenly or within a few hours of the acute event, before therapy could be started or before 
therapy took effect. Of the other patients, death resulted from acute PE that was diagnosed after 
death in 59% and only 7% of patients who died early were correctly diagnosed with PE before 
death [43]. 
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Current clinical management of the disease or health condition 
[A0024] – How is VTE currently diagnosed according  
to published guidelines and in practice? 
The diagnostic algorithms differ for DVT and PE, hence they are presented separately.  
A. Deep vein thrombosis (DVT) 
1. The initial step if patients present with signs and symptoms suggestive of DVT is to assess the 
patients for their pre-test probability, i.e. the likelihood that they have DVT using a clinical prob-
ability score (also known as pre-test probability score or clinical prediction rule). Patients are 
stratified into different risk categories to help to choose the most appropriate diagnostic and 
treatment pathway. The most commonly used clinical probability score is the Wells score, which 
has several versions: the original, an updated and its simplified versions [17]. The original Wells 
score used three levels of risk: low, intermediate and high. The updated Wells score uses only 
two risk categories: DVT likely or DVT unlikely [18]. The simplified versions aim to facilitate 
adoption into clinical practice [17]. Obtaining general medical history and physical examination 
is part of the scoring process. It is also important to look for alternative diagnoses which would 
explain the symptoms. If DVT can be ruled out at this stage, additional, more costly tests and 
radiation exposure can be avoided [17, 18]. It is recommended by the National Clinical Guide-
line Centre (NCGC) [18] to use the two-level scoring system because it reduces the risk of con-
fusion as to what to do with the moderate risk category patients. Physicians have to be trained 
how to complete the score, especially the item on “alternative diagnosis as likely as DVT” [18].  
2. Measurement of the D-dimer level in the blood has a role in the exclusion of DVT in oligosymp-
tomatic patients as a negative D-dimer assay implies that thrombosis is not occurring. On the 
other hand, a positive test can indicate not only thrombosis but also other causes, such as liver 
diseases, inflammation, malignancy, pregnancy, trauma, and recent surgery. With the change of 
the three-level scoring to the two-level scoring, the patients in the unlikely group can be more 
safely ruled out when the pre-test probability is combined with D-dimer testing [18].  
3. Ultrasound is a non-invasive imaging modality which has high sensitivity and specificity for 
proximal DVT. However, ultrasound does not identify calf vein DVT reliably. Compression ul-
trasound uses a gentle probe pressure to try and compress the vascular lumen. If no residual 
lumen is observed the vein is considered to be fully compressible, indicating the absence of 
DVT. Duplex ultrasound is similar but a Doppler signal is used to determine blood flow charac-
teristics. If the phasic pattern of venous blood flow is absent venous outflow obstruction is di-
agnosed [18]. 
Different guidelines propose different diagnostic workup based on the pre-test probability of pa-
tients. NCGC recommends the following algorithm (see Figure 9).  
• Pre-test probability unlikely (low to moderate clinical probability): D-dimer should be tested. 
If the test is positive, a proximal leg vein ultrasound should be done within 4 hours of being 
requested. If the ultrasound cannot be done within 4 hours, parenteral anticoagulant should 
be taken in 24-hour doses and a proximal leg vein ultrasound should be done within the 24 
hours. If the ultrasound is negative, alternative diagnoses should be considered.  
• Pre-test probability likely (high clinical probability): there are two possibilities, depending on 
if a proximal leg vein ultrasound is available within 4 hours.  
o If a proximal leg vein ultrasound is available, it should be done within 4 hours of being 
requested. If the result is negative D-dimer should be tested additionally. 
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o If a proximal leg vein ultrasound is not available, D-dimer should be tested immediately 
and 24 hours dose parenteral anticoagulant should be given. A proximal leg vein ul-
trasound should be done within 24 hours of being requested.  
If the D-dimer test is positive and the ultrasound is negative, the ultrasound should be re-
peated within 6-8 days. If the ultrasound and the D-dimer test are negative, or a repeated 
ultrasound is negative, an alternative diagnosis should be considered [18].  
 
Figure 9: Diagnosis algorithm DVT [18] 
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SIGN and AWMF recommend that the D-dimer level should only be measured in patients with low 
or moderate clinical probability (or PE or DVT unlikely) only. In patients with a high clinical proba-
bility (PE or DVT likely), D-dimer should not be measured before imaging to exclude VTE, but pa-
tients should proceed immediately to imaging. A normal D-dimer test result does not safely exclude 
VTE, and therefore it has no value in this group. Patients with low or moderate clinical probability 
should be tested for D-dimer and if the test is positive, the patients should proceed to imaging. If 
the test is negative, the patients should be informed that VTE might be diagnosed in the upcoming 
three months, but no further thrombosis diagnosis is required [19, 38].  
One guideline [41] recommends a slightly different algorithm. The difference is partly due to the fact 
that the three-level categories are used instead of the two-levels and that the type of the available 
D-dimer test is taken into consideration instead of the availability of ultrasound within 4 hours.  
• If a highly sensitive D-dimer test is available, the first step in both the low- and moderate-risk 
categories is to test the D-dimer level.  
o If the test result is positive, the next step is to carry out an ultrasound scan.  
If the ultrasound is negative, a repeated ultrasound is suggested.  
o If the test result is negative, clinical follow up is recommended.  
• If only moderately sensitive D-dimer test is available, it is recommended to use it as first-line 
diagnostic tool only for the testing of low-risk patients. 
o If the test result is positive, the patients should proceed to an ultrasound scan.  
o If the test result is negative, clinical follow up is suggested.  
In the moderate-risk category ultrasound is the first-line diagnostic tool. If the ultrasound is 
negative, D-dimer should be tested and if the test result is positive, ultrasound should be 
repeated. If the D-dimer test result is negative, clinical follow-up is recommended.  
B. Pulmonary embolism (PE) 
1. The initial step in the diagnosis of a patient presenting with signs and symptoms of PE is to as-
sess the likelihood of having a PE. A number of clinical prediction scores have been developed 
to assess it, based on the signs, symptoms and the medical history of the patient. As clinical 
judgements lack standardization; several clinical prediction rules are in use, of which the most 
frequently used are the Wells score, the Geneva score and the Charlotte rule. The updated 
Wells score uses two-levels (PE likely, PE unlikely) instead of the original three levels (high, 
moderate and low risk). PE is likely if the score is greater than 4, PE is unlikely if the score is 4 
or less. The Geneva score is based on risk factors and findings of a chest X-ray and arterial 
blood gases. The Charlotte rule stratifies patients into low and high-risk categories. The major 
difference compared to other scoring systems is that the Charlotte scoring system does not con-
sider active cancer or a previous history of VTE a risk for developing PE [18].  
2. D-dimer testing is combined with the clinical prediction scores to achieve additional diagnostic 
predictive value. The specificity of D-dimer for PE is poor, although the NPV is high [18].  
3. Ventilation-perfusion (V/Q) scan consists of two parts; both involve the use of radioisotopes. In 
the ventilation part the patient breaths in isotopes; in the perfusion part the patient receives in-
travenous isotope injection. Thereafter it is detected with imaging where the isotope has gone 
into the lungs. This allows for the identification of areas that are ventilated but not perfused [18].  
4. Computed tomography pulmonary angiography (CTPA) involves an intravenous contrast agent 
given to the patient and a CT of the chest afterwards. The advantage is that the CT cannot only 
detect pulmonary emboli but also other disorders that can be the cause of the patients’ symp-
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toms. The disadvantage is that the radiation is higher as compared to the V/Q scan [18]. CT 
angiography can confirm PE when it shows a clot at least at the segmental level of the pulmo-
nary arterial tree [17]. 
It is recognized in the various guidelines that the diagnostic approach to suspected PE may vary, 
depending on the availability of, and expertise in, specific tests in various hospitals and clinical set-
tings and depending on the risk score for developing PE. It needs to be mentioned that both the 
ESC guideline [17] and the NCGC guideline [18] refer to the ED setting only. It is emphasized in 
all included guidelines that D-dimer should be measured only after the prior estimation of clinical 
probability and that a pre-test probability score alone is not enough to rule out PE [17-19, 38-42]. 
The ESC differentiates suspected PE with hypotension (high-risk of PE) and without shock and 
hypotension (not high-risk of PE). After this initial risk stratification, the clinical probability is as-
sessed again to distinguish between low or intermediate (PE unlikely) and high clinical probabili-
ties (PE likely). NCGC distinguishes based on the two-level Wells score (PE likely or PE unlikely). 
In all guidelines, the assessment of the D-dimer level is only applicable in patients who have low 
or intermediate clinical probability or PE unlikely [17-19, 38-42].  
• Low or intermediate clinical probability or PE unlikely: a D-dimer test should be done imme-
diately and if the result is positive either an immediate CTPA should be done, or if it is not 
available immediately, anticoagulation therapy should be started immediately and CTPA 
should be carried out later [17, 18]. In patients with unlikely PE score and a negative D-
dimer or a positive D-dimer with a negative CTPA, an alternative diagnosis should be con-
sidered [18, 38]. The type of D-dimer test should preferably be highly sensitive [17, 40]. The 
ESC recommends that in low clinical probability patients, a highly, as well as a moderately, 
sensitive assay can be used [17].  
• High clinical probability or PE likely (also suspected PE with shock or hypotension): the first-
line diagnostic tools is CTPA (if CTPA is not available, ECG is first line) [17, 18]. If CTPA 
cannot be done instantly, immediate parenteral anticoagulation followed by CTPA later 
should be given. If the CTPA is negative, a proximal leg vein ultrasound should be consid-
ered [18]. In the PE-likely patient population, D-dimer has a low NPV, therefore D-dimer test 
is not recommended for them [17, 38]. It is also less useful in hospitalized patients because 
the number needed to test to obtain a clinically relevant negative result is high [17].  
The NCGC diagnostic algorithm provides a good overview of this process (see Figure 10).  
The use of combinations of clinical decision rules (CDRs) and D-dimer is generally applicable to 
ambulatory, non-hospitalised patients presenting with suggestive symptoms or signs of VTE; it 
should not be applied to the investigation of hospitalised patients, cancer patients, post-surgical 
patients and pregnant women in whom false-positive tests are more common and among whom 
initial investigation should be appropriate imaging [19].  
The specificity, as well as the sensitivity of the assays, should be considered when making rec-
ommendations on their use and their application in the diagnostic algorithms.  
• The specificity of D-dimer decreases steadily with age, to almost 10% in patients over 80 
years. Evidence suggests using age-adjusted cut-offs to improve the performance of D-dimer 
testing in the elderly. In a meta-analysis referenced in the ESC guideline [17], age-adjusted 
cut-off values (age x 10 mg/L above 50 years) allowed increasing specificity from 34-46% 
while retaining a sensitivity above 97% [17]. 
• The sensitivity of the assay is affected by the duration of symptoms and the use of antico-
agulants [19, 41]. The sensitivity of the D-dimer test is reduced if the duration of symptoms 
or signs exceeds 2 or 3 days prior to the test or with the use of heparin before testing [41].  
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Figure 10: Diagnostic algorithm PE [18] 
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DVT [41], whilst four guidelines include recommendations both on PE and DVT [18, 19, 38, 42]. 
Two guidelines [15, 29] contain recommendations on the diagnosis of several health conditions in-
cluding ACS. Therefore we included this guideline in the guideline synopsis on both troponin and 
D-dimer POCT. One of these guidelines was developed to make recommendations if the patients 
present with chest pain, which can include the diagnosis of both PE and ACS [15]. The other guide-
line was developed specifically for unusual conditions such as natural disasters and cardiovascu-
lar care and includes recommendations on the diagnosis of both DVT and ACS in these unusual 
conditions [29].  
Different guidelines come to different conclusions regarding the use of these assays. Eight guide-
lines conclude that POCT can be used to exclude suspected PE or DVT [18, 19, 29, 38, 39, 41-
43]. One guideline conclude that no recommendations can be made in terms of the use of POCT 
due to lack of or weak evidence [40]. Finally, one guideline makes recommendation for the inpatient 
setting and does not recommend using manual qualitative or semi-quantitative tests that are of-
fered in doctors’ offices [15].  
Four guidelines highlight the importance of the type of assay chosen as different assays have differ-
ent characteristics (sensitivities and specificities) and therefore require differing recommendations 
[15, 18, 40, 41]. Five guidelines[19, 38, 39, 41, 43] recommend the use of POCT only in low-risk 
patients (or PE-unlikely patients); one of these guidelines explicitly states that it is not recommend-
ed for moderate or high-risk pre-test probability patients [41]. One guideline makes recommenda-
tion indirectly on the use of D-dimer POCT, stating that there is no need for ultrasound imaging if 
D-dimer level can be determined with POCT [29]. Only three guidelines [19, 29, 40] indicate the 
level of evidence and/or class of recommendations. The quality appraisal of the guidelines can be 
found in Table A14. A major limitation of the guideline synopsis is that only one recent guideline 
[43], published in the last three years, could be identified. This must be taken into consideration 
when relying on the conclusions of the guidelines as there might be a need for an update especially 
given rapid technological developments in the field. Furthermore, there is little evidence from the 
primary care setting. Additionally, the guidelines used various terms to distinguish D-dimer test, 
such as qualitative, semi-quantitative and quantitative D-dimer assays, rapid D-dimer tests, high-
ly-sensitive, moderate- and low-sensitivity assays, but failed to specify which tests are considered 
POCT based on these categories. The main focus of some guidelines was on the treatment, pre-
vention or other diagnostic forms of VTE; here D-dimer testing is only mentioned and described 
briefly.  
 
[A0025] – How is VTE currently managed according to published guidelines and in practice? 
The current standard practice for the treatment of VTE is anticoagulation. These drugs “thin” the 
blood and prevent further clotting. There is a wide variation in practice, but patients are usually 
given a brief course of heparin treatment initially, while they start on a 3–6-month course of warfa-
rin. Patients who have had recurrent VTE or who are at high risk of recurrence may be given in-
definite treatment with anticoagulants to prevent further VTE episodes. However, anticoagulation 
treatment carries the risk of bleeding and requires the patient to have regular monitoring blood 
tests. In addition, there is a wide variation in practice regarding when to test for thrombophilia after 
VTE and controversy as to how thrombophilia should be managed if it is found on testing [18]. 
There is also the potential to dissolve the clots using drugs termed thrombolytics which can be used 
both for DVT and PE. Dissolving the clots in the pulmonary arteries may reduce the risk of fatal 
PE and longer-term problems with CTEPH. In the case of DVT, thrombolysis may reduce the risk 
of fatal PE and PTS. However, the use of thrombolytics may cause side-effects such as bleeding 
and guidance is needed as to which patients may benefit from their use [18].  
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Target population 
[A0007] – What is the target population of this assessment? 
The target population for the use of D-dimer POCT is adult patients at low to moderate risk for 
presenting with DVT or PE according to the three-level Wells score or PE or DVT unlikely accord-
ing to the two-level Wells score. Specific high-risk groups, such as pregnant women are excluded 
from the analysis. In these selected patients, a negative D-dimer combined with the low pre-test 
probability score can safely rule out DVT and PE and therefore could reduce the need for further 
imaging and other diagnostics [18]. 
 
[A0023] – How many people belong to the target population? 
VTE is the third most frequent cardiovascular disease. The overall annual incidence is 100-200 
per 100,000 inhabitants in Europe [17]. DVT presents with clinical symptoms in about 1 per 1,000 
people per year in the general population [19]. The estimated number of deaths due to VTE in the 
EU in 2004 was over 500,000 [18]. 34% of the deaths were due to sudden fatal PE, whereas 59% 
were due to PE that remained undiagnosed. Only 7% of the deaths were formerly diagnosed with 
PE before death [17]. In the United States, it is estimated that 650,000 to 900,000 individuals have 
acute PE each year of which 200,000 are fatal [40]. 
 
[A0011] – How much are the technologies utilized?  
The standard diagnostic workup for DVT includes imaging. However, the costs of imaging modali-
ties and the increasing number of negative tests has led to a reconsideration of the diagnostic 
strategies. In some patients there is no need for diagnostic imaging to exclude the disease; the 
diagnostic workup relies only on the information from the clinical history and examination (pre-test 
probability assessment), complemented by the D-dimer test results [18]. According to a Dutch pri-
mary care study referenced by the ESC guideline, PE could be ruled out in 46 percent of low-risk 
patients with suspected PE without proceeding to imaging tests (with a failure rate of 1.5 percent) 
[43].  
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6 CLINICAL EFFECTIVENESS (EFF) AND SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
D0001 What is the expected beneficial effect of the technology on mortality? 
D0026 How does the technology modify the effectiveness of subsequent interventions?  
D0032 How does the test-treatment intervention modify the magnitude  
and frequency of morbidity?  
D0016 How does the use of the technology affect activities of daily living? 
D0012 What is the effect of the technology on generic health-related quality of life?  
D0013 What is the effect of the technology on disease-specific quality of life? 
D0030 Does the knowledge of the test result affect the patient’s non-health-related 
quality of life?  
D0017 Were patients satisfied with the technology? 
D0024 Is there an effective treatment for the condition the test is detecting? 
D1001 What is the accuracy of the test against the reference standard? 
D1002 How does the test compare to other optional tests in terms of accuracy measures? 
D1003 What is the reference standard and how likely does it classify ‘the target 
condition correctly?  
D1004 What are the requirements for accuracy in the context the technology will be used? 
D1005 What is the optimal threshold value in this context?  
D1006 Does the test reliably rule in or rule out the target condition?  
D1007 How does test accuracy vary in different settings?  
D1008 What is known about the intra- and inter-observer variation in test interpretation?  
D1019 Is there evidence that the replacing test is more specific or safer than the old one?  
C0006 What are the consequences of false positive, false negative and incidental 
findings generated by using the technology from the viewpoint of patient safety? 
C0008 How safe is the technology in relation to the comparator(s)? 
C0002 Are the harms related to applying the technology? 
C0004 How does the frequency or severity of harms change over time ‘or in different 
settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of the technology? 
C0007 Are the technology and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use  
of the technology and the comparator? 
D0020 Does use of the test lead to improved detection of the condition? 
D0021 How does use of the test change physicians’ management decisions? 
D0010 How does the technology modify the need for hospitalisation? 
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The results will be reported – if possible – according to the setting: primary and community care or 
emergency medicine. The latter was split into ED [94] and pre-hospital emergency medicine (PHEM) 
that includes the ambulance emergency transport [95]. It needs to be highlighted that we expected 
that PHEM has no access, and primary or community care were also unlikely to have, access to a 
CL. The ED, on the contrary, is highly likely to have access to a CL. 
 
6.2 Results for the use of Tn-POCT 
Included studies 
For the evaluation of the effectiveness of implementing Tn-POCT, two systematic reviews were 
included [25, 26]. One systematic review [25] from the CADTH evaluated, inter alia, the DTA and 
clinical utility of Tn-POCT in different settings.  
The systematic search of the included systematic reviews covered the periods up until 2014 [26] 
and 2016 [25] respectively. As a result, an update search was conducted but we could not identify 
any additional primary studies for the update of these systematic reviews in the time period be-
tween 2016 and 2019 (see 3.4 Study selection). 
The two systematic reviews [25, 26] consisted of a combined total of 42 primary studies. The 
CADTH report [25] identified 41 primary studies. Of these, nine studies investigated the DTA of 
Tn-POCT and 30 studies assessed clinical utility. Further two studies were included that investi-
gated both DTA and clinical utility. The other included systematic review [26] identified two studies 
in the primary care settings, one of which was also included in the CADTH report [25]. 
The total number of patients was not reported by the CADTH report [25] and was 545 in the other 
systematic review [26]. 
Settings & outcomes measured 
Evidence in the CADTH report [25] relating to the effects of Tn-POCT (clinical utility) consisted of 
seven randomised controlled trials (RCTs) and 25 observational studies.  
The setting of these studies was dominated by the ED, with 21 included studies. Furthermore, the 
review identified three studies with a pre-hospital or ambulance setting and one study in primary 
health care centres and remote centres respectively. Besides, the CADTH report [25] included four 
studies conducted in coronary care units, a setting that is beyond the scope of this EUnetHTA as-
sessment and was therefore excluded. Similarly, one study in the review looked at staff satisfac-
tion that was not defined as a patient-relevant outcome in this assessment. The results of these 
studies will not be presented and, hence, the reader is referred to the original publication [25] for a 
detailed description of these results. The other included systematic review [26] focused only on 
primary care settings and included two prospective comparative cohort studies for Tn-POCT. 
We selected mortality/morbidity, QoL as well as impact on patient management as relevant out-
comes. For patient management, nine sub-categories of outcomes were identified: number of hos-
pital admissions, treatment initiation, referral rates (RR), door-to-needle time (DNT), turnaround 
time (TAT), time to discharge (TTD), length of stay (LOS), further diagnostic testing, and time to 
clinical decision (TCD). 
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Methodological Quality/RoB assessment 
The systematic reviews reached a moderate [26] and high [25] quality according to the AMSTAR-
2 assessment respectively (see Table A10 in the appendix). 
The methodological quality of the included studies was assessed using QUADAS-2 (diagnostic 
studies) in both systematic reviews for DTA studies [25, 26]. For RCTs, one systematic review used 
the Cochrane Risk of Bias tool [26] and the other systematic review used the Downs and Black 
checklist [25]. An overall score of the risk of bias of included studies was absent in both systemat-
ic reviews. 
Synthesis 
Both of the systematic reviews [25, 26] conducted a qualitative evidence synthesis and none of 
the identified systematic reviews used a standardised tool such as GRADE [49] to grade the iden-
tified evidence across studies. One systematic review rated the available evidence as limited and 
inconclusive [26] and the other systematic review also highlighted that the quality of the included 
studies is limited [25]. 
Index tests and reference standards 
Both reviews [25, 26] used diverse types of index tests and types of reference standards. Neither 
of the reviews clearly described the algorithms for the diagnosis of ACS used within the primary 
studies. The reader is referred to the data-extraction table (Table A4) found in the appendix for 
more information. 
Funding 
In the CADTH report [25], it was reported that the organisation received funding from Canada’s 
federal, provincial and territorial governments, with the exception of Quebec. Across all included 
studies, it was stated that 22/41 studies had authors with a conflict of interest (CoI) due to industry 
sponsoring. The other review [26] was funded by the Netherlands Organisation for Health Research 
and Development (ZonMw) but did not report the funding of the included primary studies. 
Further notes 
The inclusion criteria were, except for the aforementioned discrepancy regarding defined settings, 
aligned with the inclusion criteria of this overview of reviews.  
 
Mortality 
[D0001] – What is the expected beneficial effect of the technology on mortality? 
The CADTH report [25] found limited evidence indicating that the use of Tn-POCT does not statis-
tically change mortality compared with CL up to one year follow-up (FU) in the ED setting. The 
primary studies included in the CADTH report [25] consisted of two RCTs and three observational 
studies investigating the effect of implementing Tn-POCT on mortality in the ED. The two RCTs 
used cTnT or cTnI testing and enrolled 487 and 2,243 patients, respectively. Both of the studies 
compared POCT with CL result with one study finding a mortality rate of 0.5% and 0% respectively 
(p-value not reported). The other study found mortality data of 1% in the POCT group as opposed 
to 0.2% in the CL group (n. s., with p=0.142).  
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The remaining mortality data in the ED setting derived from observational studies were incomple-
tely reported in the systematic review [25]. Besides, none of these observational studies compared 
Tn-POCT with CL devices directly. 
Further, the CADTH report [25] found limited evidence that implementing Tn-POCT would not lead 
to a difference in 30-days mortality between Tn-POCT and usual care in the ambulance – a setting 
where CL testing is not available. The evidence base was one RCT with 601 enrolled patients. 
However, the reporting on this study was sparse17. 
The other included systematic review [26] did not identify studies reporting on mortality data in 
primary care settings. 
 
[D0026] – How does the technology modify the effectiveness of subsequent interventions?  
No evidence was found to answer this research question. 
 
Morbidity 
[D0032] – How does Tn-POCT modify the magnitude and frequency of morbidity?  
The CADTH report [25] found evidence on the potential effect of implementing Tn-POCT on the 
magnitude and frequency of morbidity in the ED. Evidence from two RCTs and two prospective 
studies suggests that using Tn-POCT would not statistically change the frequency of severe ad-
verse events when compared to conventional CL testing up to one year FU.  
The same systematic review [25] reported on two prospective studies elaborating on cardiac events 
in the ED using cTnI or cTnT testing. Of these, one prospective study enrolled 704 patients and 
compared the 30 day cardiac event rate of Tn-POCT with conventional CL Tn testing (low-risk pts: 
0% (95%CI: 0-25.9) versus 0% (95%CI: 0-21.5), p-value NR; high-risk pts: 24.8% (95%CI: 20.1-
30.1) versus 28.6% (95%CI: 23.4-34.4), p-value NR). The other prospective study included 1,410 
patients and compared Tn-POCT with CL testing with a cardiac event rate after one year of 2.1% 
(95%CI: 1.5-3) and 2.2% (95%CI:1.6-3.1) respectively. 
Additionally, the systematic review [25] reported on other adverse events (AE) and composite end-
points in the ED consisting of two RCTs using cTnT or cTnI testing. Major AE after three months 
follow up was measured by one included RCT (2,243 enrolled patients) comparing Tn-POCT with 
CL testing, with a rate of 3% and 2% respectively (diff. n. s., with p=0.313). CEP events18 at six 
months were measured by the other RCT (487 enrolled pts), with 10.4% (Tn-POCT) and 5.4% 
(CL) suffering from CEP events after six months respectively (p-value: NR). 
The other identified systematic review [26] did not find evidence answering this research question 
in the primary care setting. 
 
                                                     
17 Data on studies within settings where CL testing is unavailable where only briefly reported narratively in text of the SR 
without creating a data-extraction table for this evidence. 
18 AMI, coronary revascularization, cardiac arrest, or mortality in patients with a negative first cTn test at 3 m FU 
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Function 
[D0016] How does the use of the technology affect activities of daily living?  
No evidence was found to answer the research question. 
 
Health-related quality of life 
[D0012] – What is the effect of the technology on generic health-related quality of life? 
[D0013] – What is the effect of the technology on disease-specific quality of life? 
[D0030] – Does the knowledge of the test result affect the patient’s  
non-health-related quality of life?  
One included systematic review [25] identified evidence on the effect of implementing Tn-POCT 
on QoL in the ED setting. The evidence consisted of one RCT (2,243 enrolled patients, cTnI test-
ing), comparing the QoL between Tn-POCT and CL testing and found no statistically significant 
difference in the QoL scores (measured with the EQ-5D) between groups, with 0.742 and 0.759 
QoL scores after one month and 0.752 and 0.759 after three months respectively (p>0.05). 
The other systematic review [26] did not find any evidence regarding the effect of implementing 
Tn-POCT on QoL in primary care settings. 
 
Satisfaction 
[D0017] – Were patients satisfied with the technology?  
No evidence was found to answer the research question. 
 
Test-treatment chain  
[D0024] – Is there an effective treatment for the condition the test is detecting?  
Effective treatment does exist for the ACS. The reader is referred to chapter 5 for a nuanced  
description. 
 
Test accuracy 
Two systematic reviews assessed the test accuracy of Tn-POCT [25, 26]. 
 
[D1001] – What is the accuracy of the test against reference standard? 
[D1002] – How does the test compare to other optional tests in terms of accuracy measures? 
[D1003] – What is the reference standard and how likely does it classify  
the target condition correctly?  
The CADTH report [25] assessed the DTA and included eleven DTA studies and two companion 
reports across numerous different settings. There were 16 different POCT devices with an analyt-
ical performance ranging from 0.014-0.08 mcg/L at the 99th percentile. The reference standard 
was clinical adjudication (e.g., final diagnosis using laboratory data, independent adjudication by a 
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cardiologist and cardiology research clinician). The reader is referred to the data extraction table 
to be found in the appendix (see Table A4) and the original publication [25] for more information.  
Compared with CL testing, Tn-POCT tended to have a lower sensitivity, lower NPV, higher speci-
ficity and higher positive predictive value (PPV) in this systematic review [25]. This trend was gen-
erally seen across all of the identified studies and there appeared to be no systematic differences 
(e.g., depending on cTnI or cTnT). The sensitivity of Tn-POCT at admission ranged from 26% to 
88% for Tn-POCT and 68% to 100% when using CL testing. The specificity for Tn-POCT ranged 
from 84% to 98% as opposed to a range of 75% to 94% for CL testing. In addition, the PPV of all 
included DTA studies ranged from 31% to 85% for Tn-POCT and 10%-82% for CL testing. Lastly, 
the NPV was 90% to 99% for Tn-POCT and 95% to 100% for CL troponin measurements. 
The other systematic review [26] included two DTA studies in primary care settings. The brand 
names of the evaluated Tn-POCT devices were not reported. However, the cut-off values were 
0.08ug/l and 0.03ug/l in the included studies respectively. The studies used either common prac-
tice, including follow up only or evaluation of hospital records, ECG and GP’s clinical evaluation or 
telephone interviews as reference standards. The reader is referred to the data extraction table to 
be found in the appendix (see Table A4) and the original publication [26] for more information. This 
systematic review [26] did not identify clinical studies comparing the DTA between Tn-POCT and 
CL testing in primary care settings. Yet, two non-comparative clinical studies focusing on DTA 
were identified: For MI, the sensitivity was 67% and 83% in the two included studies respectively, 
while the specificity was 98% and 100% respectively. The PPV was 40% in one study and 100% 
in the other study. The NPV for MI was 99% and 99.7%. For the diagnosis of MI and UA, the sen-
sitivity in these two studies was 21% and 29% respectively, while the specificity was 98% and 
100% respectively. The PPV and NPV were 100% and 94% in one study, and 40% and 96% in 
the other study respectively [26]. 
 
[D1004] – What are the requirements for accuracy in the context  
the technology will be used? 
[D1005] – What is the optimal threshold value in this context?  
No evidence was identified to answer the research questions. It appears that different troponin cut-
offs are currently used. The systematic review by CADTH [25] highlighted that different troponin 
cut-offs were used in their included studies leading to variations in DTA. The CADTH report [25], 
however, tried to minimise these variations by only including studies with the 99th percentile cut-off 
threshold (0.014-0.08 mcg/L). The other systematic review [26] identified studies that did not clear-
ly report on whether the 99th percentile was used in their included studies, but reported on 0.03ug/L 
and 0.08ug/L in their included studies respectively. 
 
[D1006] – Does the test reliably rule in or rule out the target condition?  
The reader is referred to the results on diagnostic accuracy described above. 
 
[D1007] – How does test accuracy vary in different settings?  
None of the included studies included evidence that may answer this research question. However, 
in both systematic reviews [25, 26] there was a wide variability of the DTA performance. 
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[D1008] – What is known about the intra- and inter-observer variation in test interpretation?  
No evidence found to answer the research question. 
 
[D1019] – Is there evidence that the replacing test is more specific or safer than the old one?  
The reader is referred to D1001-D1003. 
 
Safety 
[C0006] – What are the consequences of false-positive, false-negative and  
incidental findings generated by using the technology from the viewpoint of patient safety?  
The potential harms of discharged patients with an acute MI was specifically reported in one sys-
tematic review [26], although the other systematic review [25] indirectly also highlighted the harm 
of discharged patients with an ACS. The evidence consisted of one cohort study in the primary 
care setting that reported a decrease in referrals that may increase the risk of missing out patients 
with an acute MI or UA. Two out of 178 patients in the Tn-POCT group needed – but did not re-
ceive – a referral (referral rate: 25% and 43% of patients managed by physicians using and not 
using Tn-POCT respectively). However, the p-value was not reported/available. 
 
[C0008] – How safe is the technology in relation to (the) comparator(s)? 
[C0002] – Are the harms related to applying the technology? 
[C0004] – How does the frequency or severity of harms change over time  
or in different settings? 
[C0005] – What are the susceptible patient groups that are more likely to be harmed 
through the use of the technology? 
[C0007] – Are the technology and comparator(s) associated with user-dependent harms? 
[B0010] – What kind of data/records and/or registry is needed to monitor  
the use of the technology and the comparator? 
No evidence was found to answer these research question. 
 
Change in management  
[D0020] – Does the use of the test lead to improved detection of the condition? 
[D0021] – How does use of the test change physicians' management decisions? 
[D0010] – How does the technology modify the need for hospitalisation?  
For the impact of implementing Tn-POCT on patient management, nine outcomes were selected: 
number of hospital admissions, treatment initiation, RR, DNT, TAT, TTD, LOS, further diagnostic 
testing, and TCD. 
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Number of hospital admission 
The number of hospital admissions was reported in one out of two included systematic reviews 
[25]: The review identified one RCT with 601 enrolled patients, comparing Tn-POCT with usual care 
in the ambulance – a setting where no CL testing is available. No difference in hospitalisation bet-
ween groups was found hereby. However, the systematic review sparsely reported on this study19. 
Treatment initiation 
The outcome treatment initiation was not reported in any of the included studies.  
Referral rates (RR) 
The RR were reported in both included systematic reviews: One cohort study was identified by both 
reviews [25, 26]. This study used cTnT testing with 196 enrolled patients in the primary health care 
centres where CL testing was not available. The study found a reduction of 18% (p-value not re-
ported); however, it is necessary to highlight that this study also noted that two patients were not 
referred and also missed cases: one acute myocardial infarction (AMI) and one UA respectively. 
As a consequence, this reduction may come at the cost of an increased risk of missing patients 
with an AMI or UA.  
Door-to-needle time (DNT) 
The DNT was not reported in any of the included systematic reviews. 
Turnaround time (TAT) 
The TAT was reported in one out of two included systematic reviews [25]: The review identified 
comparative evidence (Tn-POCT versus CL) in the ED setting, consisting of two RCTs and eleven 
observational studies (both prospective and retrospective). The evidence derived from RCTs indi-
cates that it may reduce the TAT between 43 and 147 minutes (median). Yet, this reduction was 
only statistically significant in one RCT and not reported in the other RCT. The evidence derived 
from observational studies shows a reduction in all eleven studies, with a mean or median time 
ranging from 18 to 93 minutes, although the p-value was only reported in 5/11 studies, with statis-
tically significant differences in these studies.  
The same review [25] included an observational study investigating the use of Tn-POCT in the 
ambulance by paramedics. This uncontrolled study included 928 patients and measured a median 
time from symptom onset to blood sampling of 83 minutes (range: 46-167). 
Time to discharge (TTD) 
The outcome TTD was reported in one of the two included systematic reviews [25]: The review iden-
tified comparative evidence (Tn-POCT versus CL) in the ED setting, consisting of two RCTs (487 
and 2,134 enrolled pts) and one observational study (n=4,886), using a test strategy including 
cTnT/cTnI and Tn in combination with other biomarker testing respectively. The evidence derived 
from RCTs shows a reduction in 2/2 studies, with a reduction of 5 minutes (mean; s. s., with p<0.05) 
and 7 minutes (median; p-value not available) when using Tn-POCT respectively. The evidence 
                                                     
19 Data on studies within settings where CL testing is unavailable were only briefly reported by the included review  
(narratively without  data presented in data-extraction table for this outcome). 
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derived from observational studies shows a mean reduction of 26 minutes in 1/1 study (p-value 
not available). However, it is to be highlighted that the observational study used multiple bio-
marker testing, which is not within the scope of this systematic review. 
Additionally, further evidence for the outcome TTD was found from one of the systematic reviews 
[25] in a pre-hospital setting with no access to CL testing (ambulance). One RCT was included by 
the systematic review that found a reduction in TTD when comparing Tn-POCT to usual care, with 
a median time of 8.8 and 9.1 hours in these groups respectively (p=0.05). 
Length of stay (LOS) 
The outcome LOS was reported in one of two included systematic reviews [25]: The review identi-
fied comparative evidence (Tn-POCT versus CL) in the ED setting. All of the studies tested for cTnT 
or cTnI. The evidence consisted of three RCTs and two observational studies for ED20 stay and 
one further RCT investigating hospital stay in the ED. For the former, the evidence derived from 
RCTs (487-912 enrolled pts) shows a non-statistically significant mean or median reduction in 2/3 
studies (0.2-0.8h), while also a non-statistically significant median increase in 1/3 studies (0.1 h) 
was notable. The two observational studies (pre-post design) measured a reduction of 1.9 hours 
(mean; p-value not reported) and 2-2.7 hours (median; statistically significant). For the latter (hos-
pital stay in ED), the evidence consisting of one RCT showed a non-statistical mean reduction of 
2.2 hours. 
Further Testing 
The outcome of further diagnostic testing was not reported in any of the included  
systematic reviews. 
Time to clinical decision (TCD) 
The outcome time to TCD was reported in one out of two included systematic reviews [25]: The 
review identified comparative evidence (Tn-POCT versus CL) in the ED setting. The evidence con-
sisted of one RCT and one further observational study. The evidence of the RCT (cTnI testing, 
2,134 enrolled pts) shows a median reduction of TCD of nine minutes when using Tn-POCT, alt-
hough the p-value was not available. The evidence of the observational study shows a reduction 
of 26 minutes (mean; p-value not available). However, the observational study used multiple bio-
markers, which is not within the scope of this systematic review. 
  
                                                     
20 In fact, the original study used the term emergency room stay, but it was judged to be the same as emergency department. 
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6.3 Results for the use of D-dimer POCT 
Included studies 
The search and selection process identified six systematic reviews for inclusion [26, 31-35]. The 
combined total number of patients from individual studies included in the reviews ranged from 199 
[32] to 55,268 [34]. The publications of two primary studies [36, 37] were additionally included that 
specifically considered DVT, which had not been adequately addressed in the reviews.  
Settings & outcomes measured 
Evidence was identified in ambulatory (primary and community) care and emergency care. Three 
systematic reviews [26, 31, 33] reported on evidence in ambulatory care (primary and community 
care), whilst two reviews [34, 35] restricted their review to the emergency department or hospital 
emergency care settings. One further review [32] did not specify the setting and only mentioned the 
outpatient setting (without further description). Two primary studies [36, 37] were further identified 
that focused on primary care. 
The two included primary studies took place in the Netherlands in the primary care setting and 
both evaluated clinical utility and DTA outcomes. One study [36] combined D-dimer testing with a 
clinical decision rule. In terms of primary endpoints, one study [37] looked at DTA and patient man-
agement (speed of testing) whilst the other study [36] considered the proportion of non-referred 
patients (efficiency) and proportion of missed cases (failure rate). Age and sex distributions were 
similar in both studies; in one study [36] there was some loss to follow up to note in the usual care 
group (11%).  
We selected mortality/morbidity, QoL as well as impact on patient management as relevant out-
comes. For patient management, nine outcomes were selected: number of hospital admissions, 
treatment initiation, referral rates (RR), door-to-needle time (DNT), turnaround time (TAT), time to 
discharge (TTD), length of stay (LOS), further diagnostic testing, and time to clinical decision (TCD). 
Methodological Quality/RoB assessment 
The included systematic reviews reached a moderate [26, 32, 35] to high [31, 33, 34] quality ac-
cording to the AMSTAR-2 assessment (see Table A12). 
In terms of risk of bias, one study [37] was considered to have a moderate risk of bias for the patient 
management outcomes while risk of bias of the other study [36] was rated as severe. The end-
points of mortality/morbidity, QoL and safety were not considered by either study (see Table A13). 
Synthesis 
Three reviews [31, 32, 34] included a meta-analysis although the combined meta-analytic results 
from one of these reviews [32] could not be reported as this incorporated laboratory and POCT. 
Another review [33] also conducted a primary validation of the models found in the systematic re-
view using an available dataset.  
None of the identified systematic reviews used a standardised tool such as GRADE [49] to grade 
the identified evidence across studies. 
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Index tests and reference standards 
The included studies used diverse types of D-dimer POCTs (e.g., both qualitative and quantitative) 
as well as different types of reference standards. The reader is referred to the data-extraction ta-
bles for more information (see Table A5-A8). 
Funding 
Funding was not reported in two reviews [32, 35] and the remaining reviews were funded by the 
following institutions: Netherlands Organisation for Health Research and Development (ZonMw) 
[26], Dutch Heart Foundation [34], Netherlands Organisation for Scientific Research [33], Nether-
lands Heart foundation [31]. 
None of the included systematic reviews reported on source of funding of their included primary 
studies. 
One of the included primary studies [36] was funded by the Netherlands Organization for Health 
Research & Development (ZonMw) and the other primary study [37] did not specifically report on 
funding but stated that no direct financial support was received. 
 
Mortality 
[D0001] – What is the expected beneficial effect of the technology on mortality? 
Mortality was only mentioned in one of six reviews [32]. The review included one study that re-
ported on one person who died (2%) due to VTE (despite a negative D-dimer test and low clinical 
probability).  
Neither of the included primary studies [36, 37] reported on mortality. 
 
[D0026] – How does the technology modify the effectiveness of subsequent interventions?  
There is no evidence that the D-dimer test has an influence on subsequent interventions for venous 
thromboembolism. However, subsequent interventions (e.g. imaging) are likely to be influenced. 
 
Morbidity 
[D0032] – How does the test-treatment intervention modify the magnitude  
and frequency of morbidity?  
No evidence was found to answer the research question. 
 
Function 
[D0016] – How does the use of the technology affect activities of daily living?  
No evidence was found to answer the research question. 
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Health-related quality of life 
[D0012] – What is the effect of the technology on generic health-related quality of life?  
No evidence was found to answer the research question. 
 
[D0013] – What is the effect of the technology on disease-specific quality of life?  
No evidence was found to answer the research question. 
 
[D0030] – Does the knowledge of the test result affect the patient’s  
non-health-related quality of life?  
No evidence was found to answer the research question. 
 
Satisfaction 
[D0017] – Were patients satisfied with the technology?  
No evidence was found to answer the research question. 
 
Test-treatment chain  
[D0024] – Is there an effective treatment for the condition the test is detecting?  
Effective treatment does exist. The reader is referred to chapter 5 for a nuanced description. 
 
Test accuracy 
[D1001] – What is the accuracy of the test against reference standard? 
Two reviews looked at the DTA of a stand-alone D-dimer POCT [26, 31] and reported sensitivity 
of 84-96%, specificity of 48-74%, PPV of 24% (only reported by one review [26]) and NPV of 96% 
(only reported by [26]). Diagnostic accuracy was shown by one review [31] to vary widely depend-
ing on which POCT was used with Cardiac D-dimer showing the highest sensitivity and SimpliRED 
showing the highest specificity. PPV of the stand-alone D-dimer was 24% [26] and NPV was 96% 
[26]; and another review [31] did not report on these measurements. 
In combination with the Wells rule, sensitivity of D-dimer was reported to be 94-95% for a cut-
off of ≤4 and 97% for a cut-off of ≤2 in one review [26], which accords with the 95- 96% observed 
for the original (≤4), modified (≤2) and simplified (≤1) Wells models reported by another review [33]. 
The specificity of D-dimer in combination with the Wells rule was reported in one review [26] to be 
38-51% (depending on which study) for a cut-off of ≤4 and 32% for a cut-off of ≤2. Another review 
[33] reported specificity rates between 49% (for the simplified Wells with a cut-off of ≤1) and 51% 
(for the original Wells with a cut-off of ≤4). PPV was 21-37% for a cut-off of ≤4 and 20% for a cut-
off of ≤ 2 [26] and 21% for a cut-off of ≤4, ≤2 and ≤1 [33]. NPV was reported to be 94-99% for a 
cut-off of ≤4 and 99% for a cut-off of ≤2 [26] and 99% for all Wells cut-offs [33]. 
Regarding D-dimer in combination with other clinical decision rules (CDRs), one review [33] 
reports on the test accuracy results of D-dimer combined with either the original revised Geneva 
(cut-off of ≤5) or the simplified revised Geneva (cut-off of ≤2). This was associated with a worse 
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sensitivity than the Wells rule and D-dimer combination as follows: 88% (cut-off ≤2) and 90% (cut-
off ≤2). In terms of specificity, the original revised Geneva ≤5 performed the worst of all test/CDR 
combinations (48%) but the simplified revised Geneva ≤2 performed slightly better than all Wells 
rules in combination with D-dimer (at 53%). The PPV of the original revised Geneva ≤5 scored the 
worst of all the tests (20%) whilst the ≤2 performed the best at 21%. The NPV of the Geneva ≤5 
was 97%, whilst for the ≤2 it was 97%.  
Of the primary studies, one study [37] reported on diagnostic accuracy for the stand-alone POCT 
Simplify and in combination with clinical decision rules. The Simplify test reached a sensitivity of 
91%, which was further improved in combination with a clinical decision rule to 95% (76-100%). The 
specificity was between 60.8% (stand-alone) and 62.8% (in combination with a Wells cut-off of <2). 
 
[D1002] – How does the test compare to other optional tests in terms  
of accuracy measures?  
No evidence was found directly comparing the accuracy of D-dimer POCT to other ways  
of diagnosing venous thromboembolism.  
 
[D1003] – What is the reference standard and how likely does it classify  
the target condition correctly?  
One review [26] referred to a composite reference standard used by the included studies (noted in 
a footnote to be spiral CT, ventilation-perfusion scan, pulmonary angiography, leg ultrasonography 
and/or three months follow up). Another review [31] included studies either using compression ul-
trasonography, venography, impedance plethysmography or uneventful follow up (no VTE at three 
months) for DVT or CT pulmonary angiography, ventilation-perfusion lung scanning, pulmonary 
angiography or uneventful follow up for PE. One further review [33] refers to validation of the tests 
using the AMUSE-2 cohort and a composite reference standard of all diagnostic imaging tests per-
formed at the hospital (spiral computed tomography, ventilation-perfusion scanning, pulmonary 
angiography, leg ultrasonography and clinical probability assessment). 
The reference standard employed by one primary study [37] was compression ultrasonography 
whilst the other primary study [36] considered whether a DVT had taken place within the three 
months FU.  
 
[D1004] – What are the requirements for accuracy in the context  
the technology will be used?  
Among populations with a low clinical probability of PE or DVT, a test with a high NPV can be used 
to rule out the presence of the disease. 
 
[D1005] – What is the optimal threshold value in this context?  
No evidence was found to answer the research question. 
 
[D1006] – Does the test reliably rule in or rule out the target condition? 
The reader is referred to the results on diagnostic accuracy described above. 
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[D1007] – How does test accuracy vary in different settings?  
No evidence was found to answer the research question. The reader is referred to chapter 5 for 
information on different settings where D-dimer POCT may be utilised.  
 
[D1008] – What is known about the intra- and inter-observer variation in test interpretation?  
No evidence was found to answer the research question. It is worth noting that each test has its 
own calibration and interpretation values.  
 
[D1019] – Is there evidence that the replacing test is more specific or safer than the old one?  
There is no alternative POCT for diagnosing VTE. 
 
Safety 
[C0006] – What are the consequences of false positive, false negative and  
incidental findings generated by using the technology from the viewpoint of patient safety?  
See answers below on clinical utility, in particular a reduction in the use of imaging would have 
safety benefits for patients in terms of reduced radiation. 
 
[C0008] – How safe is the technology in relation to (the) comparator(s)? 
[C0002] – Are the harms related to applying the technology? 
[C0004] – How does the frequency or severity of harms change over time  
or in different settings? 
[C0005] – What are the susceptible patient groups that are more likely to be harmed 
through the use of the technology? 
[C0007] – Are the technology and comparator(s) associated with user-dependent harms? 
[B0010] – What kind of data/records and/or registry is needed to monitor  
the use of the technology and the comparator? 
No evidence was found to answer these research question. 
 
Change-in management  
[D0020] – Does the use of the test lead to improved detection of the condition? 
[D0021] – How does use of the test change physicians’ management decisions? 
[D0010] – How does the technology modify the need for hospitalisation?  
For the impact of implementing D-dimer POCT on patient management, nine outcomes were se-
lected: number of hospital admissions, treatment initiation, RR, DNT, TAT, TTD, LOS, further diag-
nostic testing, and TCD. 
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Number of hospital admissions 
The outcome number of hospital admissions was reported by one review [35]: The review includ-
ed one before-after study with 462 enrolled patients that found a decrease of 13.8% after imple-
menting the D-dimer POCT in the ED. However, the review sparsely reported on the study and no 
p-values were reported. 
Treatment initiation 
The outcome treatment initiation was not reported in any of the included studies. 
Referral rates (RR) 
The RR was not reported in any of the included systematic reviews. One out of two identified pri-
mary studies [36] reported on this outcome: No significant differences in patients referred, not 
referred and the proportion of VTE in patients referred/not referred between the intervention and 
usual care groups were found. 
Door-to-needle time (DNT) 
The DNT was not reported in any of the included studies. 
Turnaround time (TAT) 
The TAT was reported in one systematic review [35] and one primary study [37]. There was no 
hard evidence on TAT although the systematic review [35] found evidence in the ED and conclud-
ed narratively (no data are shown) that there was a reduction in TAT that was reflected in reduced 
LOS and clinical decision-making times and overall shorter patient journey times. The evidence 
consisted of six observational studies with overall 3,279 patients. In four studies included in this 
review (comparative; both prospective and retrospective) a reduction of TAT average values be-
tween 10 and 95 minutes was found when comparing the use of D-dimer POCT versus conven-
tional D-dimer testing in the ED. For the remaining studies, the review by Marquardt and Apau [35] 
either did not sufficiently report on data with regard to TAT or only provide non-comparative data 
respectively.  
The included primary study [37] reported a faster TAT for Simplify than most of the CL tests. 
Time to discharge (TTD) 
The outcome TTD was not reported in any of the included studies. 
Length of stay (LOS) 
LOS was reported in one systematic review [35]: one before-after study, with 462 enrolled patients, 
was included. The study found a non-statistically significant decrease, with a change in mean LOS 
of 8.46 to 7.14 hrs before and after implementing D-dimer POCT in the ED respectively (p=0.16). 
Further diagnostic testing 
One review [32] reported on a study showing that in 25% of patients – those with an unlikely clinical 
probability and normal D-dimer results – CT scans could be withheld. 
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Time to clinical decision (TCD) 
The outcome TCD was not reported in any of the included studies. 
Further outcomes 
In addition to the selected outcomes in this report, two reviews [33, 34] reported on efficiency, which 
assesses the successful avoidance of imaging, and failure rates, which assesses the proportion of 
missed cases. Results for D-dimer combined with the Wells CDR (in different versions) were simi-
lar across the two reviews: failure rates ranged between 0.9% and 1.7% and efficiency rates ranged 
between 40% and 46%. For D-dimer testing combined with the two versions of the Geneva CDR, 
somewhat higher failure rates of 2.7% and 3.1% but similar efficiency rates (44-48%) to D-dimer 
combined with the Wells CDR were reported.  
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7 EXPERT INPUT 
To address country-specific context factors, experts were consulted about the potential benefit of 
POCTs in the health care sector at different service provision levels (primary care, office-based 
specialists in the community, emergency medicine).  
All experts were asked pre-defined questions and the answers were recorded. After each consul-
tation, a summary was written and verified by the expert. In case a face-to-face consultation was 
not possible, the questions were sent to the expert and directly answered in written form. 
The pre-defined questions and the summary of all expert consultations can be found in Appendix 5. 
 
7.1 Austria 
In the Austrian context, three experts were consulted. Two experts with experience in an ambula-
tory care (primary or community care) setting and one expert with experience working in the ED. 
Of these, two had already experience with at least one of these POCTs under evaluation. 
 
Current use of the tests  
The three clinical experts highlight that it is not quite clear how these POCT are currently used in 
Austria. One expert states that these POCT devices are randomly (without a general refunding 
process) used in general practice. In this context, it is highlighted that the patient or the doctor pay 
the testing. Another expert stated that he may not be able to answer the question on the current 
use in detail but is willing to reflect on how it may be used. The explanations of the third expert 
also only reflect on the potential use of POCT in Austria. 
For the use of Tn-POCT in general practice, one expert states GPs who perform acute medicine 
or emergency medicine or so-called “Gemeinde- und Sprengelärzte” could justifiably have access 
to troponin testing if they are far away from hospitals or centres. However, it is highlighted that Tn 
testing must not be interpreted without at least clinical history, presentation and ECG reading. 
Another clinical expert reflected on the Austrian system that is quite hospital-based, meaning that 
the patients are usually referred to the hospital quickly where no Tn-POCT is done. The ED would 
usually have access to CL testing. Another expert mentions that no quantification on the use of 
Tn-POCT is possible because it is not refunded. 
For the use of troponin as a diagnostics in the context of ACS, one clinical expert specifically 
mentions that the current ESC guideline is to be followed [14]. 
For D-dimer POCT, one expert did not specifically reflect on the use of D-dimer POCT in general 
practice or ED and another expert mentioned that D-Dimer is being used, but no quantification is 
possible because the costs are not refunded. One further expert did not know if the D-dimer test is 
used currently in office-based practices in Austria.  
According to one expert, there is potentially an alternative role for D-dimer as a biomarker screen-
ing tool as it can rule out many diseases. The same expert warned that  
“D-dimer is a very unspecific marker, which may also be positive due to inflammation. Even 
uncomplicated infections often show positive test results. Therefore, POC D-dimer test should 
have a limited availability and should be used only in selected departments in hospitals, in the 
EDs and by selected community-based specialists”. 
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However, one expert interprets the D-dimer test as highly valuable in general practice according 
to own experience, while this expert had no experience with Tn-POCT in general practice, high-
lighting that no exclusion is possible with this test: 
D-dimer: yes (s. above; (fear or symptoms of) DVT and PE rather frequent reasons for en-
counter: highly valuable in daily practice, Troponin: no – no exclusion possible, applicable after 
hours after symptom onset, so rather infrequent and good chance or expiring unused (no re-
fund either). 
 
Settings for POCT diagnostics  
The first expert is somewhat sceptical to the potential benefit of using D-dimer POCT while reflect-
ing somewhat positively on the value of Tn-POCT. However, the specific settings in which these 
would be beneficial are only vaguely answered: 
“(...) The main aim of POCT is to rule out the disease and if the physician has a strong suspect 
that the patient has the disease, the patient will be sent to the hospital, and no POCT will be 
done. There is not a high risk of treating DVT later (e.g. 3 hours) if you do not do POCT, the 
only risk is that the patient will get PE, but it is very unlikely. (...) Tn-POCT makes more sense 
because coronary artery syndrome is a more severe disease. Nevertheless, it is unlikely that a 
patient would have ACS and not present symptoms. In ACS, an ECG is done first. If the result 
is clear it is not necessary to do the Tn test.” 
The second clinical expert describes the use of Tn-POCT or D-dimer POCT useful depending on 
the setting. Tn-POCT may, for instance, to be seen as  
“(...) one helpful tool in a bigger picture, for family practice and outpatient units. CL test take 
more than few hours in any extramural setting: patient at risk of DVT/PE or coronary heart dis-
ease (CHD) cannot be sent to CL, sending blood samples takes too much time: decisions 
have to be made within minutes. Unavailable POCT (D-dimer) means: either admission to 
hospital, or organisation of imaging: venous ultrasound also not generally refunded for outpa-
tients, so mostly angiography is performed (for: refunded): higher potential harm, no higher 
benefit, invasive, painful.” 
The third clinical expert highlights that it is dependent on the setting if such a test may be useful. 
The blurry and unstandardized definitions make it challenging to describe the value of POCTs in 
the different settings: In Austria, for example, EDs are heterogeneous, central and decentral: 
“(...) Settings for these POC tests may include hospital units, such as wards, perioperative units, 
intensive care units, and emergency departments, outpatient departments, specialist offices, 
GP offices and mobile units, such as ambulance vehicles. These settings itself are heteroge-
neous, centralised and decentralised, some very remote. Even some hospital settings do not 
have a central lab available 24/7”. 
Summing up the content of all three expert consultations, the potential value of these POCT devic-
es was interpreted differently. For D-dimer POCT, for instance, one expert reflects on it positively, 
while another expert does not see the point in using this POC diagnostic test. Consensus exists 
regarding the potential value of Tn-POCT in settings where a CL would not be available or would 
take too long to get the results. However, one expert doubts whether these settings would actually 
exist in Austria (because of the hospital-based healthcare system). 
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7.2 Romania 
In the Romanian context four experts were consulted: one cardiologist, one emergency doctor, and 
two family physicians.  
 
Experts’ opinion on current use of the tests 
All four clinicians confirmed use of rapid D-dimer and Tn tests in the emergency context, referring 
mainly to the emergency hospital units, or medical centres. But these facilities use the services of 
laboratories in their own structure. They mentioned the use of POCTs in Romania, but they were 
not sure about the extent of their use. However the clinicians reported that these tests in POC 
form are not used in the primary care or community care setting. 
 
Experts’ opinion on the usefulness of the tests 
Regarding the place of the two diagnostic tests and the thresholds that may apply, almost all con-
sulted experts said that they are useful in both diagnosis and the monitoring of patients at risk. 
The utility of using troponin is underlined by one expert as follows: “These tests are useful in rapid 
diagnosis of ACS, especially in the absence of electrocardiographic changes”. A limitation in using 
these tests in the Romanian context might be: insufficient number of kits; overcrowding in emer-
gency rooms that might mean the emergency doctor refers the patient to another service straight 
away; and insufficient training of some physicians in use and interpretation of the tests. 
 
Experts’ experience of the tests 
With regard to the experts’ experience, the cardiologist and the emergency doctor had both used 
rapid D-dimer and Tn tests, whilst one of the family physicians had only used the D-dimer. They 
rather used the services of laboratories in their facility structure. The physician working in the ED 
of the university hospital mentioned that she has “been using both tests for about 10 years daily” 
and “they are very useful in refuting the diagnosis, especially as about 30% of patients presenting 
at the ED report chest pain”. 
 
Experts’ opinion on relevant settings  
All consulted experts agreed on potential settings where POCT diagnostics might sensibly be used. 
These are mainly the Permanent Care Centres (24-hour care) where people with emergencies go 
to seek health care, especially in rural remote areas. These centres arise from the agreement 
among a group of family physicians in a certain area to perform on-duty calls for their patients. At 
these centres, family physicians provide emergency care and patients attend them when their 
family physician is off service. In the experts’ opinion, the use of these tests could potentially save 
lives by enabling early diagnosis and treatment, and could potentially avoid unnecessary travel 
and use of resources for patients that are clinically suspected but in fact do not have the disease. 
In addition, one expert considered that these tests might be used in ambulatory cardiology offices 
or even in the emergency units of small hospitals. This would give the possibility of a more accu-
rate diagnosis of acute coronary artery disease and would avoid the referral of patients to the next 
level or even to university hospitals, hence reducing the burden on these services. 
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All consulted experts believed that use of these tests might change referral practice, but the car-
diologist also recommended training for those who might use these tests, in order that they may 
be able to interpret them correctly. 
 
Current clinical decision rules in Romania 
The Romanian Society of Cardiology has developed national guidelines based on those of the ESC. 
Based on the national guidelines, each medical setting has to develop its own clinical practice pro-
tocol. In some settings these protocols are not yet developed, in other settings they exist but clini-
cians do not comply with them. 
In summary, the potential value of these POCTs was considered positive by all consulted experts. 
Rural areas with no access to CL testing were highlighted as particularly relevant settings, as it 
was thought that use of these tests would change referral practices and release the burden on 
very crowded highly specialized hospitals. If this occurs, the experts expect that it would allow for 
better spending of funds and better health outcomes. 
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8 DISCUSSION 
This report aimed to evaluate the clinical utility/effectiveness and safety of Tn-POCT and D-dimer 
POCT in patients presenting to ambulatory care (primary or community care) or emergency care 
with symptoms that may indicate acute coronary syndrome, suspected deep vein thrombosis or 
pulmonary embolism.  
For Tn-POCT, we identified 15 relevant point of care devices for this rapid evidence synthesis. Of 
these, 14 devices measure troponin quantitatively. For D-dimer POCT, eleven devices were iden-
tified, eight of which measure D-dimer quantitatively (see chapter 4). POCT devices can be classi-
fied in different ways [9] e.g., hand-held devices, fixed devices, etc., and manifest differences in 
measurement methods (e.g., quantitative vs. qualitative, the sample size and analytical range), as 
described in chapter 4. The exact nature of POCT products in use in the Austrian and Romanian 
health care systems is unknown.  
 
Tn-POCT 
The available evidence is based on two systematic reviews [25, 26] with moderate to high certain-
ty according to AMSTAR-2. These two systematic reviews included a total of 42 primary studies, 
looking at diagnostic test accuracy (10 studies) and clinical utility (30 studies). Two further studies 
looked at both clinical utility and diagnostic test accuracy. 
The results for diagnostic test accuracy show that there are significant inconsistencies in estimates 
measured across settings as evident in the comparison of diagnostic test accuracy estimates of 
the 11 studies included in the CADTH report [25] and significant limitations with the data (e.g., sole-
ly non-comparative studies in one review [26]). The comparative evidence found by the CADTH 
report [25] shows that, compared with CL testing, Tn-POCT tended to have a lower sensitivity, 
lower negative predictive value, higher specificity and higher positive predictive value. 
Of the 32 studies in the included reviews that investigated the clinical utility of Tn-POCT, seven 
were randomised controlled trials. The evidence was insufficient to show non-inferiority in compar-
ison to CL testing when implementing Tn-POCT if CL testing is onsite or readily available (e.g., in 
the emergency department). The evidence is also insufficient to clearly show superiority when com-
pared to usual care in settings without or with delayed CL testing (e.g., certain ambulatory care 
settings, pre-hospital emergency medicine). 
In the emergency department setting, evidence from the CADTH report [25] showed some limited 
evidence that implementing Tn-POCT in the emergency department reduces turnaround time (a 
reduction was reported in 2 RCTs), time to clinical decision (reduction shown in 2 RCTs & 1 ob-
servational study), and length of stay (reduction shown in 3 RCTs and 2 observational studies, but 
an increase was reported in 1 RCT). Furthermore, the use of Tn-POCT did not statistically signifi-
cantly influence mortality (results reported in 2 RCTs and 3 observational studies) or adverse events 
(results reported in 2 RCTs and 2 observational studies) compared with CL testing for a follow up 
of up to one year. Additionally, quality of life was also not statistically significantly different after up 
to three months of follow-up (1 RCT reported on this outcome). However, overall the evidence is 
insufficient to clearly show non-inferiority of Tn-POCT in comparison to CL testing, also in light of 
the poorer sensitivity and lower negative predictive value as shown above [25].  
In ambulatory (primary and community) care, insufficient evidence was found indicating superiority 
of using a pathway with Tn-POCT compared to usual care (without Tn-POCT) based on the se-
lected clinical utility outcomes: evidence based on one cohort study that was identified by both of 
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the included systematic reviews [25, 26] suggests that implementing Tn-POCT may reduce the 
referral rates but potentially with an increased risk of missing out on acute myocardial infarction or 
unstable angina. No evidence was found to conclude that implementing Tn-POCT has a beneficial 
or harmful effect on mortality/morbidity or health-related quality of life. 
In pre-hospital emergency medicine, there is also insufficient evidence indicating superiority of us-
ing a pathway with Tn-POCT compared to usual care (without Tn-POCT) in the ambulance trans-
port: The CADTH report [25] found evidence consisting of one RCT showing no difference in hos-
pital admissions and a non-statistical reduction of time from first medical contact to discharge from 
emergency department or admission to hospital whilst one non-comparative observational study 
showed a median turnaround time of 83 minutes (range: 46-187). Concerning mortality, the CADTH 
report [25] found evidence consisting of one RCT showing no difference in death in the following 
30 days, but no further information was reported (e.g., exact survival rates or p-values). No evi-
dence was found with regard to the potential effect of implementing Tn-POCT on quality of life. 
The results of the guideline synopsis highlight a potential scenario for the use of Tn-POCT: Two 
out of eight included clinical practice guidelines recommend using Tn-POCT if a turnaround time 
of 60 minutes cannot be met [27, 30]. It appears that these two guideline recommendations in 
favour of using Tn-POCTs if a rapid turnaround time cannot be ensured are consistent. The other 
relevant guideline recommendations do not directly address whether to use/not use Tn-POCT. 
One guideline from the European Society of Cardiology, for instance, also recommends that the 
results should be obtained within 60 minutes (Level A, class I), without specifically recommend-
ing/not recommending a Tn-POCT device [14]. One guideline [15] recommends not to use qualita-
tive troponin tests routinely in primary care to exclude an acute myocardial infarction. Another guide-
line from the United States [30] suggest that troponin tests should provide not only qualitative but 
also quantitative information (Level C, Class II). The remaining included guidelines are even less 
specific in their recommendations about the use of Tn-POCT.  
In terms of the Austrian situation, the experts we consulted believed that there could theoretically 
be a potential value of Tn-POCT in settings where a CL would not be available or would take too 
long to supply results. However, one of the consulted experts doubts whether this situation would 
exist in Austria (because of the hospital-based healthcare system). 
 
D-dimer POCT 
For D-dimer POCT, six systematic reviews [26, 31-35], containing between four and nine studies 
relating to between 199 and 55,268 patients were included in this assessment. The quality, ac-
cording to AMSTAR-2, was moderate to high for the included reviews. A further two non random-
ised controlled trials [36, 37] with moderate to severe risk of bias were included to update one 
systematic review to also include symptoms relating to deep vein thrombosis. One systematic re-
view [35] reported evidence regarding the effect of implementing D-dimer POCT in emergency 
care on patient management. Based on observational studies only, this review of moderate quality 
at most, found D-dimer POCT to be associated with a reduction of turnaround time, a reduction in 
number of hospital admissions and shorter length of stay. However, given the absence of RCT da-
ta, the evidence is insufficient to show a beneficial effect on patient management, and no evidence 
was found to evaluate the effect on mortality/morbidity and quality of life in the emergency depart-
ment. Similarly, only a few prospective studies evaluating the effect of GP use of POCT on clinical 
diagnostic accuracy and clinical management in primary care patients with cardiopulmonary symp-
toms have been performed [26]. As a consequence, there is a lack of reliable, good quality evidence 
to show non-inferiority compared to CL testing and superiority compared to the current situation 
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(with no immediate CL testing) in emergency care or ambulatory care (primary and community 
care) settings. There is however some evidence that using D-dimer POCT may prevent unneces-
sary referrals for imaging, with benefits for patients and budgets, however this assumes the cor-
rect use of D-Dimer POCT in combination with an established clinical prediction tool. 
Ten guidelines [15, 18, 19, 29, 38-43] from different international institutions were identified on the 
use of D-dimer POCT. Eight out of ten guidelines conclude that POCT can be used to exclude 
suspected pulmonary embolism or deep vein thrombosis in combination with low pre-test probabil-
ity [18, 19, 29, 38, 39, 41-43]. Only one guideline [40] does not make a recommendation due to 
lack of or weak evidence and one guideline makes an indirect recommendation saying that there 
is no need for an ultrasound if D-Dimer level can be measured with POCT [29]. The recommended 
settings are somewhat inconsistent in the included guidelines: three guidelines did not define the 
setting [29, 39, 42], three guidelines are applicable only in the community or primary care setting 
[15, 19, 43], one guideline is applicable in numerous settings (primary, secondary, tertiary care) 
[18], one guideline in the emergency department [40], one guideline in emergency department and 
outpatient [41]), and one guideline both in the ambulatory and inpatient setting [38]. Two guide-
lines are inconsistent in terms of the recommended sensitivity of the D-dimer test. One guideline 
[38] states that the simple qualitative D-dimer POCT in combination with clinical probability may 
be comparable in its value when compared to the quantitative ELISA test in low-risk patients, while 
another guideline [15] recommends not to use qualitative or semi-quantitative tests in primary care.  
In addition, a negative D-dimer can exclude venous thromboembolism in a low pre-test probability 
setting but a positive D-dimer can leave many diagnoses open. Combining D-dimer with pre-test 
probability leads to greater certainty when ruling out the condition. The reviews [26, 31-35] con-
firm that D-dimer testing is very sensitive with a high negative predictive value, but it is not very 
specific. The sensitivity of the D-dimer test is improved when it is combined with a pre-test clinical 
probability score. The specificity of D-dimer decreases steadily with age, so age-adjusted cut-offs 
are needed among the elderly. 
The included reviews [26, 31-35] and guidelines [15, 18, 19, 29, 38-43] suggest that D-dimer lev-
els- when considered for use in ambulatory care settings- should only ever be measured in pa-
tients with low or intermediate clinical probability of pulmonary embolism or deep vein thrombosis. 
In patients with a high clinical probability, D-dimer should not be measured but patients should pro-
ceed immediately to imaging. It is emphasized in all included guidelines and reviews that D-dimer 
should be measured only after the prior estimation of clinical probability.  
In terms of the Austrian situation, some experts believed that D-dimer POCT could only have a lim-
ited role outside the hospital setting at present, because of the shortage in the training and exper-
tise required to correctly interpret the results alongside the pre-test probability. In addition a pre-
requisite for the use of the test is familiarity with and routine use of clinical decision rules, which 
may not be the case in ambulatory care settings in Austria, unlike other healthcare systems with a 
strong primary care sector. However, one of the consulted experts believes that Austrian family 
doctors do have (must have) the needed expertise to use D-dimer POCT. This expert mentions 
that the goal is hereby to avoid unnecessary hospitalisations, and the test would be able to do that 
to a large extent. The time element is generally not considered to be as crucial for D-dimer as 
there is less danger in the patient waiting to attend hospital and have further tests there. 
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Limitations 
One limitation of our review is that, despite having included systematic reviews of moderate and 
high quality, the primary studies in the systematic reviews and those studies in the update assess-
ment were only of limited quality. One further limitation of our assessment is that the identified 
evidence may also include evidence based on older models of the test devices that may not be on 
the market any longer 21. 
In addition, it should also be mentioned that any benefits found from implementing Tn-POCT and 
D-dimer POCT are strongly dependent on the setting and health care system. For this reason, 
evaluation studies in the field of health service research, than traditional randomised controlled 
trials, might be better suited to fully determine the clinical benefit in specific settings. 
We did not assess the role of algorithms, for instance, in troponin testing or the clinical prediction 
rules to be used in conjunction with D-dimer POCT, as these aspects were beyond the scope of 
this review. Also, multi-biomarker tests that test numerous different biomarkers simultaneously were, 
as far as possible, excluded from the synthesis. These tests are promising and an evaluation of 
the clinical utility of these tests may further be necessary as these tests evolve over time [4]. 
We did not update the evidence on the diagnostic test accuracy of Tn-POCT and D-dimer POCT. 
As a consequence, the evidence of diagnostic accuracy is based on the identified systematic re-
views and may, therefore, not be up-to-date. However, improvements in diagnostic test accuracy 
only indirectly show whether implementation would result in patient-relevant benefits. The aim of 
this review is evaluating clinical utility as a final endpoint, as recommended in diverse methodo-
logical guidelines [44]. In addition, we relied on the judgement of the reviews with regard to quality 
assessment of the diagnostic test accuracy studies being a further limitation. 
 
Further considerations 
Measuring the effect of implementing a POCT device is complex to evaluate since there are many 
other confounding variables that influence the outcomes of interest. In the context of diagnosis and 
treatment of acute coronary syndrome, for instance, there are different algorithms. Usually these 
are dependent on the sensitivity of the devices used to measure troponin and on when troponin is 
tested. Hence, with increasing sensitivity of devices measuring troponin, there may not only be an 
impact on clinical utility but also on the decisional algorithm that may be used [96, 97]. A recent 
study [98], for instance, measured how successful five Tn-POCT devices could rule out non-ST 
elevation myocardial infarction using the 0h/3h algorithm. It showed that some of the devices cur-
rently on the market could even acceptably measure high sensitive troponin. With increasing ad-
vancements in diagnostic performance (esp. the ability to measure high sensitive troponin), one has 
to be aware that these advancements could potentially also have its flipside: due to lower specific-
ity when compared to conventional assays, unwarranted hospitalisations may be increased when 
using devices measuring high-sensitive troponin [97].  
Currently, the European Society of Cardiology, for instance, recommends using the 0h/3h algo-
rithm, and a newer faster approach (0h/1h) if high sensitive troponin assays are available, alt-
hough the latter has not yet been rigorously validated through RCTs [14]. Studies are ongoing to 
validate the 0h/1h strategy [99], as well as to evaluate further risk stratification strategies e.g. the 
HEART score (History, ECG, age, risk factors and initial troponin) [100].  
                                                     
21 e.g., the Clearview Simplify POCT system from Sekisui was researched but no information on whether it is still sold or 
even exists anymore is available for this product online. 
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In addition, it may be useful to identify the POCT devices with the best analytical and diagnostic 
performance, or the ones that are currently used in Austria/Romania, and conduct primary research 
on the clinical utility of these POCT devices. 
 
Ongoing studies 
The search for ongoing studies revealed that there are currently five ongoing studies evaluating 
the use of Tn-POCT in the emergency department. Two of these are RCTs and three are NRCTs. 
The estimated completion date of four of the studies has already passed (4/5 studies) and one 
study is expected to be completed in 2020. The comparators used to compare with Tn-POCT in 
these studies differ slightly but include mostly conventional diagnostic testing. The sample size 
ranges from 50 to 2,000 enrolled patients. Patient management outcomes (e.g., LOS, TTD) are 
measured in three studies whilst two studies solely evaluate the clinical performance/diagnostic 
accuracy. The reader is referred to Table A9 in the appendix for more information on relevant ongo-
ing trials. 
For D-dimer POCT, no ongoing NRCTs or RCTs were identified. 
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9 CONCLUSION 
Before such tests are implemented or their use extended, further research on specific point of care 
tests (quantitative, with certain pre-defined analytical characteristics) in specific settings in Austria 
and Romania is needed. Here a health services research approach might be more appropriate 
than traditional evidence-based medicine, to assess potential benefits in different settings from a 
systems approach. 
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APPENDIX 1: SEARCH STRATEGIES 
METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DOCUMENTATION OF THE SEARCH STRATEGIES TN-POCT 
Documentation of systematic search for clinical practice guidelines for Tn-POCT 
Embase 
Session Results 
....................................................... 
No.  Query Results Results  Date        
#18. (#13 OR #15) AND [2009-2019]/py AND     ([english]/lim OR [german]/lim) 42  24 May 2019 
#17. (#13 OR #15) AND [2009-2019]/py 43  24 May 2019 
#16. #13 OR #15 50  24 May 2019 
#15. #12 AND #14 12  24 May 2019 
#14. guideline*:ti 93,994  24 May 2019 
#13. #12 AND 'practice guideline'/de 47  24 May 2019 
#12. #5 AND #11 796  24 May 2019 
#11. #6 OR #7 OR #8 OR #9 OR #10 31,186  24 May 2019 
#10. 'poc':ti,ab 5,777  24 May 2019 
#9.  'poct':ti,ab 2,118  24 May 2019 
#8.  'point of care':ti,ab,de 28,499  24 May 2019 
#7.  'point of care testing'/exp 11,535  24 May 2019 
#6.  'point of care system'/exp 1,534  24 May 2019 
#5.  #1 OR #2 OR #3 OR #4 74,087  24 May 2019 
#4.  tn:ti,ab 17,171  24 May 2019 
#3.  troponin*:ti,ab,de 57,719  24 May 2019 
#2.  'troponin'/exp 53,782  24 May 2019 
#1.  'troponin test kit'/exp 14  24 May 2019 
.......................................................  
 
Medline 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
- without Revisions <2015 to May 21, 2019>, Ovid MEDLINE(R) <1946 to May Week 3 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Point-of-Care Systems/ (17048) 
2     exp Point-of-Care Testing/ (2307) 
3     point* of care.mp. (30367) 
4     POCT.ti,ab. (1792) 
5     POC.ti,ab. (5281) 
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6     1 or 2 or 3 or 4 or 5 (33117) 
7     exp Troponin/ (19439) 
8     troponin*.mp. (31624) 
9     Tn.ti,ab. (14756) 
10     7 or 8 or 9 (45815) 
11     limit 10 to (guideline or practice guideline) (57) 
12     6 and 10 (552) 
13     guideline*.ti,pt. (93031) 
14     practice guideline.pt. (29264) 
15     13 or 14 (103823) 
16     12 and 15 (5) 
17     11 or 16 (62) 
18     limit 17 to yr="2009 - 2019" (39) 
19     limit 18 to (english or german) (35) 
20     remove duplicates from 19 (25) 
 
*************************** 
 
23.05.2019 
 
Documentation of systematic search for systematic reviews and meta analyses 
(Tn-POCT) 
Cochrane 
Search Name: POCT_Troponin (SRs) 
Last Saved: 31/05/2019 17:20:07 
Comment: LS/GG/JE 
 
ID Search 
#1 MeSH descriptor: [Point-of-Care Systems] explode all trees 
#2 MeSH descriptor: [Point-of-Care Testing] explode all trees 
#3 ("point* of care") (Word variations have been searched) 
#4 (POCT):ti,ab,kw 
#5 (POC):ti,ab,kw 
#6 ("near patient* test*") (Word variations have been searched) 
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (Word variations have been searched) 
#8 MeSH descriptor: [Troponin] explode all trees 
#9 (troponin*) (Word variations have been searched) 
#10 (Tn):ti,ab,kw 
#11 (cTn*):ti,ab,kw 
#12 #8 OR #9 OR #10 OR #11 (Word variations have been searched) 
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#13 #7 AND #12 
#14 troponin* NEAR/5 test* 
#15 #13 OR #14 with Cochrane Library publication date Between Jan 2009 and Dec 2019, in Cochrane 
Reviews, Cochrane Protocols (Word variations have been searched) 
 
14 Hits 
 
CRD 
#### POCT_Troponin HTAs (LS/GG/JE) 
 
1 MeSH DESCRIPTOR Troponin EXPLODE ALL TREES 
2 (troponin*) 
3 (tn) 
4 (cTn) 
5 #1 OR #2 OR #3 OR #4 
6 *  IN HTA 
7 #5 AND #6 
8 *  IN HTA  FROM 2009 TO 2019 
9 #7 AND #8 
 
14 Hits 
 
28.05.2019 
 
Embase 
Session Results 
....................................................... 
No.  Query Results                                          Results  Date        
 
 
#25. #16 OR #17 OR #19 OR #24 127  31 May 2019 
#24. #15 AND #23 7  31 May 2019 
#23. #20 OR #21 OR #22 23,232  31 May 2019 
#22. hta*:ti,ab,de 7,274  31 May 2019 
#21. 'technolog* assessment*':ti,ab,de 18,752  31 May 2019 
#20. 'biomedical technology assessment'/exp 13,726  31 May 2019 
#19. #15 AND #18 112  31 May 2019 
#18. ('meta analysis'/exp OR 'systematic review'/exp       
     OR ((meta NEAR/3 analy*):ab,ti) OR  
     metaanaly*:ab,ti OR review*:ti OR overview*:ti OR  
     ((synthes* NEAR/3 (literature* OR research* OR  
     studies OR data)):ab,ti) OR (pooled AND  
     analys*:ab,ti) OR (((data NEAR/2 pool*):ab,ti)  
     AND studies:ab,ti) OR medline:ab,ti OR  
     medlars:ab,ti OR embase:ab,ti OR cinahl:ab,ti OR  
     scisearch:ab,ti OR psychinfo:ab,ti OR  
     psycinfo:ab,ti OR psychlit:ab,ti OR psyclit:ab,ti  
1,092,239  31 May 2019 
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     OR cinhal:ab,ti OR cancerlit:ab,ti OR  
     cochrane:ab,ti OR bids:ab,ti OR pubmed:ab,ti OR  
     ovid:ab,ti OR (((hand OR manual OR database* OR  
     computer*) NEAR/2 search*):ab,ti) OR ((electronic  
     NEAR/2 (database* OR 'data base' OR 'data  
     bases')):ab,ti) OR bibliograph*:ab OR 'relevant  
     journals':ab OR (((review* OR overview*) NEAR/10  
     (systematic* OR methodologic* OR quantitativ* OR  
     research* OR literature* OR studies OR trial* OR  
     effective*)):ab)) NOT ((((retrospective* OR  
     record* OR case* OR patient*) NEAR/2  
     review*):ab,ti) OR (((patient* OR review*) NEAR/2  
     chart*):ab,ti) OR rat:ab,ti OR rats:ab,ti OR  
     mouse:ab,ti OR mice:ab,ti OR hamster:ab,ti OR  
     hamsters:ab,ti OR animal:ab,ti OR animals:ab,ti  
     OR dog:ab,ti OR dogs:ab,ti OR cat:ab,ti OR  
     cats:ab,ti OR bovine:ab,ti OR sheep:ab,ti) NOT  
     ('editorial'/exp OR 'erratum'/de OR 'letter'/exp)  
     NOT (('animal'/exp OR 'nonhuman'/exp) NOT  
     (('animal'/exp OR 'nonhuman'/exp) AND  
     'human'/exp)) 
 
     research* OR literature* OR studies OR trial* OR  
     effective*)):ab)) NOT ((((retrospective* OR  
     record* OR case* OR patient*) NEAR/2  
     review*):ab,ti) OR (((patient* OR review*) NEAR/2  
     chart*):ab,ti) OR rat:ab,ti OR rats:ab,ti OR  
     mouse:ab,ti OR mice:ab,ti OR hamster:ab,ti OR  
     hamsters:ab,ti OR animal:ab,ti OR animals:ab,ti  
     OR dog:ab,ti OR dogs:ab,ti OR cat:ab,ti OR  
     cats:ab,ti OR bovine:ab,ti OR sheep:ab,ti) NOT  
     ('editorial'/exp OR 'erratum'/de OR 'letter'/exp)  
     NOT (('animal'/exp OR 'nonhuman'/exp) NOT  
     (('animal'/exp OR 'nonhuman'/exp) AND  
     'human'/exp)) 
 
 
#17. #15 AND ([cochrane review]/lim OR [systematic 
     review]/lim OR [meta analysis]/lim) 
50  31 May 2019 
#16. #15 AND ('meta analysis'/de OR 'meta analysis 
     (topic)'/de OR 'systematic review'/de OR  
     'systematic review (topic)'/de) 
58  31 May 2019 
#15. #13 OR #14 2,222  31 May 2019 
#14. (troponin* NEAR/4 test*):ti,ab,de 1,574  31 May 2019 
#13. #5 AND #12 802  31 May 2019 
#12. #6 OR #7 OR #8 OR #9 OR #10 OR #11 31,626  31 May 2019 
#11. 'near patient* test*':ti,ab,de 462  31 May 2019 
#10. 'poc':ti,ab 5,790  31 May 2019 
#9.  'poct':ti,ab 2,120  31 May 2019 
#8.  'point of care':ti,ab,de 28,585  31 May 2019 
#7.  'point of care testing'/exp 11,574  31 May 2019 
#6.  'point of care system'/exp 1,546  31 May 2019 
#5.  #1 OR #2 OR #3 OR #4 74,210  31 May 2019 
#4.  tn:ti,ab 17,208  31 May 2019 
#3.  troponin*:ti,ab,de 57,805  31 May 2019 
#2.  'troponin'/exp 53,863  31 May 2019 
#1.  'troponin test kit'/exp 
....................................................... 
15  31 May 2019 
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Medline 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
- without Revisions <2015 to May 24, 2019>, Ovid MEDLINE(R) <1946 to May Week 3 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Point-of-Care Systems/ (17055) 
2     exp Point-of-Care Testing/ (2307) 
3     point* of care.mp. (30385) 
4     POCT.ti,ab. (1792) 
5     POC.ti,ab. (5274) 
6     near patient* test*.mp. (340) 
7     1 or 2 or 3 or 4 or 5 or 6 (33332) 
8     exp Troponin/ (19445) 
9     troponin*.mp. (31635) 
10     Tn.ti,ab. (14774) 
11     cTn*.ti,ab. (11725) 
12     8 or 9 or 10 or 11 (50895) 
13     7 and 12 (559) 
14     ((troponin* or tn or cTnI or cTnT) adj5 test*).mp. (1677) 
15     13 or 14 (2083) 
16     limit 15 to (meta analysis or "systematic review" or systematic reviews as topic) (31) 
17     (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-
analy* or metaanaly* or "research synthesis" or ((information or data) adj3 synthesis) or (data adj2 
extract*))).ti,ab. or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not "psycinfo 
database") or pubmed or scopus or "sociological abstracts" or "web of science").ab. or ("cochrane database 
of systematic reviews" or evidence report technology assessment or evidence report technology assessment 
summary).jn. or Evidence Report: Technology Assessment*.jn. or ((review* adj5 (rationale or evidence or 
study or studies)).ti,ab. and review.pt.) or meta-analysis as topic/ or Meta-Analysis.pt. (575103) 
18     15 and 17 (77) 
19     technology assessment*.mp. (15521) 
20     exp Technology Assessment, Biomedical/ (11858) 
21     HTA.ti,ab. (3320) 
22     19 or 20 or 21 (17946) 
23     15 and 22 (11) 
24     16 or 18 or 23 (85) 
25     limit 24 to yr="2009 - 2019" (77) 
26     limit 25 to (english or german) (77) 
27     remove duplicates from 26 (55) 
 
*************************** 
 
27.05.2019 
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Documentation of systematic search for primary studies (Tn-POCT) 
Cochrane  
Search Name: Troponin primary lit 
Last Saved: 07/07/2019 22:25:08 
Comment: Update CADTH/Schols (GG070719) 
 
ID Search 
#1 MeSH descriptor: [Point-of-Care Systems] explode all trees 
#2 ("point* of care"):ti,ab,kw (Word variations have been searched) 
#3 (office*):ti,ab,kw 
#4 (bedside*):ti,ab,kw (Word variations have been searched) 
#5 (bed-side*):ti,ab,kw 
#6 ("near patient*"):ti,ab,kw (Word variations have been searched) 
#7 POC:ti,ab 
#8 (on-site):ti,ab,kw (Word variations have been searched) 
#9 (rapid):ti,ab,kw 
#10 (ultra-rapid):ti,ab,kw (Word variations have been searched) 
#11 (portable):ti,ab,kw 
#12 (hand-held):ti,ab,kw (Word variations have been searched) 
#13 (hand-held):ti,ab,kw 
#14 (ambulatory):ti,ab,kw 
#15 (transportable):ti,ab,kw 
#16 (quick):ti,ab,kw 
#17 (remote*):ti,ab,kw 
#18 (immediate):ti,ab,kw 
#19 (mobile):ti,ab,kw 
#20 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 
#21 (test*):ti,ab,kw 
#22 (assay*):ti,ab,kw 
#23 (immunoassay*):ti,ab,kw (Word variations have been searched) 
#24 (immuno-assay*):ti,ab,kw 
#25 MeSH descriptor: [Point-of-Care Testing] explode all trees 
#26 POCT:ti,ab 
#27 #21 OR #22 OR #23 OR #24 OR #25 OR #26 
#28 #20 AND #27 
#29 MeSH descriptor: [Troponin] explode all trees 
#30 (troponin*):ti,ab,kw 
#31 TnI*:ti,ab 
#32 TnT*:ti,ab 
#33 cTn*:ti,ab 
#34 hsTn*:ti,ab 
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#35 hs-Tn*:ti,ab 
#36 #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 
#37 #28 AND #36 
#38 #37 with Cochrane Library publication date Between Oct 2014 and Jul 2019 
#39 #37 with Publication Year from 2014 to 2019, in Trials 
#40 #38 OR #39 
 
208 Hits 
 
CINAHL 
#  
 
Query  Limiters/Expanders  
 
Last Run 
Via 
S18 S8 AND S16 Limiters - Published 
Date: 
20141001-20190731 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S17 S8 AND S16 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S16 S9 OR S10 
OR S11 OR 
S12 OR S13 
OR S14 OR S15 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S15 TI hs-Tn* OR 
AB hs-Tn* 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S14 TI hsTn* OR 
AB hsTn* 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S13 TI cTn* OR AB Search modes - Interface - 
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cTn* Boolean/Phrase EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S12 TI TnT* OR 
AB TnT 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S11 TI TnI* OR AB 
TnI* 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S10 troponin* Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - Basic Search 
Database - 
CINAHL 
S9 MH 
"Troponin+" 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S8 S3 AND S7 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S7 S4 OR S5 OR 
S6 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search Database - 
CINAHL 
S6 TI POCT OR 
AB POCT 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
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Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S5 MH "Point-of- 
Care Testing+" 
Search modes - 
Boolean/Phrase 
 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S4 test* OR 
assay* OR 
immunoassay* 
OR immunoassay* 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - CINAHL 
S3 S1 OR S2 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S2 "point* of care" 
OR point*-ofcare 
OR 
office* OR 
bedside* OR 
bed-side OR 
"near patient*" 
OR POC OR 
on-site OR 
rapid OR ultrarapid 
OR 
portable OR 
hand-held OR 
handheld OR 
ambulatory 
OR 
transportable 
OR quick OR 
remote* OR 
immediate OR 
mobile 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S1 MH "Point-of- 
Care 
Systems+" 
Search modes - 
SmartText Searching 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
184 hits 
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Embase  
Session Results  
No.  Query  Results  Date        
#14. #13 AND [1-10-2014]/sd NOT [8-7-2019]/sd                    689  7 Jul 2019 
#13. #11 NOT #12                                               1,722  7 Jul 2019 
#12. #10 AND 'human'/de AND 'Conference Abstract'/it           1,159  7 Jul 2019 
#11. #10 AND 'human'/de                                        2,881  7 Jul 2019 
#10. #1 AND #9                                                 3,632  7 Jul 2019 
#9.  #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8                  114,079  7 Jul 2019 
#8.  'hs-tn*':ti,ab                                           47,467  7 Jul 2019 
#7.  hstn*:ti,ab                                               1,153  7 Jul 2019 
#6.  ctn*:ti,ab                                               15,632  7 Jul 2019 
#5.  tnt*:ti,ab                                                 5,912  7 Jul 2019 
#4.  tni*:ti,ab                                                3,411  7 Jul 2019 
#3.  troponin*:ti,ab,de,tn                                    58,231  7 Jul 2019 
#2.  'troponin'/exp                                           54,281  7 Jul 2019 
#1.  ('point of care system':de,ti,ab,tn OR 'point* of       
     care':ti,ab,de,tn OR office*:ti,ab,de,tn OR  
     bedside*:ti,ab,de,tn OR 'bed side':ti,ab,de,tn OR  
     'near patient*':ti,ab,de,tn OR poc:ti,ab,de,tn OR  
     'on site':ti,ab,de,tn OR rapid:ti,ab,de,tn OR  
     'ultra rapid':ti,ab,de,tn OR portable:ti,ab,de,tn  
     OR 'hand held':ti,ab,de,tn OR  
     handheld:ti,ab,de,tn OR ambulatory:ti,ab,de,tn OR  
     transportable:ti,ab,de,tn OR quick:ti,ab,de,tn OR  
     remote*:ti,ab,de,tn OR immediate:ti,ab,de,tn OR  
     mobile:ti,ab,de,tn) AND (test*:ti,ab,de,tn OR  
     assay*:ti,ab,de,tn OR immunoassay*:ti,ab,de,tn OR  
     'immuno assay*':ti,ab,de,tn) OR 'point-of-care  
     testing'/exp OR poct:ti,ab 
....................................................... 
421,075  7 Jul 2019 
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Medline 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
- without Revisions <2015 to July 03, 2019>, Ovid MEDLINE(R) <1946 to June Week 5 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((exp Point-of-Care Systems/ or point* of care or point*-of-care or office* or bedside* or bed-side or near 
patient* or POC or on-site or rapid or ultra-rapid or portable or hand-held or handheld or ambulatory or 
transportable or quick or remote* or immediate or mobile) and (test* or assay* or immunoassay* or immuno-
assay*)).mp. or exp Point-of-Care Testing/ or POCT.ti,ab. (366755) 
2     exp Troponin/ (19655) 
3     troponin*.mp. (31988) 
4     TnI*.ti,ab. (2360) 
5     TnT*.ti,ab. (5046) 
6     cTn*.ti,ab. (11921) 
7     hsTn*.ti,ab. (555) 
8     hs-Tn*.ti,ab. (454) 
9     2 or 3 or 4 or 5 or 6 or 7 or 8 (41559) 
10     1 and 9 (1640) 
11     exp animals/ not humans.sh. (5022795) 
12     10 not 11 (1525) 
13     limit 12 to ed=20160213-20190705 (541) 
14     remove duplicates from 13 (290) 
 
*************************** 
 
05.07.2019 
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DOCUMENTATION OF THE SEARCH STRATEGIES D-DIMER POCT 
 
Documentation of systematic search for clinical practice guidelines (D-dimer POCT) 
 
Embase 
No.                                               Query Results      Date 
#39.                                                 #27 AND #38 68 23 May 2019 
#38.     (#6 OR #35) AND [2009-2019]/py AND ([english]/lim OR 
[german]/lim) 
101 23 May 2019 
#37.                             (#6 OR #35) AND [2009-2019]/py   108 23 May 2019 
#36.                                                 #6 OR #35 148 23 May 2019 
#35.                                                      #29 OR #34 8 23 May 2019 
#34.                                                 #28 AND #33 8 23 May 2019 
#33.                                     #30 OR #31 OR #32   522826 23 May 2019 
#32.                                 guideline*:ti      93958 23 May 2019 
#31.                                              'guideline'/exp 141 23 May 2019 
#30.                              'practice guideline'/exp    495957 23 May 2019 
#29.                             #28 AND 'practice guideline'/de    6 23 May 2019 
#28.                                              #13 AND #27 189 23 May 2019 
#27.       #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 
OR #22 OR #23 OR #24 OR #25 OR #26 
1047060 23 May 2019 
#26.  stroke*:ti, ab, de 405896 23 May 2019 
#25.                                  'brain ischemia'/exp    170336 23 May 2019 
#24.                           cerebrovascular accident'/exp 304508 23 May 2019 
#23.  vte:ti, ab 18609 23 May 2019 
#22. dvt:ti, ab 18035 23 May 2019 
#21.  pe:ti, ab 56694 23 May 2019 
#20.   'pulmonary embolism*':ti, ab, de 48368 23 May 2019 
#19.                                    'lung embolism'/exp    91016 23 May 2019 
#18.  thrombo embolism*':ti, ab, de 1349 23 May 2019 
#17.  thromboembolism*:ti, ab, de 114959 23 May 2019 
#16.                                'thromboembolism'/exp     482650 23 May 2019 
#15.  thrombos*:ti, ab, de 347401 23 May 2019 
#14.                                      'thrombosis'/exp    319904 23 May 2019 
#13.                                               #4 AND #12 296 23 May 2019 
#12.                          #7 OR #8 OR #9 OR #10 OR #11     31167 23 May 2019 
#11.  'poc':ti, ab 5773 23 May 2019 
#10.   'poct':ti, ab 2116 23 May 2019 
#9.   'point of care':ti, ab, de 28483 23 May 2019 
#8.                                point of care testing'/exp 11529 23 May 2019 
#7.                                 'point of care system'/exp  1533 23 May 2019 
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#6.                                                     #4 AND #5 140 23 May 2019 
#5.                                           guideline*:ti 93958 23 May 2019 
#4.                                          #1 OR #2 OR #3   147907 23 May 2019 
#3.   dimer*:ti, ab, de 147907 23 May 2019 
#2.   'd dimer*':ti, ab, de 21872 23 May 2019 
#1.                                          'd dimer test'/exp    51 23 May 2019 
 
Medline 
No. Query  Results Date 
1 exp Point-of-Care Systems/  17010 22 May 2019 
2 exp Point-of-Care Testing/  2296 22 May 2019 
3 point* of care.mp.  30319 22 May 2019 
4 POCT.ti ab. 1781 22 May 2019 
5 POC.ti ab. 5259 22 May 2019 
6 1 or 2 or 3 or 4 or 5  33051 22 May 2019 
7 d-dimer*.mp.  11396 22 May 2019 
8 dimer*.mp.  147086 22 May 2019 
9 7 or 8  147086 22 May 2019 
10 limit 9 to (guideline or practice guideline)  30 22 May 2019 
11 exp Guideline/  36540 22 May 2019 
12 exp Practice Guideline/  29235 22 May 2019 
13 exp Practice Guidelines as Topic/  131734 22 May 2019 
14 guideline*.mp.  508405 22 May 2019 
15 11 or 12 or 13 or 14  508405 22 May 2019 
16 6 and 9  172 22 May 2019 
17 limit 16 to (guideline or practice guideline)  0 22 May 2019 
18 15 and 16  6 22 May 2019 
19 10 or 18 36 22 May 2019 
20 limit 19 to yr="2009 - 2019"  23 22 May 2019 
21 limit 20 to (english or german)  19 22 May 2019 
22 remove duplicates from 21 13 22 May 2019 
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Documentation of systematic search for systematic reviews and meta analyses (D-
dimer POCT) 
Cochrane 
Last Saved: 31/05/2019 18:44:05 
ID Search 
#1 MeSH descriptor: [Point-of-Care Systems] explode all trees 
#2 MeSH descriptor: [Point-of-Care Testing] explode all trees 
#3 ("point* of care") (Word variations have been searched) 
#4 (POCT):ti,ab,kw 
#5 (POC):ti,ab,kw 
#6 ("near patient* test*") (Word variations have been searched) 
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (Word variations have been searched) 
#8 (D-Dimer*) (Word variations have been searched) 
#9 dimer* (Word variations have been searched) 
#10 MeSH descriptor: [Fibrin Fibrinogen Degradation Products] explode all trees 
#11 #8 OR #9 OR #10 (Word variations have been searched) 
#12 #7 AND #11 
#13 (D-Dimer* OR dimer*) NEAR test* (Word variations have been searched) 
#14 #12 OR #13 with Cochrane Library publication date Between Jan 2009 and Dec 2019, in 
Cochrane Reviews, Cochrane Protocols (Word variations have been searched) 
21 Hits 
Last Saved: 31/05/2019 18:44:05 
 
 
CRD 
1 (D-Dimer*) 
2 (dimer*) 
3 MeSH DESCRIPTOR Fibrin Fibrinogen Degradation Products EXPLODE ALL TREES 
4 #1 OR #2 OR #3 
5 *  FROM 2009 TO 2019 
6 #4 AND #5 
7 (#6) IN HTA 
 
2 Hits 
 
31.05.2019 
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Embase 
Session Results   
.......................................................   
No.  Query Results Results Date 
#27. (#16 OR #17 OR #19 OR #24) AND [2009-2019]/py AND 127           31 May 2019 
     ([english]/lim OR [german]/lim)   
#26. (#16 OR #17 OR #19 OR #24) AND [2009-2019]/py 
2019 
133 
 
31 May  
 
#25. #16 OR #17 OR #19 OR #24 
2019 
183 
 
31 May  
 
#24. #15 AND #23 
2019 
4 
 
31 May  
 
#23. #20 OR #21 OR #22 
2019 
23,232 
 
31 May  
 
#22. hta*:ti,ab,de 
2019 
7,274 
 
31 May  
 
#21. 'technolog* assessment*':ti,ab,de 
2019 
18,752 
 
31 May  
 
#20. 'biomedical technology assessment'/exp 
2019 
13,726 
 
31 May  
 
#19. #15 AND #18 
2019 
172 
 
31 May  
 
#18. ('meta analysis'/exp OR 'systematic review'/exp 
2019 
1,092,239 
 
31 May  
 
     OR ((meta NEAR/3 analy*):ab,ti) OR    
     metaanaly*:ab,ti OR review*:ti OR overview*:ti OR    
     ((synthes* NEAR/3 (literature* OR research* OR    
     studies OR data)):ab,ti) OR (pooled AND    
     analys*:ab,ti) OR (((data NEAR/2 pool*):ab,ti)    
     AND studies:ab,ti) OR medline:ab,ti OR    
     medlars:ab,ti OR embase:ab,ti OR cinahl:ab,ti OR    
     scisearch:ab,ti OR psychinfo:ab,ti OR    
     psycinfo:ab,ti OR psychlit:ab,ti OR psyclit:ab,ti    
     OR cinhal:ab,ti OR cancerlit:ab,ti OR    
     cochrane:ab,ti OR bids:ab,ti OR pubmed:ab,ti OR    
     ovid:ab,ti OR (((hand OR manual OR database* OR    
     computer*) NEAR/2 search*):ab,ti) OR ((electronic    
     NEAR/2 (database* OR 'data base' OR 'data    
     bases')):ab,ti) OR bibliograph*:ab OR 'relevant    
     journals':ab OR (((review* OR overview*) NEAR/10    
     (systematic* OR methodologic* OR quantitativ* OR    
     research* OR literature* OR studies OR trial* OR    
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     effective*)):ab)) NOT ((((retrospective* OR    
     record* OR case* OR patient*) NEAR/2    
     review*):ab,ti) OR (((patient* OR review*) NEAR/2    
     chart*):ab,ti) OR rat:ab,ti OR rats:ab,ti OR    
     mouse:ab,ti OR mice:ab,ti OR hamster:ab,ti OR    
     hamsters:ab,ti OR animal:ab,ti OR animals:ab,ti    
     OR dog:ab,ti OR dogs:ab,ti OR cat:ab,ti OR    
     cats:ab,ti OR bovine:ab,ti OR sheep:ab,ti) NOT    
     ('editorial'/exp OR 'erratum'/de OR 'letter'/exp)    
     NOT (('animal'/exp OR 'nonhuman'/exp) NOT    
     (('animal'/exp OR 'nonhuman'/exp) AND    
     'human'/exp))   
#17. #15 AND ([cochrane review]/lim OR [systematic 
2019 
90 
 
31 May  
 
     review]/lim OR [meta analysis]/lim)   
#16. #15 AND ('meta analysis'/de OR 'meta analysis 
2019 
95 
 
31 May  
 
     (topic)'/de OR 'systematic review'/de OR    
     'systematic review (topic)'/de)   
#15. #13 OR #14 
2019 
2,796 
 
31 May  
 
#14. (('d dimer*' OR dimer*) NEAR/4 test*):ti,ab,de 
2019 
2,590 
 
31 May  
 
#13. #5 AND #12 
2019 
297 
 
31 May  
 
#12. #6 OR #7 OR #8 OR #9 OR #10 OR #11 
2019 
31,626 
 
31 May  
 
#11. 'near patient* test*':ti,ab,de 
2019 
462 
 
31 May  
 
#10. 'poc':ti,ab 
2019 
5,790 
 
31 May  
 
#9.  'poct':ti,ab 
2019 
2,120 
 
31 May  
 
#8.  'point of care':ti,ab,de 
2019 
28,585 
 
31 May  
 
#7.  'point of care testing'/exp 
2019 
11,574 
 
31 May  
 
#6.  'point of care system'/exp 
2019 
1,546 
 
31 May  
 
#5.  #1 OR #2 OR #3 OR #4 
2019 
148,048 
 
31 May  
 
#4.  'd dimer'/exp 
2019 
18,475 
 
31 May  
 
#3.  dimer*:ti,ab,de 
2019 
148,048 
 
31 May  
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#2.  'd dimer*':ti,ab,de 
2019 
21,904 
 
31 May  
 
#1.  'd dimer test'/exp 
2019 
51 
 
31 May  
 
.......................................................   
 
Medline 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Point-of-Care Systems/ (17093) 
2     exp Point-of-Care Testing/ (2316) 
3     point* of care.mp. (30466) 
4     POCT.ti,ab. (1797) 
5     POC.ti,ab. (5302) 
6     near patient* test*.mp. (340) 
7     1 or 2 or 3 or 4 or 5 or 6 (33430) 
8     D-dimer*.mp. (11433) 
9     dimer*.mp. (147344) 
10     exp Fibrin Fibrinogen Degradation Products/ (9252) 
11     8 or 9 or 10 (151007) 
12     7 and 11 (188) 
13     ((D-Dimer or dimer*) adj5 test*).mp. (2018) 
14     12 or 13 (2135) 
15     limit 14 to (meta analysis or "systematic review" or systematic reviews as topic) (55) 
16     (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-
analy* or metaanaly* or "research synthesis" or ((information or data) adj3 synthesis) or (data adj2 
extract*))).ti,ab. or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not "psycinfo 
database") or pubmed or scopus or "sociological abstracts" or "web of science").ab. or ("cochrane database 
of systematic reviews" or evidence report technology assessment or evidence report technology assessment 
summary).jn. or Evidence Report: Technology Assessment*.jn. or ((review* adj5 (rationale or evidence or 
study or studies)).ti,ab. and review.pt.) or meta-analysis as topic/ or Meta-Analysis.pt. (576745) 
17     14 and 16 (98) 
18     technology assessment*.mp. (15538) 
19     exp Technology Assessment, Biomedical/ (11869) 
20     HTA*.ti,ab. (4685) 
21     18 or 19 or 20 (19256) 
22     14 and 21 (0) 
23     15 or 17 or 22 (98) 
24     limit 23 to yr="2009 - 2019" (69) 
25     limit 24 to (english or german) (68) 
26     remove duplicates from 25 (47) 
*************************** 
31.05.2019 
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Documentation of systematic search for primary studies: DVT in primary care 
settings (D-dimer POCT) 
Cochrane 
Search Name: D-Dimer primary lit 
Last Saved: 01/07/2019 12:19:00 
Comment: LS 01.07.2019 
 
ID Search 
#1 ("point of care" OR point-of-care OR office OR bedside OR "near patient" OR POC OR on-site OR rapid 
OR ultra-rapid) (Word variations have been searched) 
#2 test* OR assay* OR immunoassay* OR immuno-assay* OR [mh "‘Point-of-Care Systems’"] OR [mh 
"Point-of-Care Systems"] OR [mh "Point-of-Care Testing"] OR POCT:ti,ab,kw OR D-dimer* OR dimer* OR 
[mh "Fibrin Fibrinogen Degradation Products"] (Word variations have been searched) 
#3 #1 AND #2 (Word variations have been searched) 
#4 "primary care" OR "primary health care" OR "general practice*" OR "family practice*" OR "general 
practitioner*" OR GP:ti,ab,kw OR "family doctor*" OR "family physician*" OR [mh "‘Primary Health Care’"] OR 
[mh "‘Physicians, Primary Care’"] OR [mh "‘Family Practice’"] OR [mh "‘General Practitioners’"] OR [mh 
"‘Physicians, Family’"] (Word variations have been searched) 
#5 #3 AND #4 (Word variations have been searched) 
#6 MeSH descriptor: [Venous Thrombosis] explode all trees 
#7 (vein* OR ven* OR deep*) NEAR thrombo* (Word variations have been searched) 
#8 (VTE):ti,ab,kw 
#9 (DVT):ti,ab,kw 
#10 (leg* NEAR (pain OR cramp*)) (Word variations have been searched) 
#11 MeSH descriptor: [Muscle Cramp] explode all trees 
#12 MeSH descriptor: [Leg] explode all trees 
#13 #11 AND #12 (Word variations have been searched) 
#14 #6 OR #7 OR #8 OR #9 OR #10 OR #12 (Word variations have been searched) 
#15 #5 AND #14 (Word variations have been searched) 
#16 #15 with Cochrane Library publication date Between Oct 2014 and Jun 2019 (Word variations have 
been searched) 
#17 #15 with Publication Year from 2014 to 2019, in Trials (Word variations have been searched) 
#18 #16 OR #17 (Word variations have been searched) 
63 Hits 
 
CINAHL 
#  
 
Query  
 
Limiters/Expanders  
 
Last Run 
Via 
S12 S1 AND S10 Limiters - 
Erscheinungsdatum: 
20141001-20190631 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
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CINAHL 
S11 S1 AND S10 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S10 S2 OR S3 OR 
S4 OR S5 OR S6 OR S9 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S9 S7 AND S8 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S8 (MH "Leg+") Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S7 (MH "Muscle 
Cramp+") 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S6 (leg* N3 (pain 
OR cramp*)) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S5 TI DVT OR AB 
DVT 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
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Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
S4 TI VTE OR AB 
VTE 
Search modes -
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S3 ((vein* OR 
ven* OR 
deep*) N5 
thrombo*) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S2 (MH "Venous 
Thrombosis+") 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic Search 
Database - 
CINAHL 
S1 ("point of care" 
OR point-ofcare 
OR office 
OR bedside 
OR "near 
patient" OR 
POC OR onsite 
OR rapid 
OR ultra-rapid) 
AND (test* OR 
assay* OR 
immunoassay* 
OR immuneassays* 
OR 
(MH "‘Point-of- 
Care 
Systems’+") 
OR (MH 
"Point-of-Care 
Testing+") OR 
POCT OR 
D-dimer* OR 
dimer* OR (MH 
"Fibrin 
Fibrinogen 
Degradation 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
88 Hits 
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Embase 
No.  Query Results  
Results  Date        
#20. #19 AND [1-10-2014]/sd NOT [29-6-2019]/sd 101  28 Jun 2019 
#19. #10 AND #18 389  28 Jun 2019 
#18. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17           244,361  28 Jun 2019 
#17. 'leg cramp'/exp 2,111  28 Jun 2019 
#16. 'leg pain'/exp 45,848  28 Jun 2019 
#15. (leg* NEAR/2 (pain OR cramp*)):ti,ab,de                  23,871  28 Jun 2019 
#14. dvt:ti,ab 18,148  28 Jun 2019 
#13. vte:ti,ab 18,770  28 Jun 2019 
#12. ((vein* OR ven* OR deep*) NEAR/4                            
thrombo*):ti,ab,de 
175,204  28 Jun 2019 
#11. 'vein thrombosis'/exp 127,891  28 Jun 2019 
#10. #1 AND #9 1,809  28 Jun 2019 
#9.  #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8                  151,142  28 Jun 2019 
#8.  'fibrin degradation product'/exp 3,897  28 Jun 2019 
#7.  dimer*:ti,ab,de,tn                                      148,769  28 Jun 2019 
#6.  'd-dimer*':ti,ab,de,tn                                   22,030  28 Jun 2019 
#5.  'd dimer assay'/exp 15  28 Jun 2019 
#4.  'd dimer blood level'/exp 19  28 Jun 2019 
#3.  'd dimer test'/exp 51  28 Jun 2019 
#2.  'd dimer'/exp                                            18,590  28 Jun 2019 
#1.  (('point* of care':ti,ab,de OR office*:ti,ab,de 
     OR bedside*:ti,ab,de OR 'near patient*':ti,ab,de  
     OR poc:ti,ab,de OR 'on site':ti,ab,de OR  
     rapid:ti,ab,de OR 'ultra rapid':ti,ab,de) AND  
     (test*:ti,ab,de OR assay*:ti,ab,de OR  
     immunoassay*:ti,ab,de OR 'immuno assay*':ti,ab,de  
     OR 'point-of-care systems'/exp) OR 'point-of-care  
     testing'/exp OR poct:ti,ab,de) AND ('primary  
     care':ti,ab,de OR 'primary health care':ti,ab,de  
     OR 'general practice*':ti,ab,de OR 'family  
     practice*':ti,ab,de OR 'general  
     practitioner*':ti,ab,de OR gp*:ti,ab,de OR  
     'family doctor*':ti,ab,de OR 'family  
     physician*':ti,ab,de OR 'primary health care'/exp  
     OR 'physicians, primary care'/exp OR 'family  
     practice'/exp OR 'general practitioners'/exp OR  
     'physicians, family'/exp) 
....................................................... 
276,985  28 Jun 2019 
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Medline 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
- without Revisions <2015 to June 27, 2019>, Ovid MEDLINE(R) <1946 to June Week 4 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (((point* of care or point*-of-care or office* or bedside* or near patient* or POC or on-site or rapid or 
ultra-rapid).mp. and ((test* or assay* or immunoassay* or immuno-assay*).mp. or exp Point-of-Care 
Systems/)) or exp Point-of-Care Testing/ or POCT.mp. or D-dimer*.mp. or dimer*.mp. or exp Fibrin 
Fibrinogen Degradation Products/) and ((primary care or primary health care or general practice* or family 
practice* or general practitioner* or GP* or family doctor* or family physician*).mp. or exp Primary Health 
Care/ or exp Physicians, Primary Care/ or exp Family Practice/ or exp General Practitioners/ or exp 
Physicians, Family/) (10357) 
2     exp Venous Thrombosis/ (59129) 
3     ((vein* or ven* or deep*) adj5 thrombo*).mp. (99640) 
4     VTE.ti,ab. (12377) 
5     DVT.ti,ab. (11089) 
6     (leg* adj3 (pain* or cramp*)).mp. (9011) 
7     exp Muscle Cramp/ (2295) 
8     exp Leg/ (65791) 
9     7 and 8 (253) 
10     2 or 3 or 4 or 5 or 6 or 9 (127405) 
11     1 and 10 (127) 
12     limit 11 to ed=20160301-20190628 (29) 
13     remove duplicates from 12 (16) 
 
*************************** 
 
28.06.2019 
 
 
Documentation of systematic search for primary studies in emergency care 
settings (D-dimer POCT) 
Cochrane  
ID Search 
#1 ("point* of care" OR point-of-care OR office* OR bedside OR "near Patient*" OR POC:ti,ab,kw OR [mh 
"‘Point-of-Care Systems’"] OR on-site OR rapid OR ultra-rapid) OR D-dimer* OR dimer* OR [mh "Fibrin 
Fibrinogen Degradation Products"] (Word variations have been searched) 
#2 test* OR assay* OR immunoassay* OR immuno-assay* OR [mh "Point-of-Care Testing"] OR 
POCT:ti,ab,kw (Word variations have been searched) 
#3 #1 AND #2 (Word variations have been searched) 
#4 MeSH descriptor: [Emergency Service, Hospital] explode all trees 
#5 (Emergency department*):ti,ab,kw (Word variations have been searched) 
#6 (Accident* & Emergenc*):ti,ab,kw (Word variations have been searched) 
#7 ((Accident* and Emergenc*)):ti,ab,kw (Word variations have been searched) 
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#8 ("A and E"):ti,ab,kw (Word variations have been searched) 
#9 A&E 
#10 "A & E" 
#11 (casualty):ti,ab,kw 
#12 ((casualty OR emergenc*) NEAR (department* OR ward* OR station* OR unit* OR room*)):ti,ab,kw 
(Word variations have been searched) 
#13 (walk-in centre*):ti,ab,kw (Word variations have been searched) 
#14 (walk-in center*):ti,ab,kw (Word variations have been searched) 
#15 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 (Word variations 
have been searched) 
#16 #3 AND #15 (Word variations have been searched) 
#17 MeSH descriptor: [Venous Thrombosis] explode all trees 
#18 (vein* OR ven* OR deep*) NEAR thrombo* (Word variations have been searched) 
#19 (VTE):ti,ab,kw 
#20 (DVT):ti,ab,kw 
#21 (leg* NEXT (pain* OR cramp*)):ti,ab,kw (Word variations have been searched) 
#22 MeSH descriptor: [Muscle Cramp] explode all trees 
#23 MeSH descriptor: [Leg] explode all trees 
#24 #22 AND #23 (Word variations have been searched) 
#25 #17 OR #18 OR #19 OR #20 OR #21 OR #24 (Word variations have been searched) 
#26 ("cardio-pulmonary disease*" OR "cardiopulmonary disease*" OR "pulmonary disease*" OR 
"thromboembolic event*" OR dyspnoea OR "pulmonary embolism*" OR "lung embolism*" OR pneumonia* 
OR "lower respiratory infect*" OR cough* OR bronchit* OR asthma* OR COPD OR pleuritis):ti,ab,kw OR [mh 
"Pulmonary Heart Disease"] OR [mh "Lung Diseases"] OR [mh "Lung Diseases, Obstructive"] OR [mh 
Thromboembolism] OR [mh Dyspnea] OR [mh "Pulmonary Embolism"] OR [mh Pneumonia] OR [mh 
"Pneumonia, Bacterial"] OR [mh "Pneumonia, Viral"] OR [mh Cough] OR [mh Bronchitis] OR [mh Asthma] 
OR [mh "Pulmonary Disease, Chronic Obstructive"] OR [mh Pleurisy] (Word variations have been searched) 
#27 #25 OR #26 (Word variations have been searched) 
#28 #16 AND #27 (Word variations have been searched) 
#29 #28 with Cochrane Library publication date Between Oct 2014 and Jun 2019 (Word variations have 
been searched) 
#30 #28 with Publication Year from 2014 to 2019, in Trials (Word variations have been searched) 
#31 #29 OR #30 (Word variations have been searched) 
 
131 Hits 
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CINAHL 
# Query Limiters/Expanders Last Run via 
S28 (S1 AND S12) AND 
(S25 AND S26) 
Limiters - Published 
Date: 
20141001-20190731 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S27 (S1 AND S12) AND 
(S25 AND S26) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S26 S1 AND S12 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
S25 S13 OR S14 OR S15 
OR S16 OR S17 OR 
S18 OR S19 OR S20 
OR S21 OR S22 OR 
S23 OR S24 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S24 ("walk-in center*") Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S23 ("walk-in centre*") Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S22 (casualty OR 
emergenc*) N3 
(department* OR 
ward* OR station* OR 
unit* OR room*) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
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Search 
Database - 
CINAHL 
S21 (casualty) Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - CINAHL 
S20 "casualty department" Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S19 ("A & E") Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S18 A&E Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced Search 
Database - 
CINAHL 
S17 "A and E" Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S16 "Accident* and 
Emergenc*" 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S15 "Accident* & Search modes - Interface - 
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Emergenc*" Boolean/Phrase EBSCOhost 
Research 
Databases 
Search Screen - 
Advanced 
Search 
Database - 
CINAHL 
S14 "Emergency 
department*" 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S13 (MH "Emergency 
Service, Hospital+") 
Expanders - Apply 
related words; Apply 
equivalent subjects 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
S12 S10 OR S11 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
S11 ("cardio-pulmonary 
disease*" OR 
"cardiopulmonary 
disease*" OR 
"pulmonary disease*" 
OR "thromboembolic 
event*" OR dyspnoea 
OR "pulmonary 
embolism*" OR "lung 
embolism*" OR 
pneumonia* OR 
"lower respiratory 
infect*" OR cough* 
OR bronchit* OR 
asthma* OR COPD 
OR pleuritis) OR (MH 
"Pulmonary Heart 
Disease+") OR (MH 
"Lung Diseases+") 
OR (MH "Lung 
Diseases, 
Obstructive+") OR (MH 
"Thromboembolism+") 
OR (MH "Dyspnea+") 
OR (MH "Pulmonary 
Embolism+") OR (MH 
"Pneumonia+") OR 
(MH "Pneumonia, 
Bacterial+") OR (MH 
"Pneumonia, Viral+") 
OR (MH "Cough+") 
OR (MH 
"Bronchitis+") OR 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
Search 
Database - 
CINAHL 
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(MH "Asthma+") OR 
(MH "Pulmonary 
Disease, Chronic 
Obstructive+") OR 
(MH "Pleurisy+") 
S10 S2 OR S3 OR S4 OR 
S5 OR S6 OR S9 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S9 S7 AND S8 Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S8 (MH "Leg+") Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S7 (MH "Muscle 
Cramp+") 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S6 (leg* N3 (pain OR 
cramp*)) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S5 TI DVT OR AB DVT Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
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Database - 
CINAHL 
S4 TI VTE OR AB VTE Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - CINAHL 
S3 ((vein* OR ven* OR 
deep*) N5 thrombo*) 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S2 (MH "Venous 
Thrombosis+") 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Basic 
Search 
Database - 
CINAHL 
S1 ("point of care" OR 
point-of-care OR 
office OR bedside OR 
"near patient" OR 
POC OR on-site OR 
rapid OR ultra-rapid) 
AND (test* OR assay* 
Search modes - 
Boolean/Phrase 
Interface - 
EBSCOhost 
Research 
Databases 
Search 
Screen - 
Advanced 
137 hits 
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Embase  
Session Results 
....................................................... 
No.  Query Results Results  Date        
#33. #32 AND [1-10-2014]/sd NOT [3-7-2019]/sd 590  2 Jul 2019  
#32. #23 AND #31 1,224  2 Jul 2019  
#31. #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 151,197  2 Jul 2019  
#30. 'fibrin degradation product'/exp 3,898  2 Jul 2019  
#29. dimer*:ti,ab,de,tn 148,823  2 Jul 2019  
#28. 'd-dimer*':ti,ab,de,tn 22,042  2 Jul 2019  
#27. 'd dimer assay'/exp 15  2 Jul 2019  
#26. 'd dimer blood level'/exp 19  2 Jul 2019  
#25. 'd dimer test'/exp 51  2 Jul 2019  
#24. 'd dimer'/exp 18,602  2 Jul 2019  
#23. #13 AND #22 2,544  2 Jul 2019  
#22. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR 
     #21 
2,339,841  2 Jul 2019  
 
#21. 'leg cramp'/exp 2,111  2 Jul 2019  
#20. 'leg pain'/exp 45,870  2 Jul 2019  
#19. (leg* NEAR/2 (pain OR cramp*)):ti,ab,de 23,879  2 Jul 2019  
#18. dvt:ti,ab 18,160  2 Jul 2019  
#17. vte:ti,ab 18,781  2 Jul 2019  
#16. ((vein* OR ven* OR deep*) NEAR/4 
     thrombo*):ti,ab,de 
175,271  2 Jul 2019  
#15. 'vein thrombosis'/exp 127,935  2 Jul 2019  
#14. 'cardio-pulmonary disease*':ti,ab,de OR 
     'cardiopulmonary disease*':ti,ab,de OR 'pulmonary  
     disease*':ti,ab,de OR 'thromboembolic  
     event*':ti,ab,de OR dyspnoea:ti,ab,de OR  
     'pulmonary embolism*':ti,ab,de OR 'lung  
     embolism*':ti,ab,de OR pneumonia*:ti,ab,de OR  
     'lower respiratory infect*':ti,ab,de OR  
     cough*:ti,ab,de OR bronchit*:ti,ab,de OR  
     asthma*:ti,ab,de OR copd:ti,ab,de OR  
     pleuritis:ti,ab,de OR 'pulmonary heart  
     disease'/exp OR 'lung diseases'/exp OR 'lung  
     diseases, obstructive'/exp OR  
     'thromboembolism'/exp OR 'dyspnea'/exp OR  
     'pulmonary embolism'/exp OR 'pneumonia'/exp OR  
     'pneumonia, bacterial'/exp OR 'pneumonia,  
     viral'/exp OR 'cough'/exp OR 'bronchitis'/exp OR  
     'asthma'/exp OR 'pulmonary disease, chronic  
     obstructive'/exp OR 'pleurisy'/exp 
2,278,833  2 Jul 2019  
 
#13. #1 AND #12 8,606  2 Jul 2019  
#12. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR 
     #10 OR #11 
210,161  2 Jul 2019  
 
#11. 'walk-in center*':ti,ab,de 21  2 Jul 2019  
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#10. 'walk-in centre*':ti,ab,de 162  2 Jul 2019  
#9.  ((casualty OR emergenc*) NEAR/2 (department* OR 
     ward* OR station* OR unit* OR room*)):ti,ab,de 
190,015  2 Jul 2019  
 
#8.  casualty:ti,ab,de 6,347  2 Jul 2019  
#7.  'a & e':ti,ab,de 11,471  2 Jul 2019  
#6.  a&e:ti,ab 11,401  2 Jul 2019  
#5.  'a and e':ti,ab,de 4,046  2 Jul 2019  
#4.  'accident* and emergenc*':ti,ab,de 5,382  2 Jul 2019  
#3.  'accident* & emergenc*':ti,ab,de 472  2 Jul 2019  
#2.  'emergency ward'/exp 127,928  2 Jul 2019  
#1.  ('point* of care':ti,ab,de OR office*:ti,ab,de OR       
     bedside*:ti,ab,de OR 'near patient*':ti,ab,de OR  
     poc:ti,ab,de OR 'on site':ti,ab,de OR  
     rapid:ti,ab,de OR 'ultra rapid':ti,ab,de) AND  
     (test*:ti,ab,de OR assay*:ti,ab,de OR  
     immunoassay*:ti,ab,de OR 'immuno assay*':ti,ab,de  
     OR 'point-of-care systems'/exp) OR 'point-of-care  
     testing'/exp OR 'fibrin fibrinogen degradation  
     products'/exp OR poct:ti,ab,de OR 'd  
     dimer*':ti,ab,de OR dimer*:ti,ab,de 
....................................................... 
426,365  2 Jul 2019 
 
Medline 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
- without Revisions <2015 to June 27, 2019>, Ovid MEDLINE(R) <1946 to June Week 4 2019> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((point* of care or point*-of-care or office* or bedside* or near patient* or POC or on-site or rapid or ultra-
rapid) and (test* or assay* or immunoassay* or immuno-assay*)).mp. or exp Point-of-Care Systems/ or exp 
Point-of-Care Testing/ or exp Fibrin Fibrinogen Degradation Products/ or (POCT or D-dimer* or dimer*).mp. 
(391653) 
2     exp Emergency Service, Hospital/ (88709) 
3     Emergency department*.mp. (101775) 
4     Accident* & Emergenc*.mp. (813) 
5     "Accident* and Emergenc*".mp. (5006) 
6     "A and E".mp. (28830) 
7     A&E.mp. (25331) 
8     A & E.mp. (9368) 
9     casualty.mp. (7705) 
10     ((casualty or emergenc*) adj3 (department* or ward* or station* or unit* or room*)).mp. (128129) 
11     walk-in centre*.mp. (156) 
12     walk-in center*.mp. (15) 
13     2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (223712) 
14     1 and 13 (7050) 
15     exp Venous Thrombosis/ (59129) 
16     ((vein* or ven* or deep*) adj5 thrombo*).mp. (99640) 
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17     VTE.ti,ab. (12377) 
18     DVT.ti,ab. (11089) 
19     (leg* adj3 (pain* or cramp*)).mp. (9011) 
20     exp Muscle Cramp/ (2295) 
21     exp Leg/ (65791) 
22     20 and 21 (253) 
23     (cardio-pulmonary disease* or cardiopulmonary disease* or pulmonary disease* or thromboembolic 
event* or dyspnoea or pulmonary embolism* or lung embolism* or pneumonia* or lower respiratory infect* or 
cough* or bronchit* or asthma* or COPD or pleuritis).mp. or exp Pulmonary Heart Disease/ or exp Lung 
Diseases/ or exp Lung Diseases, Obstructive/ or exp Thromboembolism/ or exp Dyspnea/ or exp Pulmonary 
Embolism/ or exp Pneumonia/ or exp Pneumonia, Bacterial/ or exp Pneumonia, Viral/ or exp Cough/ or exp 
Bronchitis/ or exp Asthma/ or exp Pulmonary Disease, Chronic Obstructive/ or exp Pleurisy/ (1265615) 
24     15 or 16 or 17 or 18 or 19 or 22 or 23 (1350232) 
25     14 and 24 (1202) 
26     limit 25 to ed=20160301-20190702 (444) 
27     remove duplicates from 26 (234) 
 
*************************** 
 
02.07.2019 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
Table A1: Summary of (reimbursement) recommendations in European countries for the 
technology 
Country  Summary of (reimbursement)  
recommendations and restrictions on 
D-dimer POCT 
Summary (reimbursement)  
recommendations and restrictions on 
Tn-POCT 
England1 Positive recommendation. The technology 
is reimbursed. 
https://www.nice.org.uk/guidance/cg144/c
hapter/Recommendations  
Positive recommendation. The technology 
is reimbursed. 
https://www.nice.org.uk/guidance/dg15/ch
apter/1-Recommendations 
Italy1,2 No details are available about the status 
of recommendation. The technology is 
reimbursed only in hospital use and part 
of DRG. 
No details are available about the status 
of recommendation. The technology is 
reimbursed only in hospital use and part 
of DRG. 
Germany1,2 The technology has not been assessed. It 
is reimbursed. 
The technology has not been assessed. It 
is reimbursed. 
Norway1 The technology has not been assessed. It 
is reimbursed. 
The technology has not been assessed. It 
is reimbursed. 
Austria1 The technology has not been assessed. 
Reimbursement differs between the social 
security institutions 
The technology has not been assessed. 
Reimbursement differs between the social 
security institutions 
Switzerland1,2 No details are available about the status 
of recommendation. It is reimbursed. 
No details are available about the status 
of recommendation. It is reimbursed. 
Belgium2 No details are available about the status 
of recommendation. It is reimbursed. 
No details are available about the status 
of recommendation. It is reimbursed. 
The Netherlands2 No details are available about the status 
of recommendation. It is reimbursed. 
No details are available about the status 
of recommendation. It is reimbursed. 
France2 No details are available about the status 
of recommendation. It is reimbursed. 
No details are available about the status 
of recommendation. It is reimbursed. 
Czech Republic2 No details are available about the status 
of recommendation. It is reimbursed. 
No details are available about the status 
of recommendation. It is reimbursed. 
Abbreviations: DRG 
1 EUnetHTA partners from the respective countries provided the information.  
2 Radiometer Medical ApS provided this information regarding their products.  
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APPENDIX 3: DESCRIPTION OF THE EVIDENCE USED  
DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A2: Overview of guidelines on the use of Tn-POCT 
Name of 
society/organisatio
n issuing guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Setting in which 
applicable 
Summary of 
recommendation 
Level of 
evidence 
(A,B,C)/ 
class of 
recommen
dation (I, 
IIa, IIb, III) 
AHA/ACC [11] 2014 U.S. ED and outpatient 
facilities 
Point-of-care troponin 
values may provide 
initial diagnostic 
information, although 
their sensitivity is 
substantially below 
that of central 
laboratory methods. 
In addition, the 
rigorous quantitative 
assay standardization 
needed for routine 
diagnosis favours 
central laboratory 
testing. 
NA 
SIGN [28] 2016 UK ED, pre-hospital, 
ambulance, 
specialist offices 
Troponin point-of-
care testing assays 
currently licensed in 
the UK are equivalent 
in sensitivity to 12-
hour laboratory-
based standard 
troponin assays. 
Good 
practice 
recommend
ation 
ANZCOR [16] 2016 Australia 
and New 
Zealand 
Chest pain 
observation units 
There has been a 
lack of evidence of 
supporting the routine 
use of point of care 
troponin testing in 
isolation as the 
primary test in a pre-
hospital setting to 
evaluate patients with 
ACS. 
NA 
ESC [14] 2016 Europe NA It is recommended to 
measure cardiac 
troponins with 
sensitive or high-
sensitivity assays and 
obtain the results 
within 60 min. 
Level A, 
Class I 
DEGAM [15] 
 
2011 Germany Primary care In primary care area 
there are various 
qualitative and 
quantitative tests as a 
point-of-care tests 
Level A, DI 
(strong 
recommend
ation, 
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Name of 
society/organisatio
n issuing guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Setting in which 
applicable 
Summary of 
recommendation 
Level of 
evidence 
(A,B,C)/ 
class of 
recommen
dation (I, 
IIa, IIb, III) 
available, which 
allows for the 
determination of 
various biomarkers, 
partly also in 
combination. 
The routine use of a 
qualitative troponin 
tests or other 
biomarker tests to 
exclude an acute 
myocardial infarction 
is not recommended 
in primary care. A 
troponin test is 
appropriate to 
exclude myocardial 
infarction only in 
clinically ambiguous 
cases (intermediate 
clinical probability of 
an ACS) when the 
onset of symptoms is 
>12 hours and the 
ECG is 
unremarkable. 
highest 
level of 
evidence) 
Oman Heart 
Association [27] 
2012 Oman Applicable for all 
cardiac caregivers. 
Blood has to be 
drawn promptly for 
troponin (cardiac Tn T 
or I) measurement. 
The result should be 
available within 60 
minutes. If the local 
laboratory cannot 
provide Tn results 
within 60 minutes, 
point-of-care testing 
should be performed.  
NA 
Japanese Circulation 
Society [29] 
2016 Japan  Disaster medicine ECG and whole-
blood rapid cardiac 
troponin T assay or a 
human fatty acid-
binding protein (H-
FABP) ELISA kit 
should be used to 
enable early 
diagnosis of ACS. 
Level C 
NACB [30] 2007 U.S. Outpatient facilities The laboratory should 
perform cardiac 
marker testing with a 
TAT of 1 h, optimally 
30 min, or less.  
Institutions that 
cannot consistently 
deliver cardiac 
marker TATs of 
approximately 1 h 
Level A, 
Class II 
 
 
 
Level B, 
Class II 
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Name of 
society/organisatio
n issuing guidance 
Date 
of 
issue 
Country/ies  
to which 
applicable 
Setting in which 
applicable 
Summary of 
recommendation 
Level of 
evidence 
(A,B,C)/ 
class of 
recommen
dation (I, 
IIa, IIb, III) 
should implement 
POCT devices. 
Performance 
specifications and 
characteristics for 
central laboratory and 
POC platforms should 
not differ. 
It is recommended 
that POC systems 
provide quantitative 
results, not only 
qualitative 
information.  
Manufacturers and 
professional 
organizations should 
collaborate to 
develop committees 
for the 
standardization of 
new analytes. 
Implementation of 
new tests is more 
easily integrated into 
the laboratory when 
these markers are 
available on a wide 
spectrum of 
analyzers. 
 
 
Level A, 
Class III 
 
 
 
 
Level C, 
Class II 
 
 
 
 
Level A, 
Class III 
Abbreviations: DEGAM Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, AHA/ACC American Heart 
Association/American College of Cardiology, SIGN Scottish Intercollegiate Guidelines Network, ANZCOR Australian and 
New Zealand Resuscitation Council, ESC European Society of Cardiology, ACS Acute Coronary Syndrome, NA Not 
available, U.S. United States, UK United Kingdom, Tn Troponin, ECG Electrocardiograph, AWMF Arbeitsgemeinschaft der 
Wissenschaftlichen Medizinischen Fachgesellschaften, POC point-of-care, POCT point-of-care test, TAT turnaround time, 
ELISA enzyme-linked immunosorbent assay, NACB National Academy of Clinical Biochemistry 
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Table A3: Overview of guidelines on the use of D-dimer POCT 
Name of 
society/ 
organi-
sation 
issuing 
guidance 
Date 
of 
issue 
Country/ 
ies to 
which 
applic-
able 
Setting in which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/  
class of 
recommen
dation (I, 
IIa, IIb, III) 
SIGN [19]  2014 Scotland Primary care 
(GPs, nurses, 
pharmacists) 
In patients with a first episode of VTE, the 
combination of a low probability clinical 
decision rule or ‘DVT or PE unlikely’ and a 
negative D-dimer test can be used to safely 
exclude a diagnosis of VTE. A variety of D-
dimer tests, including POCTs can be used 
in the exclusion of suspected VTE in low 
probability patients. 
Level B 
ESC  
[43] 
2019 Europe In- and 
outpatient 
In community or primary care medicine, POC 
D-dimer testing may have advantages over 
referring a patient to a central laboratory. 
This may particularly apply to remote areas 
where access to healthcare is limited. How-
ever, POC assays have a lower sensitivity 
and negative predictive value compared 
with laboratory-based D-dimer tests. POC 
D-dimer assays should only be used in 
patients with a low pre-test probability.  
NA 
 
NCGC 
[18] 
2012 UK Primary, 
secondary and 
tertiary care  
There are various D-dimer tests available, 
including POCTs which can be done in the 
community, for example by a GP. The 
sensitivity of the assays chosen is very 
important as different tests have varying 
sensitivities. 
NA 
NICE  
[42] 
2012 UK NA A laboratory or POC test can be done to 
assess the concentration of D-dimer in a 
person's blood. The threshold for a positive 
result varies with the type of D-dimer test 
used and is determined locally. The result 
of the D-dimer test can be used as part of 
probability assessment when DVT or PE is 
suspected. 
NA 
AWMF 
[38] 
2015 Germany Ambulatory 
care, inpatient 
(e.g., inpatient, 
day clinics) 
In low-risk patients, a simple qualitative 
bedside test for D-dimer determination in 
combination with the clinical probability 
compared to the more elaborate quantitative 
ELISA test was comparable in its value. 
NA 
DEGAM 
[15] 
2011 Germany Primary care The diagnostic value depends on the type 
of test, the comorbidities, the age and the 
duration of the symptoms. The classic ELI-
SA and the rapid ELISA tests are moderate-
ly specific and highly sensitive in the inpa-
tient setting and therefore recommended to 
exclude PE. It is not recommended to apply 
less sensitive tests like manual qualitative 
or semi-quantitative agglutination tests that 
are also offered in the GP praxis’s.  
NA 
DGK  
[39] 
2009 Germany NA If, in place of the highly sensitive ELISA-D-
dimer test, a qualitative "bedside" test is 
used, this should be done only in patients 
with low clinical probability (or PE unlikely) 
to exclude a PE. 
In hospitalized patients, the diagnostic 
value of the D-dimer assessment is low. 
NA 
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Name of 
society/ 
organi-
sation 
issuing 
guidance 
Date 
of 
issue 
Country/ 
ies to 
which 
applic-
able 
Setting in which 
applicable 
Summary of recommendation Level of 
evidence 
(A,B,C)/  
class of 
recommen
dation (I, 
IIa, IIb, III) 
Jaeschke 
[41] 
2009 NA Outpatient or 
emergency 
room, i.e., not 
among 
hospitalized 
patients 
The guideline concludes that different D-
dimer tests have different characteristics 
and thus require differing recommendations 
for use. 
Moderate sensitivity rapid D-dimer assays 
can effectively rule out DVT in patients with 
a low pre-test probability. Nevertheless, in 
patients with moderate or high pre-test 
probability, the initial use of the moderately 
sensitive D-dimer assay to exclude DVT is 
not recommended.  
NA 
Fesmire 
[40] 
2001 US ED The guideline committee decided not to 
assess the evidence for qualitative D-dimer 
tests used as point-of-care tests because of 
the problems with variability in their 
interpretation and lower sensitivity reported 
in many studies. The guideline also 
highlights that the only RCT directly 
assessing the impact of a D-dimer strategy 
used POCT (SimpliRED).   
Level A 
Japanese 
Circula-
tion Soci-
ety [29] 
2016 Japan Disaster 
medicine 
Upper leg venous ultrasound imaging is  
not necessary for people in whom D-dimer 
levels may be determined with POCT. 
Level B 
Abbreviations: SIGN Scottish Intercollegiate Guidelines Network, ED emergency department, ESC European Society of 
Cardiology, NA Not available, U.S. United States, UK United Kingdom, AWMF Arbeitsgemeinschaft der Wissenschaftlichen 
Medizinischen Fachgesellschaften, POCT point of care test, DVT deep vein thrombosis, VTE venous thromboembolism, 
GP general practicioner, PE pulmonary embolism, NICE National Institute for Health and Care Excellence, NCGC National 
Clinical Guideline Centre, DGK Deutsche Gesellschaft für Kardiologie – Herz und Kreislaufforschung e.V., ELISA enzyme-
linked immunosorbent assay 
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Evidence tables of individual studies included for clinical effectiveness and safety 
 
Table A4: Characteristics of eligible systematic reviews for Tn-POCT 
Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
Number and 
type of included 
studies 
41 primary studies, 5 companion reports, 2 evidence based 
guidelines 
 
Overall: 
7 RCTs 
22 prospective observational studies 
10 retrospective observational studies 
2 surveys 
2 evidence based guidelines 
 
DTA: 
9 studies (+1 companion report) 
Clinical utility: 
30 studies (+3 companion reports) 
2 guidelines 
 
2 further studies that looked at both DTA and clinical utility 
7 studies in total of which 2 studies 
contained Tn- POCT 
 
2 prospective comparative cohort 
studies 
Planer 2006 
Nillsson 2013 
Setting No filter: incl. ED & primary care Primary care 
Search period   14/01/2015, regular alerts until 12/02/2016 To October 2014 
Databases/ 
sources 
searched 
MEDLINE (updates via Ovid), Embase (updates via Ovid), 
The Cochrane Library, PubMed 
Additional handsearch for grey literature 
PubMed, EMBASE, CINAHL, 
Cochrane Library 
Funding/ 
sponsor of SR 
 
Funding/ 
sponsor of 
included studies 
“CADTH receives funding from Canada’s federal, provincial, 
and territorial governments, with the exception of Quebec”. 
 
Industry or author COI: 22 studies  
NR: 16 studies 
No funding from industry and no author CoI: 3 studies 
Netherlands Organisation for Health 
Research and Development (ZonMw) 
 
 
NR 
Inclusion and 
exclusion 
criteria 
DTA: 
Setting:  Medical centres where central laboratory testing is 
available (such as hospital emergency departments)  
Population: Adults presenting with chest pain or other 
symptoms suggestive of ACS  
Intervention: Tn-POCT approved for use in Canada by 
Health Canada that use the 99th percentile cut-off threshold 
Central laboratory methods for measuring cTn  
Comparator: Clinical adjudication  
Outcomes: Clinical validity of Tn-POCT, including: 
sensitivity, specificity, positive predictive value, negative 
predictive value, positive-likelihood ratio, and negative-
likelihood ratio of Tn-POCT in the detection of AMI  
Study design: RCTs, cohort studies, case-control studies  
 
Clinical utility: 
Setting:   
 
Population: Included: patients with 
acute cardiopulmonary 
conditions/symptoms in primary care. 
Excluded: non-chest related conditions 
like DVT. 
Intervention: POCT 
Comparator: care as usual, no POCT 
Outcomes: included studies on clinical 
effectiveness and clinical diagnostic 
accuracy; excluded test accuracy 
studies 
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Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
• Medical centres where central laboratory testing is 
available (such as hospital emergency departments)  
• Medical centres or settings where central laboratory 
testing is not available (such as pre-hospital settings, rural 
health care centres or remote locations)  
Population: 
Adults presenting with chest pain or other symptoms 
suggestive of ACS  
Intervention: Any Tn-POCT  
Comparator: 
• For settings where a central laboratory is available: central 
laboratory methods either alone or in addition to Tn-POCT 
• For settings where central laboratory is not available: 
standard care (e.g., transfer to facility with testing 
capabilities)  
Outcomes: 
• Benefits and risks of Tn-POCT such as: turnaround time, 
time to clinical decision-making, time to discharge or 
transfer (length of hospital stay, length of emergency 
department stay), number of hospital admissions, adverse 
events rate, mortality rate, repeat emergency department 
visit  
• Behaviour/treatment patterns of health care professionals  
• Availability of the test, acceptability of and interest in the 
test for patients  
• Ethical, legal, social implications of Tn-POCT  
• Recommendations from evidence-based guidelines  
Study design: 
RCTs, cohort studies, evidence-based guidelines, surveys 
(for outcomes related to behaviour/treatment patterns, and 
availability and acceptability of tests)  
Quantitative 
synthesis 
(yes/no) 
No No 
 
Total number of 
patients across 
all included 
studies 
NR 545 
Countries of 
included studies 
United States (n=12), Australia (n=5), Sweden (n=4), Italy 
(n=4), Denmark (n=3), United Kingdom (n=3), Netherlands 
(n=2), Canada (n=1), New Zealand (n=1), Germany (n=1), 
Finland (n=1), Slovenia (n=1), France (n=1), China (n=1)  
multiple countries (n=1): Spain, the UK, Germany, Austria, 
Ireland, and Sweden 
NR 
Type of index 
tests in the 
included studies  
16 different POCT devices: 
Stratus CS, i-STAT, AQT90 FLEX, Cardiac Reader, 
PATHFAST, Triage, Cobas h232, Triage Cardiac Panel, 
Triage Profiler SOB, Triage Cardio3, Triage Meter Pro, 
Spectra Status, GEM Immuno, TropT, Cardiac T, and 
Cardio3 
99th percentile: 0.014-0.08 mcg/L 
Brand name: NR 
 
Planer 2006: Troponin T POCT 
(0.08ug/l) 
Nillsson 2013: Troponin T POCT 
(0.03ug/l) 
Type of 
reference test  
of the included 
studies 
Clinical adjudication was heterogeneous across studies and 
included but was not limited to the following:  
• Roche Modular E170 hs-cTnT + coronary angiography 
• Independent  adjudication by a cardiologist and cardiology 
Planer 2006: Common practice, 
including follow up only  
 
Nilsson 2013: Evaluation of hospital 
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Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
research clinician 
• final diagnosis of AMI using the ESC/ACC diagnostic 
criteria by cardiologists 
• determination of final diagnosis using the laboratory data 
• ECG results and clinical findings22 
records, ECG and GP’s clinical 
evaluation or telephone interviews 
Selected 
endpoints in the 
SR 
DTA, clinical utility Accuracy of clinical diagnosis and 
impact on patient management 
Results/Outcomes 
DTA 
DTA  
(SEN, SPEC, 
NPV, PPV) 
DTA at admission: range of POCT vs. range of CL 
SEN: 26%-88% vs. 68%-100%  
SPEC: 84.0%-98.0% vs. 75%-94% 
PPV: 31.0%-85.0% vs. 10%-82% 
NPV: 90%-99% vs. 95%-100% 
SEN (MI, MI+unstable angina): 
Planer et al.: 83%, 21%  
Nilsson et al.: 67%, 29% 
SPEC (MI, MI+unstable angina): 
Planer et al.: 100%, 100% 
Nilsson et al.: 98%, 98% 
PPV (MI, MI+unstable angina): 
Planer et al.: 100%, 100% 
Nilsson et al.: 40%, 40% 
NPV (MI, MI+unstable angina): 
Planer et al.: 99.7%, 94% 
Nilsson et al.: 99%, 96% 
Effectiveness /clinical utility 
No. of hospital 
admissions 
ED: NR 
Hospitalisation in pre-hospital setting with no access to 
central laboratory testing (ambulance; evidence base: 1 
RCT, 601 enrolled pts) 
• No difference between Tn-POCT and usual care (no 
further information provided) 
NR 
Treatment 
initiation 
NR NR 
Referral rates Referral rate from GP to ED (1 cohort study, cTnT testing, 
196 enrolled pts): 
• Reduction in 1/1 study: 32/128 pts (25%) vs. 29/68 pts 
(43%), p value not reported23 
Referral rate from GP to ED (1 cohort 
study, cTnT testing, 196 enrolled pts): 
Reduction in 1/1 study: 32/128 pts 
(25%) vs. 29/68 pts (43%), p value not 
reported23 
Door-to-needle 
time (DNT) 
NR NR 
Turnaround 
time (TAT)  
TAT in ED (2 RCTs, 11 observational studies using a variety 
of different definitions of TAT24) 
RCTs (2 studies, cTnI or cTnT testing, 2,134 and 833 
NR 
                                                     
22 It appeared that numerous studies did not adequately report on the reference standard as well. 
23 Yet, it is mentioned in the review that the authors of the primary study noted that there were some two patients that were 
not referred and missed cases (one AMI and one unstable angina respectively). It is therefore concluded that the use of 
Tn-POCT in pts with chest pain “may reduce emergency referrals, but probably at the cost of an increased risk to miss 
patients with an acute myocardial infarction or unstable angina”. 
24 E.g., time from blood draw to result. 
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Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
enrolled patients respectively): 
• Reduction in 2/2 studies: 43 min (median; p value not 
available) in one study, and 71 and 147 min in the other 
study25 (median; s. s., with p<0.001) 
Observational studies (5 prospective, 1 retrospective and 5 
pre-post studies respectively, cTnI or cTnT testing, 31 to 
2,386 enrolled pts) 
• Reduction in 11/11 studies: 18-93 min (p values available 
for 5/11 studies, with s. s. differences in these studies) 
TAT in the ambulance (median time from symptom onset to 
blood sampling; 1 observational study; 928 pts): 83 min 
(range: 46-167) 
Time to 
discharge (TTD) 
TTD in ED (evidence base: 2 RCTs, 1 observational study): 
RCTs (2 studies, cTnT or cTnI testing, 487 and 2,134 
enrolled pts respectively): 
• Reduction in 2/2 studies: 5 and 7 min (mean and median; 
s. s. with p=0.04 and p value not available respectively) 
Observational studies (1 pre-post study, multiple biomarkers 
4,886 enrolled pts): 
• Reduction in 1/1 study: 26 min (mean; p value not available) 
TTD in pre-hospital setting with no access to central 
laboratory testing (ambulance; evidence base: 1 RCT) 
• Reduction in 1/1 study (median time Tn-POCT vs CL): 8.8 
hours (range: 6.2 h to 10.8 h) vs. 9.1 h (range 6.7 hours to 
11.2 hours), P = 0.05. 
NR 
Length of stay 
(LOS) 
LoS in ED 
Emergency room stay (evidence base: 3 RCTs, 2 
observational studies):  
RCTs (3 studies, cTnI or cTnT testing, 487-912 enrolled pts): 
• Reduction in 2/3 studies: 0.2 and 0.8 h (mean and 
median; diff. n. s. in individual studies) 
• Increase in 1/3 studies: 0.1 h (median; diff. n. s.) 
Observational studies (2 pre-post studies, cTnI testing, 366 
and 671 enrolled pts respectively):  
• Reduction in 2/2 studies: 1.9 h (mean; p value NR) and 2-
2.7 h respectively (median; diff. s. s.) 
Hospital stay in ED (evidence base: 1 RCT) 
RCTs (1 study, cTnI testing, 2,243 enrolled pts) 
• Reduction in 1/1 study: 2.2 h (mean; diff. n. s.) 
NR 
Further 
diagnostic 
testing 
NR NR 
Time to clinical 
decision (TCD)  
TCD in ED (evidence base: 1 RCT, 1 pre-post study): 
RCTs (1 study, cTnI testing, 2,134 enrolled pts) 
• Reduction in 1/1 study: 9 min (median; p value not 
available) 
Observational studies (1 pre-post study, multiple biomarker 
testing, 4,886 enrolled pts): 
• Reduction in 1/1 study (multiple biomarkers): 26 min 
(mean; p value not available) 
NR 
                                                     
25 When using the definitions “time from collection to physician notification” and “time from presentation to anti-ischemic 
therapy” respectively. 
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Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
Mortality/ 
morbidity 
Mortality in ED (evidence base: 2 RCTs and 3 further 
observational studies) 
RCTs (2 studies; cTnT or cTnI testing, 487 and 2,243 
enrolled pts respectively) 
• POC vs. central lab: 0.5 vs. 0% in one study (p value NR) 
and 1% vs.0.2% in another study (n. s., with p=0.142) 
Observational studies (3 prospective studies; cTnI or cTnT 
testing; 508-1,410 enrolled pts) 
• None of the studies compared Tn-POCT with CL head-to-
head (statistically) 
Mortality in pre-hospital setting with no access to central 
laboratory testing (ambulance; evidence base: 1 RCT, 601 
enrolled pts) 
• Death in the next 30 days: no difference between groups 
(no further information provided) 
Cardiac events in ED (evidence base: 2 prospective studies, 
cTnI or cTnT testing) 
30 day cardiac event rate (1Iprospective study, 704 enrolled 
pts; POCT vs. central lab):  
• Low risk pts: 0% (95%CI: 0-25.9) vs. 0% (95%CI: 0-21.5), 
p value NR 
• High risk pts: 24.8% (95%CI: 20.1-30.1) vs. 28.6% 
(95%CI: 23.4-34.4), p value NR 
Cardiac events after 1 year (1 prospective study, 1,410 
enrolled pts; POCT vs central lab): 
• 2.1% (95%CI: 1.5-3) vs. 2.2% (95%CI: 1.6-3.1), p value NR 
Other Adverse events and composite end points in ED 
(evidence base: 2 RCTs, cTnT or cTnI testing) 
Major AE after 3 m FU (1 RCT, 2,243 enrolled pts; POCT vs 
central lab): 3% vs. 2%, diff. n. s., with p=0.313 
CEP events26 at 6 m (1 RCT, 487 enrolled pts; cTnT testing, 
POCT vs. central lab): 10.4% vs. 5.4%, p value NR 
NR 
Patient Quality 
of Life (QoL) 
QoL in ED (evidence base: 1 RCT, cTnI testing, 2,243 
enrolled pts using the EQ-5D questionnaire): 
POC vs. central lab:  
• After 1 m: 0.742 vs. 0.759 (n. s., with p=0.614) 
• After 3 m: 0.752 vs. 0.759 (n. s., with p=0.638) 
NR 
Harms (e.g., 
from false 
positive and 
false negative 
tests, harms 
from delayed 
treatment) 
 
NR The SR identified 1 cohort study that 
reported a decrease in referrals of TN-
POC may increase the risk of missing 
out patients with an acute myocardial 
infarction or unstable angina. 
2/128 in the TN-POC group needed 
but did not receive a referral (overall 
referral rate: 25% and 43% patients 
managed by physicians using and not 
using Tn-POCT respectively). 
Safety 
Safety 
outcomes  
NR NR 
                                                     
26 AMI, coronary revascularization, cardiac arrest, or mortality in patients with a negative first cTn test at 3 m FU 
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Author or 
Institution/ 
country, year 
CADTH/CA, 2016 [25] Schols/NE, 2018 [26] 
Conclusion “Overall, given the limitations with the data and the 
inconsistency in DTA estimates, the usefulness of [Tn-POCT27] 
in settings with access to central laboratories may be limited. 
However, in settings with no access to a central laboratory, 
such as in rural health care centres or remote settings, [Tn-
POCT] may be useful due to the potential to help reduce 
unnecessary transfer of patients to larger centres.” 
No conclusion made on Tn-POCT: 
 
“With regards to the clinical value of 
Troponin POCT in a secondary care 
population, the literature is 
inconclusive”28 
Abbreviations: ACC – American College of Cardiology; ACS – acute coronary syndrome; ACS – acute coronary 
syndrome; CA – Canada; CADTH – Canadian Agency of Drugs and Technologies in Health; CL – central laboratory;  
COI – conflict of interest; cTn – cardiac troponin; DTA – diagnostic test accuracy; DVT – deep vein thrombosis; ECG – 
electrocardiogram; ED – emergency department; ESC – European Society of Cardiology; FU – follow up; GP – general 
practitioner; h – hour(s); h – hours; m – month(s); NR – not reported; n. s. – not statistically significant; NE – Netherlands; 
NPV – negative predictive value; POCT – point of care testing; PPV – positive predictive value; pts – patients; QoL – 
quality of life; RCT – randomised controlled trial; s. s. – statistically significant; SEN – sensitivity; SPEC – specificity;  
SR – systematic review. 
 
Table A5: Characteristics of eligible systematic reviews for D-dimer POCT (part 1) 
Author/Institution/country, 
year 
Pasha, 2010 [32] Schols, 2018 [26] 
Number and type of included 
studies 
4 studies with D-dimer and Wells rule, 1 of which 
was POC 
7 studies in total of which 2 
studies (4 papers) contained D-
dimer POCT data; RCTs or non-
randomised controlled trials 
Setting only "outpatients" stated in the only relevant study 
(Rodger) in this review that used a POCT but not 
defined further (i.e. if primary care or ED) 
primary care 
Search period   2000 (introduction of Wells score) to 2008 To October 2014 (with PubMed 
search update from October 
2014 to February 2016) 
Databases/sources searched Medline, Embase, Cochrane PubMed, EMBASE, CINAHL, 
Cochrane Library, reference lists, 
contact with authors 
Funding/sponsor of SR NR Netherlands Organisation for 
Health Research and 
Development (ZonMw) 
Inclusion and exclusion 
criteria 
Included study type: prospective studies with a 
minimum 3 month clinical follow up using a 
diagnostic strategy including a dichotomized clinical 
decision rule and a D-dimer test to rule out PE. 
Included population: all patients with an unlikely 
clinical probability and normal D-dimer who did not 
undergo radiological imaging 
Population: Included: patients 
with acute cardiopulmonary 
conditions/symptoms (acute 
conditions or symptoms of either 
the heart, lungs or vascular blood 
supply of these organs at the 
height of the chest cavity) in 
primary care in western 
/developed countries. Excluded: 
non-chest related conditions like 
DVT. 
Intervention: POCT 
Comparator: care as usual, no 
POCT 
Outcomes: included studies on 
clinical effectiveness and clinical 
                                                     
27 Note: The synonymous term “POC cTn testing” was used instead of the term Tn-POCT in the report. 
28 It is further stated that: “If a validated cardiac clinical decision rule like the MHS [note: Marburg Heart Score] would be 
added to a Troponin POCT, this would most likely lead to a more effective and safer exclusion of acute cardiac patholo-
gy. More research is necessary to investigate whether the combination of the two leads to a high enough NPV to safely 
exclude cardiac pathology” 
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Author/Institution/country, 
year 
Pasha, 2010 [32] Schols, 2018 [26] 
diagnostic accuracy; excluded 
analytical test accuracy studies 
Quantitative synthesis 
(yes/no) 
Yes No 
Total number of patients 
across all included studies 
4,384 but only 1 study (199 patients) included 
relevant intervention (POC) 
892 
Countries of included studies NR NR 
Type of index tests in the 
included studies (n of studies) 
POC study: Simplired and Acculot 
Laboratory studies: VIDAS and Tinaquant 
NR 
Type of reference test of the 
included studies 
N/A Composite reference standard 
Selected endpoints in the SR Primary endpoints were the recurrence rate of 
venous thromboembolism (VTE) and PE-related 
mortality during 3-months follow up.  
Accuracy of clinical diagnosis 
and impact on patient 
management 
Results/Outcomes 
DTA 
DTA rates (SEN, SPEC, 
NPV, PPV) 
Incidence of VTE despite negative testing and 
unlikely clinical probability: 2% (95% CI: 0.1-10.1%) 
SEN: stand alone D-dimer 84%; 
Wells ≤4 + D-dimer 94- 95%; 
Wells ≤2 + D-dimer 97%. 
SPEC: stand-alone D-dimer 62%; 
Wells ≤4 + D-dimer 38- 51%; 
Wells ≤2 + D-dimer 32%. 
PPV: stand alone D-dimer 24%;  
Wells ≤4 + D-dimer 21- 37%; 
Wells ≤2 + D-dimer 20%. 
NPV: stand alone D-dimer 96%;  
Wells ≤4 + D-dimer 94- 99%; 
Wells ≤2 + D-dimer 99%. 
Effectiveness/clinical utility 
No. of hospital admissions NR NR 
Treatment initiation NR NR 
Referral rates NR NR 
Door-to-needle time (DNT) NR NR 
Turnaround time NR NR 
Time to discharge (TTD) NR NR 
Length of stay (LOS) NR NR 
Further diagnostic testing In 49/199 (25%) patients with unlikely clinical probability 
and normal D-dimer CT scans could be withheld.  
NR 
Time to clinical decision 
(TCD)  
NR NR 
Failure rate/efficacy/ 
efficiency 
NR NR 
Mortality/morbidity Mortality: 1 person (2%) NR 
Patient Quality of Life (QoL) NR NR 
Safety 
Safety outcomes NR NR 
Conclusion Overall (across POCT and lab tests) pooled incidence 
of morbidity was 0.34% (95%CI 0.036-0.96%) and 
combined incidence of death (across POCT and lab 
tests) was 0.1% (95% CI 0.0-0.5%). Combined 3-
month mortality risk of PE (across POCT and lab 
tests) was 0.10% (95%CI 0.002-0.46%). 
No studies assessed the effects 
of D-dimer on treatment initiation 
or referral rates. All studies were 
considered at high risk of bias. 
Evidence suggests combining D-
dimer with a clinical decision rule 
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Author/Institution/country, 
year 
Pasha, 2010 [32] Schols, 2018 [26] 
1 death occurred across all studies (this was in the 
POCT study). 
Ruling our PE on basis of unlikely clinical probability 
and normal D-dimer is very safe.   
(e.g. when GP use of a D-dimer 
POCT is combined with the Wells 
clinical decision rule) leads to 
more accurate diagnosis. Further 
research on clinical effectiveness 
is necessary. 
Abbreviations: CI – confidence interval; CT – computer tomography; ED – emergency department; n – number; No. – 
number; NPV – negative predictive value; NR – not reported; PE – pulmonary embolism; POCT – point of care testing; 
PPV – positive predictive value; SEN – sensitivity; SPEC – specificity; SR – systematic review; VTE – venous 
thromboembolism. 
 
Table A6: Characteristics of eligible systematic reviews for D-dimer POCT (part 2) 
Author/Institution/country, 
year 
Lucassen, 2011 [34] Hendriksen, 2015 [33] 
Number and type of included 
studies 
52 prospective studies including 
consecutive patients suspected of having 
PE. 
10 published prediction models for the 
diagnosis of PE. 5 models were validated 
with the primary care dataset (AMUSE-2). 
Setting Hospital setting (emergency department, 
outpatients or inpatients) 
primary care 
Search period   1966-2011 January 2010-October 2014 (update of 
Lucassen systematic review) 
Databases/sources searched MEDLINE and EMBASE PUBMED and EMBASE 
Funding/sponsor of SR Dutch Heart Foundation The Netherlands Organization for Scientific 
Research 
Inclusion and exclusion 
criteria 
Included: Patients aged 16 years+ with 
symptoms suggesting acute PE and use 
gestalt or a clinical decision rule to 
estimate the clinical probability of PE. 
Clinical decision rules had to be based on 
a multivariate logistic regression model 
and provide data enabling the 
construction of a 2x2 table. Diagnosis of 
PE had to be confirmed with an 
“appropriate” reference standard. 
Diagnostic prediction model development 
studies with or without external validation in 
independent data. Primary care patients in 
whom the diagnosis pulmonary embolism is 
considered: 
• Unexplained acute dyspnoea, and/ or 
• Unexplained cough, and/ or 
• Pain on inspiration  
Quantitative synthesis 
(yes/no) 
Yes Yes 
Total number of patients 
across all included studies 
55,268 NR 
Countries of included studies NR NR 
Type of index tests in the 
included studies (n of 
studies) 
11 studies using qualitative d-dimer 
testing as part of the clinical decision rule 
Diagnostic prediction models (including point 
of care d-dimer) for use in primary care 
Type of reference test of the 
included studies 
Ventilation-perfusion lung scanning, CT, 
pulmonary angiography, autopsy 
Established reference standard, such as 
spiral CT scanning, pulmonary angiography, 
ventilation-perfusion scanning, clinical follow 
up or a combination. 
Selected endpoints in the SR Failure rate and efficiency  Sensitivity, specificity, efficiency, failure 
rates  
Results/Outcomes 
DTA 
DTA rates (SEN, SPEC, 
NPV, PPV) 
NR specifically for qualitative D-
dimer/POCT 
Sensitivity*: 88% (78%-94%) for simplified 
revised Geneva ≤2 model; 90% (81-96%) for 
original revised Geneva ≤5; 95% (87%-98%) 
for original Wells ≤4; 95% (87-98%) for 
modified Wells ≤2; 96% (88%-99%) for 
simplified Wells ≤1. 
Specificity*: 48% (44%-53%) for original 
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Author/Institution/country, 
year 
Lucassen, 2011 [34] Hendriksen, 2015 [33] 
revised Geneva ≤5; 49% (45-53%) for the 
simplified Wells ≤1; 50% (46-55%) for the 
modified Wells ≤2; 51% (47-55%) for the 
original Wells ≤4; 53% (49%-57%) for 
simplified revised Geneva ≤2. 
PPV*: 20% (15%-24%) for original revised 
Geneva ≤5; 21% (17-26%) for original Wells 
≤4; 21% (17-26%) for modified Wells ≤2; 
21% (17-25%) for simplified Wells ≤1; 21% 
(16-26%) for simplified revised Geneva ≤2. 
NPV*: 97% (95-99%) original revised 
Geneva ≤5; 97% (94-99%) simplified revised 
Geneva ≤2; 99% (96-100%) original Wells 
≤4; 99% (96-100%) modified Wells ≤2; 99% 
(97-100%) simplified Wells ≤1.  
*Data are ordered by values of the test 
accuracy rate. 
Effectiveness/clinical utility 
No. of hospital admissions NR NR 
Treatment initiation NR NR 
Referral rates (RR) NR NR 
Door-to-needle time (DNT) NR NR 
Turnaround time (TAT) NR NR 
Time to discharge (TTD) NR NR 
Length of stay (LOS) NR NR 
Further diagnostic testing NR NR 
Time to clinical decision (TCD)  NR NR 
Failure 
rate/efficacy/efficiency  
(% & 95% CI) 
Failure rate: Across all studies with 
qualitative D-dimer testing: 1.0% (95%CI 
0.8-1.3%); combined with gestalt 0.7% 
(95%CI 0.4-1.2%); combined with Wells 
cutoff value ≤4: 1.7% (95%CI 1.0-2.8%); 
combined with Wells cutoff value <2: 
0.9% (95%CI 0.6-1.5%). 
Efficiency: Across all studies with 
qualitative d-dimer testing: 45% (95%CI 
39-52%); combined with gestalt 52% 
(95%CI 40-64%); combined with Wells 
cutoff value ≤4: 42% (95%CI 32-52%); 
combined with Wells cutoff value <2: 
40% (95%CI 33-48%). 
Failure rates across all models: 1.2% 
(95%CI 0.2%-3.3%) for simplified Wells ≤1; 
1.5% (95%CI 0.4-3.7%) for original Wells ≤4; 
1.5% (95%CI 0.4-3.8%) for modified Wells 
≤2; 2.7% (95%CI 1.1-5.4%) for original 
revised Geneva ≤5;  3.1% (95%CI 1.4%-
5.9%) for simplified revised Geneva ≤2. 
Efficiency across all models: 43% (95%CI 
39%-48%) for simplified Wells ≤1; 44% 
(95%CI 40-48%) for original revised Geneva 
≤5; 45% (95%CI 41-49%) for modified Wells 
≤2; 46% (95%CI 41-50%) for original Wells 
≤4; 48% (95%CI 44%-52%) for simplified 
revised Geneva ≤2.  
Mortality/morbidity NR NR 
Patient Quality of Life (QoL) NR NR 
Safety 
Safety outcomes NR NR 
Conclusion Combining a decision rule and gestalt 
can safely exclude PE when combined 
with sensitive D-dimer testing except 
when the less sensitive Wells rule (cutoff 
value ≤4) is combined with qualitative D-
dimer POCT  
Efficiency was comparable across all models 
but the Wells rules combined with D-dimer 
POCT gave the best performance in terms 
of lower failure rates 
Abbreviations: CT – computer tomography; DTA – diagnostic test accuracy; No. – number; NPV – negative predictive 
value; NR – not reported; PE – pulmonary embolism; POCT – point of care testing; PPV – positive predictive value;  
SEN – sensitivity; SPEC – specificity; SR – systematic review. 
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Table A7: Characteristics of eligible systematic reviews for D-dimer POCT (part 3) 
Author/Institution/country, 
year 
Geersing, 2009 [31] Marquardt, 2015 [35] 
Number and type of included 
studies 
23 studies on the diagnostic accuracy of D-
dimer POCT in outpatients 
9 prospective or retrospective studies 
(7 related to turnaround time and 2 to 
cost-effectiveness).  
Setting Primary or secondary care ED 
Search period   January 1995-September 2008 Various, widest date range 1980-2015 
Databases/sources searched Medline & Embase, reference lists, expert 
contact 
Embase, Medline, Cochrane, EBM and 
NHS Economic Evaluation Database, 
Ovid Nursing Full Text Plus, grey 
literature and product literature 
Funding/sponsor of SR Netherlands Heart Foundation & Zilveren Kruis 
Achmea 
NR 
Inclusion and exclusion 
criteria 
Studies were included if: 
• Adult study population of consecutive 
outpatients in primary or secondary care 
suspected of DVT and/or PE 
• POC test used (not routine laboratory machine) 
• Use reference test for DVT 
• Use follow up reference test 
• Include calculation of SENS, SPEC, NPV, 
PPV and prevalence 
Studies were excluded if they were not 
primary studies. Studies were included 
if they focused on D-dimer POCT and 
at least one of the following criteria: 
turnaround time, quality of care, cost-
effectiveness, user-friendliness, length 
of stay, time to diagnosis, time to 
result. 
Quantitative synthesis 
(yes/no) 
Yes  No 
Total number of patients 
across all included studies 
13,959 3,279 (turnaround studies) 
Countries of included studies NR NR 
Type of index tests in the 
included studies (n of 
studies) 
SimpliRED D-dimer (12 studies) 
Clearview Simplify D-dimer (7 studies) 
Cardiac D-dimer (4 studies) 
Triage D-dimer (2 studies) 
11 D-dimer POCTs were used across 
all studies 
Type of reference test of the 
included studies 
Reference test for DVT: Compression 
ultrasonography, venography, impedance 
plethysmography, or uneventful follow up (no 
DVT or PE in 3 months).  
Reference test for PE: computerised 
tomography pulmonary angiography, 
ventilation-perfusion lung scanning, pulmonary 
angiography or uneventful follow up. 
NR 
Selected endpoints in the SR Diagnostic accuracy Turnaround times and time to 
diagnosis, referral or discharge 
Results/Outcomes 
DTA 
DTA rates (SEN, SPEC, 
NPV, PPV) 
SEN: 0.85 (95%CI 0.78-0.90) for SimpliRED D-
dimer; 0.87 (0.81-0.91) for Clearview Simplify 
D-dimer;0.93 (0.88-0.97) for Triage D-dimer; 
0.96 (0.91-0.98) for Cardiac D-Dimer. 
SPEC: 0.48 (95% CI 0.33-0.62) for Triage D-
dimer; 0.57 (0.52-0.62) for Cardiac D-dimer; 
0.62 (0.54-0.69) for Clearview Simplify D-dimer; 
0.74 (95%CI 0.69-0.78) for SimpliRED 
Likelihood ratio of a negative test result: 0.07 
(95%CI 0.04-0.16) for Cardiac D-dimer; 0.18 
(95%CI 0.08-0.43) for Triage D-dimer; 0.21 
(0.15-0.29) for SimpliRED D-dimer; 0.22 (95% 
CI 0.15 to 0.29) for Clearview Simplify D-dimer.  
NR 
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Author/Institution/country, 
year 
Geersing, 2009 [31] Marquardt, 2015 [35] 
Effectiveness/Clinical utility 
No. of hospital admissions NR No. of hospital admissions (one 
before-after study, 462 pts) 
decreased by 13.8% 
Treatment initiation NR NR 
Referral rates NR NR 
Door-to-needle time (DNT) NR NR 
Turnaround time (TAT) NR TAT in ED (evidence base: 7 
observational studies29, 3,279 pts): 
• Reduction in 5 studies 
(comparative; prospective and 
retrospective): 10-101.5 min (using 
different measures of central 
tendency; p-values and information 
on stat. testing NR) 
• No comparative data shown in  
2 studies30  
Time to discharge (TTD) NR NR 
Length of stay (LOS) NR LoS in ED (evidence base:  
1 before-after study, 462 pts): 
• Decrease in mean LoS  
(8.46 to 7.14 hrs; n. s. with p=0.16) 
Further diagnostic testing NR NR 
Time to clinical decision 
(TCD)  
NR NR 
Failure rate/efficacy/ 
efficiency (% & 95% CI) 
NR NR 
Mortality/morbidity NR NR 
Patient Quality of Life (QoL) NR NR 
Safety 
Safety outcomes NR NR 
Conclusion The two quantitative tests (Cardiac D-dimer 
and Triage D-dimer) scored most favourably. 
In outpatients suspected of VTE, D-dimer POCT 
can contribute important information and guide 
patient management, especially in low-risk 
patients (i.e. with low score on a clinical 
decision rule).  
D-dimer POCT can safely improve 
patient journey times 
Abbreviations: DVT – deep vein thrombosis; ED – emergency department; n – number; No. – number; NPV – negative 
predictive value; NR – not reported; POC – point of care; PPV – positive predictive value; SEN – sensitivity; SPEC; 
specificity; TAT – turnaround time. 
  
                                                     
29 While the review reported initially on seven included studies on TAT, data are only presented for six studies. 
30 Non-comparative data was shown in one study (time to result: 10-38 min) and not reported at all in another study that 
the review described.  
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Table A8: Characteristics of eligible primary studies for D-dimer POCT 
Author, year 
[reference number] 
Oude Elferink, 2015 [37] Kingma, 2017 [36] 
Study design Non-randomised controlled trial Non-randomised controlled trial 
Country Netherlands Netherlands 
Funding/Sponsor Statement that no direct financial 
support was received 
Netherlands Organization for Health Research & 
Development (ZonMw) 
Intervention (IG) | 
Product 
8 different D-dimer tests, one of which 
was POCT (Simplify)   
Implementation of a guideline consisting of clinical 
decision rule combined with negative D-dimer test 
Comparator (usual care; 
UC) 
DVT diagnosed by compression 
ultrasonography 
Usual care (no guideline implementation strategy) 
Number of patients 290 consecutive primary care patients 
over a period of 23 months divided into 2 
groups on the basis of clinical decision 
criteria (from 305 patients with 
suspected DVT) 
Intervention group : 217 GPs with 619 patients  
Usual care (UC): 32 GPs with 62 patients 
Inclusion/exclusion 
criteria 
Exclusion criteria: age below 18, 
anticoagulant therapy with vitamin K 
antagonists and/or low molecular-weight 
heparin 
Inclusion criteria: patients with symptoms 
of pain, swelling and/or redness of leg 
NR 
Patients in the intervention group were included 
from 10/2013 to 06/2015. 
Patients in the usual care group were included 
from 05/2014 to 06/2016. 
Selected endpoints in 
the SR 
DTA and turnaround time Effectiveness, as measured by (i) Proportion of 
non-referred patients; (ii) proportion of missed 
DVT cases; (iii) proportion of patients in whom 
guideline incorrectly applied  
Follow up (months) NR 3 months (to identify potentially missed DVT cases) 
Drop-outs (n (%) None Intervention group: 6/625 patients (<1%) were lost 
to follow up 
Usual care group: 8/70 patients (11%) 
Patient characteristics 
Age of patients (yrs.) CDR≤3: M 56 (R18-88) 
CDR>3: M 62 (R 19-83) 
Wells score <2: M 56 (R 18-88) 
Wells score ≥2: M 60 (R 19-84) 
IG: M 62 (R15-96) 
UC: M 59 (R 17-90) 
Sex (% female) CDR≤3:61% 
CDR>3: 48% 
Wells score <2: 60% 
Wells score ≥2: 62% 
IG: 62% 
Usual care group: 66% 
Comorbidity /risk factors  Contraceptive use (female): IG 9%; UC 13% 
Cancer in last 6 mnths: IG 5%, UC 5% 
Surgery in last month: IG  6% UC 2% 
DTA rates (SEN, SPEC, 
NPV, PPV) 
Results for Simplify: 
SENS all patients 91.3%, CDR ≤3 
95.2%, Wells <2 91.7% 
SPEC all patients 60.8%, CDR ≤3 
62.7%, Wells <2 62.8% 
NPV all patients 98.7% CDR ≤3 99.3%, 
Wells <2 99.1% 
NR 
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Author, year 
[reference number] 
Oude Elferink, 2015 [37] Kingma, 2017 [36] 
Clinical utility/effectiveness outcomes 
Mortality/Morbidity NR NR 
QoL NR NR 
 NR NR 
No. of hospital 
admissions 
NR NR 
Treatment initiation NR NR 
Referral rates NR Patients referred: 
IG: 284/619 (46%) 
UC: 31/62 (50%), p=ns 
Proportion of VTE in patients referred: 
IG: 120/284 (42%) 
UC: 11/31 (36%), p=ns 
Patients not referred: 
IG: 335/619 (54%) 
UC: 31/62 (50%), p=NR 
Proportion of VTE in patients not referred: 
IG: 6*/335 (1.8; 95%CI 0.7-0.39) 
UC: 0 (0.0; 95%CI 0-11.2), p=ns 
* 3 patients were deliberately not referred due to 
shared decision making 
Door-to-needle time 
(DNT) 
NR NR 
Turnaround time Simplify had analysis time of 10 minutes. 
Turnaround time of laboratory tests 
ranged between <5 minutes (Liatest) 
and 34 minutes (Vidas)  
NR 
Time to clinical decision  NR NR 
Time to discharge NR NR 
Length of stay  NR NR 
Further diagnostic 
testing 
NR NR 
Failure rate/efficacy/ 
efficiency 
NR NR 
Safety 
Safety NR NR 
Abbreviations: CDR – clinical decision rule; DTA – diagnosic test accuracy; DVT – deep vein thrombosis; IG – intervention 
group; n – number; No. – number; NPV – negative predictive value; NR – not reported; PPV – positive predictive value; 
SEN – sensitivity; SPEC – specificity; SR – systematic review; UC – usual care. 
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List of ongoing and planned studies 
 
Table A9: List of ongoing studies with Tn-POCT 
Study identifier Study 
Designs 
Status Setting Interventions Outcome Measures Enrolment Age Sponsor/Collaborators Funded By Completion 
Date 
NCT03102216 RCT Completed ED Diagnostic Test: iSTAT 
Diagnostic Test: CBC 
Diagnostic Test: ECG 
Diagnostic Test: Lodox 
Decrease waiting and 
disposition times for 
patients presenting to the 
Emergency Department| 
Decrease the costs of 
special investigations for 
patients presenting to the 
Emergency Department 
1134 ≥18 y. o. Helen Joseph Hospital 
Abbott Point of Care 
University of 
Johannesburg|Lodox 
Systems (Ltd) 
Other|Industry June 30, 
2017 
NCT00222352 NRCT Completed ED Diagnostic Test: Point of 
Care cTnL testing 
Traditional central laboratory 
testing 
Time to disposition from 
the ED| 
Time to departure 
2000 ≥18 y. o. University of Cincinnati 
Abbott|Jewish Hospital, 
Cincinnati, Ohio 
University of 
Pennsylvania|Stanford 
University|Mayo Clinic 
Other|Industry March 2007 
NCT02972814 NRCT Recruiting ED Device: Laboratory based 
troponin test 
Device: Point of care based 
troponin ( Radiometer EQT 
90 Flex) 
Device: Point of care based 
troponin ( Philips Minicare I-20) 
Time delay until troponin 
test results are known 
50 ≥18 y. o. Ziekenhuis Oost-Limburg Other February 
2020 
NCT02620397 NRCT N/A ED Subjects will have up to 4 
blood samples collected for 
cTnI testing using the Meritas 
Troponin I test and Meritas 
point-of-care (POC) Analyzer. 
Blood draws and testing will 
occur at 4 intervals over 24 
hours. 
Clinical performance of the 
Meritas Troponin I test| 
Prognostic capability of 
sponsor's Meritas Troponin 
I to predict mortality (all-
cause death) and cardiac 
events (i.e., MI, cardiac 
death). 
1500 ≥21 y. o. Trinity Biotech Industry November 
2016 
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Study identifier Study 
Designs 
Status Setting Interventions Outcome Measures Enrolment Age Sponsor/Collaborators Funded By Completion 
Date 
DRKS00000709 RCT N/A N/A Intervention 1: Point-of-care 
testing group (POCT group): 
before making a working 
diagnosis, the physicians can 
analyse troponin T, NT-
proBNP and/or D-dimer with 
a diagnostic device (Cardiac 
Reader, Roche Diagnostic).  
Intervention 2 (Control): 
conventional diagnostic 
process 
Primary: Diagnostic 
accuracy: working 
diagnosis vs. 
confirmed/Follow up 
diagnosis (about 3 weeks 
after working diagnosis) 
Secondary: Resource 
utilisation (consultation, 
transport, hospitalisation) 
and workdays lost between 
baseline and follow up 
1000 ≥18 y. o. Roche Diagnostic 
(Schweiz) AG 
Roche 
Diagnostic 
(Schweiz) AG 
N/A 
Abbreviations: CBC – complete blood count; ECG – electrocardiography; NRCT – non-randomised controlled trial; ED – emergency department; RCT – randomised controlled trial. 
 
 
Risk of bias tables Tn-POCT 
 
Table A10: Risk of Bias (Tn-POCT) – study level (systematic reviews and meta analyses)  
Author, year Bruins Slot, 
2013 [101]  
CADTH, 2016 
[25] 
Pecoraro, 
2014 [102] 
Pecoraro, 
2017 [103] 
Schols, 2018 
[26] 
1. Did the research questions and inclusion criteria for the review include the components of PICO? Yes Yes Yes No Yes 
2. Did the report of the review contain an explicit statement that the review methods were 
established prior to the conduct of the review and did the report justify any significant deviations 
from the protocol? 
No Yes No No Partial Yes 
3. Did the review authors explain their selection of the study designs for inclusion in the review? Yes Yes Yes Yes Yes 
4. Did the review authors use a comprehensive literature search strategy? No Partial Yes Partial Yes Partial Yes Partial Yes 
5. Did the review authors perform study selection in duplicate? Yes Yes Yes No Yes 
6. Did the review authors perform data extraction in duplicate? Yes Yes Yes Yes No 
7. Did the review authors provide a list of excluded studies and justify the exclusions? No Yes No No No 
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Author, year Bruins Slot, 
2013 [101]  
CADTH, 2016 
[25] 
Pecoraro, 
2014 [102] 
Pecoraro, 
2017 [103] 
Schols, 2018 
[26] 
8. Did the review authors describe the included studies in adequate detail? Partial Yes Yes No Yes Yes 
9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in 
individual studies that were included in the review? 
RCTs 
Yes Yes No No Yes 
10. Did the review authors report on the sources of funding for the studies included in the review? No Yes No No No 
11. If meta-analysis was performed did the review authors use appropriate methods for statistical 
combination of results? 
RCTs 
NA NA NA NA NA 
12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in 
individual studies on the results of the meta-analysis or other evidence synthesis? 
NA NA NA NA NA 
13. Did the review authors account for RoB in individual studies when interpreting/ discussing the 
results of the review? 
No Yes No No Yes 
14. Did the review authors provide a satisfactory explanation for, and discussion of, any 
heterogeneity observed in the results of the review? 
Yes Yes No Yes Partial Yes 
15. If they performed quantitative synthesis did the review authors carry out an adequate investigation 
of publication bias (small study bias) and discuss its likely impact on the results of the review? 
NA NA NA NA NA 
16. Did the review authors report any potential sources of conflict of interest, including any funding 
they received for conducting the review? 
Yes Yes Yes Yes Yes 
Overall Confidence Critically low31 High32 Critically low33 Critically low34 Moderate35 
  
                                                     
31 Critical flaws: Only one database considered for literature search, consideration of RoB when interpreting the results of the review absent. 
32 No critical flaws suspected. Adequacy of "Downs and Black" checklist for clinical utility studies was discussed within the project team but considered as adequate.  
CADTH also did not search trial/study registries, which was considered as a non-critical weakness. 
33 Critical flaws: RoB assessment unclear (no standardised tool) & incomplete, consideration of RoB when interpreting the results of the review absent. 
34 Critical flaws: RoB assessment unclear (no standardised tool), consideration of RoB when interpreting the results of the review absent. 
35 No critical flaw suspected. Several non-critical flaws: e.g., did not search trial/study registries within their search, data-extraction not in duplicate, etc. 
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Table A11: AGREE II quality appraisal of guidelines on the use of Tn-POCT  
Domain Item 
AGREE II Score 
DEGAM AHA/ 
ACC 
SIGN Oman Heart 
Ass. 
ANZCOR ESC Japanese 
Circ.Soc. 
NACB 
Scope and 
purpose 
 
1. The overall objective(s) of the guideline 
is (are) specifically described. 
7 7 7 7 7 7 7 7 
2. The health question(s) covered by the 
guideline is (are) specifically described. 
7 7 7 7 6 7 7 7 
3. The population (patients, public, etc.) to 
whom the guideline is meant to apply is 
specifically described. 
7 7 7 7 7 7 7 7 
Stakehold-
er involve-
ment 
4. The guideline development group 
includes individuals from all the 
relevant professional groups. 
7 7 7 1 1 7 7 4 
5. The views and preferences of the 
target population (patients, public, etc.) 
have been sought. 
6 1 7 1 1 5 1 2 
6. The target users of the guideline are 
clearly defined. 
7 7 7 7 7 7 7 3 
Rigor of 
develop-
ment 
7. Systematic methods were used to 
search for evidence. 
7 7 7 1 1 7 7 7 
8. The criteria for selecting the evidence 
are clearly described. 
7 7 7 1 1 7 7 7 
9. The strengths and limitations of the 
body of evidence are clearly described. 
7 7 7 1 1 7 7 7 
10. The methods for formulating the 
recommendations are clearly 
described. 
7 7 7 1 1 7 7 7 
11. The health benefits, side effects and 
risks have been considered in 
formulating the recommendations. 
7 7 7 5 4 7 7 7 
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Domain Item 
AGREE II Score 
DEGAM AHA/ 
ACC 
SIGN Oman Heart 
Ass. 
ANZCOR ESC Japanese 
Circ.Soc. 
NACB 
12. There is an explicit link between the 
recommendations and the supporting 
evidence. 
7 7 7 5 6 7 7 7 
13. The guideline has been externally 
reviewed by experts prior to its 
publication. 
7 7 7 1 1 7 1 5 
14. A procedure for updating the guideline 
is provided. 
7 7 7 1 1 1 3 1 
Clarity of 
presenta-
tion 
15. The recommendations are specific and 
unambiguous. 
7 7 7 7 7 7 7 7 
16. The different options for management 
of the condition or health issue are 
clearly presented. 
7 7 7 7 7 7 7 1 
17. Key recommendations are easily 
identifiable. 
7 7 7 5 7 7 7 7 
Applicabil-
ity 
18. The guideline describes facilitators and 
barriers to its application. 
7 7 7 5 4 7 7 7 
19. The guideline provides advice and/or 
tools on how the recommendations can 
be put into practice. 
7 7 7 5 4 7 7 7 
20. The potential resource implications of 
applying the recommendations have 
been considered. 
7 7 7 5 1 1 1 7 
21. The guideline presents monitoring and/ 
or auditing criteria. 
7 7 7 1 1 7 1 7 
Editorial 
independ-
ence 
22. The views of the funding body have not 
influenced the content of the guideline. 
7 7 7 1 1 7 1 3 
23. Competing interests of guideline 
development group members have 
been recorded and addressed. 
7 7 7 1 1 7 5 1 
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Domain Item 
AGREE II Score 
DEGAM AHA/ 
ACC 
SIGN Oman Heart 
Ass. 
ANZCOR ESC Japanese 
Circ.Soc. 
NACB 
Overall 
Guideline 
Assess-
ment 
1. Rate the overall quality of this 
guideline. 6.96 6.74 7 3.60 3.39 6.39 5.43 5.43 
Overall 
Guideline 
Assess-
ment 
2. I would recommend this guideline for 
use. 
Yes, with 
modifications 
Note: Excellent 
methodological 
quality. How-
ever, not up-to-
date (update to 
be published 
Dec.2019) 
Yes Yes No 
Note: 
methodology 
is not clearly 
described, 
editorial 
independence 
not described. 
No 
Note: 
methodology, 
editorial 
independence 
and 
applicability 
are not clearly 
described. 
Yes Yes, with 
modifications 
Note: the 
guideline is 
applicable in 
a special 
setting i.e. 
disaster in 
Japan 
Yes, with 
modifications 
Note: this guideline is 
not up-to-date and 
there is no 
recommendation on 
the update process 
and timeline, but it is 
already archived. The 
guideline is specifically 
on POCT in various 
disease areas. 
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Risk of bias tables: D-dimer POCT 
 
Table A12: Risk of Bias (D-dimer POCT) – study level (systematic reviews and meta analyses)  
Author, year CADTH, 
2016 [104] 
Geersing, 
2009 [31] 
Lucassen, 
2011 [34] 
Hendrisksen, 
2015 [33] 
Hendriksen, 
2015 [105] 
Schols, 
2018 [26] 
Pasha, 2009 
[32] 
Florkowski, 
2017 [4] 
Marquardt, 
2015 [35] 
1. Did the research questions and 
inclusion criteria for the review include 
the components of PICO? 
Yes Yes Yes Yes No Yes Partial yes No Partial yes 
2. Did the report of the review contain an 
explicit statement that the review methods 
were established prior to the conduct of 
the review and did the report justify any 
significant deviations from the protocol? 
No Partial yes No No No Partial yes No No No 
3. Did the review authors explain their 
selection of the study designs for 
inclusion in the review? 
Yes Yes Yes Yes Yes Yes Yes Yes Partial yes 
4. Did the review authors use a compre-
hensive literature search strategy? 
Partial yes Partial yes Partial yes Partial yes No Partial yes Partial yes No Yes 
5. Did the review authors perform study 
selection in duplicate? 
No Partial yes Yes Yes No Yes Yes No No 
6. Did the review authors perform data 
extraction in duplicate? 
No Yes Yes Yes No No No No No 
7. Did the review authors provide a list of 
excluded studies and justify the 
exclusions? 
No No No No No No No No No 
8. Did the review authors describe the 
included studies in adequate detail? 
Partial yes Partial yes Yes Yes Yes Yes Yes No Partial yes 
9. Did the review authors use a satisfactory 
technique for assessing the risk of bias 
(RoB) in individual studies that were 
included in the review? 
RCTs 
Partial yes Yes Yes Partial yes No Yes Partial yes No Partial yes 
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Author, year CADTH, 
2016 [104] 
Geersing, 
2009 [31] 
Lucassen, 
2011 [34] 
Hendrisksen, 
2015 [33] 
Hendriksen, 
2015 [105] 
Schols, 
2018 [26] 
Pasha, 2009 
[32] 
Florkowski, 
2017 [4] 
Marquardt, 
2015 [35] 
10. Did the review authors report on the 
sources of funding for the studies 
included in the review? 
No No No  No No No Yes No No 
11. If meta-analysis was performed did the 
review authors use appropriate methods 
for statistical combination of results? 
RCTs 
NA Yes Yes Yes NA NA Yes NA NA 
12. If meta-analysis was performed, did the 
review authors assess the potential 
impact of RoB in individual studies on 
the results of the meta-analysis or other 
evidence synthesis? 
NA Yes Partial yes No NA N/A No NA NA 
13. Did the review authors account for RoB 
in individual studies when interpreting/ 
discussing the results of the review? 
Partial yes Yes Partial yes No No Yes Yes No Partial yes 
14. Did the review authors provide a 
satisfactory explanation for, and 
discussion of, any heterogeneity 
observed in the results of the review? 
No Yes Yes Yes No Partial Yes Yes No No 
15. If they performed quantitative synthesis 
did the review authors carry out an 
adequate investigation of publication 
bias (small study bias) and discuss its 
likely impact on the results of the review? 
NA Yes No No NA NA Yes NA NA 
16. Did the review authors report any 
potential sources of conflict of interest, 
including any funding they received for 
conducting the review? 
No Yes Yes Yes Yes Yes Partial yes NA Partial yes 
Overall Confidence Critically 
low 
High High High Critically 
low 
Moderate Moderate Critically 
low 
Moderate 
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Table A13: Risk of bias (D-dimer POCT) – outcome level of non randomised studies comparing the use of D-dimer POCT versus usual care  
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MORTALITY/MORBIDITY, QUALITY OF LIFE, SAFETY 
Oude Elferink, 2015 [37] Not defined as outcome 
Kingma, 2017 [36] Not defined as outcome 
PATIENT MANAGEMENT 
Oude Elferink, 2015 [37] L  
 
L 
 
L L L 
 
M 
Low prevalence of DVT  
in this sample resulted in 
small number of events 
L  
 
M 
Kingma, 2017[36] L 
 
S 
Bias possible, particularly 
in the usual care group, 
selection of patients (not 
consecutive) 
L L M 
11% missing data in 
the usual care group 
L L S 
Abbreviations: L – low; M – moderate; S – severe. 
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Table A14: AGREE II quality appraisal of the guidelines on the use of D-dimer POCT 
Domain Item 
AGREE II Score 
DEGAM AWMF SIGN Fesmire Jaeschke ESC NCGC NICE DGK 
Japan 
Circ.Soc
. 
Scope and 
purpose 
 
1. The overall objective(s) of the guideline 
is (are) specifically described. 
7 7 7 7 7 7 7 7 7 7 
2. The health question(s) covered by the 
guideline is (are) specifically described. 
7 7 7 7 7 7 7 7 7 7 
3. The population (patients, public, etc.) to 
whom the guideline is meant to apply is 
specifically described. 
7 7 7 7 7 7 7 7 7 7 
Stakehold-
er involve-
ment 
4. The guideline development group 
includes individuals from all the relevant 
professional groups. 
7 7 7 7 7 7 7 7 7 7 
5. The views and preferences of the target 
population (patients, public, etc.) have 
been sought. 
6 6 7 1 1 1 7 7 1 1 
6. The target users of the guideline are 
clearly defined. 
7 7 7 7 7 7 7 7 7 7 
Rigor of 
develop-
ment 
7. Systematic methods were used to 
search for evidence. 
7 3 7 7 7 7 7 7 7 7 
8. The criteria for selecting the evidence 
are clearly described. 
7 3 7 7 7 7 7 7 7 7 
9. The strengths and limitations of the 
body of evidence are clearly described. 
7 3 7 7 7 7 7 7 7 7 
10. The methods for formulating the 
recommendations are clearly described. 
7 7 7 7 7 7 7 7 7 7 
11. The health benefits, side effects and 
risks have been considered in 
formulating the recommendations. 
7 7 7 7 7 7 7 7 7 7 
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Domain Item 
AGREE II Score 
DEGAM AWMF SIGN Fesmire Jaeschke ESC NCGC NICE DGK 
Japan 
Circ.Soc
. 
12. There is an explicit link between the 
recommendations and the supporting 
evidence. 
7 7 7 7 7 7 7 7 7 7 
13. The guideline has been externally re-
viewed by experts prior to its publication. 
7 6 7 7 3 7 7 7 7 1 
14. A procedure for updating the guideline 
is provided. 
7 6 7 7 1 7 7 7 7 3 
Clarity of 
presenta-
tion 
15. The recommendations are specific and 
unambiguous. 
7 7 7 7 7 7 7 7 7 7 
16. The different options for management of 
the condition or health issue are clearly 
presented. 
7 7 7 7 7 7 7 7 7 7 
17. Key recommendations are easily 
identifiable. 
7 7 7 7 7 7 7 7 7 7 
Applicabil-
ity 
18. The guideline describes facilitators and 
barriers to its application. 
7 7 7 6 7 7 7 7 7 7 
19. The guideline provides advice and/or 
tools on how the recommendations can 
be put into practice. 
7 7 7 6 7 7 7 7 7 7 
20. The potential resource implications of 
applying the recommendations have 
been considered. 
7 7 7 7 1 7 7 7 7 1 
21. The guideline presents monitoring and/ 
or auditing criteria. 
7 7 7 1 1 5 7 7 5 1 
Editorial 
independ-
ence 
22. The views of the funding body have not 
influenced the content of the guideline. 
7 7 7 7 1 7 7 7 7 1 
23. Competing interests of guideline 
development group members have 
been recorded and addressed. 
7 6 7 1 1 7 7 7 7 5 
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Domain Item 
AGREE II Score 
DEGAM AWMF SIGN Fesmire Jaeschke ESC NCGC NICE DGK 
Japan 
Circ.Soc
. 
Overall 
Guideline 
Assess-
ment 
1. Rate the overall quality of this guideline. 
6.96 6.3 7 6.13 5.26 6.65 7 7 6.65 5.43 
Overall 
Guideline 
Assess-
ment 
2. I would recommend this guideline for 
use. 
Yes, with 
modifica-
tions. 
Note:  
Excellent 
methodo-
logical 
quality. 
However, 
not up-to-
date 
(update 
to be 
published 
Dec.2019
) and 
can, 
therefore, 
not be 
used 
without 
caution. 
Yes  
Note: 
This is a 
consen-
sus 
based 
guideline. 
Evidence 
was not 
reviewed 
in a sys-
tematic 
way and 
there 
was no 
grading 
of the 
evidence. 
Yes, with 
modifica-
tions. 
Note: 
The 
focus of 
the 
guide-
lines is 
on pre-
vention 
and 
man-
agement 
of DVT, 
the diag-
nosis is 
only a 
small 
part of 
the 
guideline.  
Yes, with 
modifications. 
Note: The 
main focus is 
on high sen-
sitivityquanti-
tative D-
dimer tests, 
however the 
qualitative 
tests (often 
used in point-
of-care pan-
els) are men-
tionedtoo. 
Evidence 
was not as-
sessed for 
qualitative 
tests due to 
the limitations 
in terms of 
their interpre-
tation and 
lower sensi-
tivity. 
Yes, with modifi-
cations. 
Note: This is not 
a classical guide-
line but the main 
objective was to 
test the GRADE 
approach on this 
example. The 
methods are 
rigorous, but the 
Appendix where 
some further 
details could 
have been found 
is not published.  
Some additional 
information 
would be neces-
sary to know 
which D-dimer 
tests have high 
and moderate 
sensitivity. 
Yes  Yes  Yes  
Note: this 
guidance 
is based 
on the 
NCGC 
full re-
port. 
Yes  
Note: this 
is the 
German 
summary 
of and 
state-
ment on 
the ESC 
guideline  
Yes, with 
modifica-
tions. 
Note: the 
guideline 
is appli-
cable in 
a special 
setting 
i.e. dis-
aster in 
Japan 
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Table A15: Summary table of the results on the use of Tn-POCT 
Effectiveness and diagnostic accuracy of Tn-POCT: Summary of the evidence 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
CADTH, 
2016 
[25] 
SR 41 / NR Diverse 
(incl. ED 
and 
primary 
care 
settings) 
High DTA results (at admission: range of POCT vs. range of CL): 
SEN: 26%-88% vs. 68%-100%  
SPEC: 84.0%-98.0% vs. 75%-94% 
PPV: 31.0%-85.0% vs. 10%-82% 
NPV: 90%-99% vs. 95%-100% 
 
Clinical utility: 
“In Settings Where a Central Laboratory is Available  
 
[Tn-POCT] tended to shorten  
turnaround time (TAT),  
length of hospital stay, and  
time to discharge.  
 
The use of [Tn-POCT] did not statistically change  
mortality rates or severe adverse events compared with a central laboratory in most studies, in up to one year 
of follow-up.  
 
There was no difference in quality of life among patients who were tested using POC or central laboratory within up 
to three months’ follow-up. Subgroup analyses of clinical-utility studies based on study design, setting, the level of 
sensitivity of the central laboratory methods, the types of cTn (I or T), and funding status did not show any 
differences in findings. (…). 
 
“Overall, given the 
limitations with the data 
and the inconsistency in 
DTA estimates, the 
usefulness of [Tn-POCT] 
in settings with access to 
central laboratories may 
be limited.”  
“In settings with no access 
to a central laboratory, 
such as in rural health 
care centres or remote 
settings, [Tn-POCT] may 
be useful due to the 
potential to help reduce 
unnecessary transfer of 
patients to larger centres.” 
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Effectiveness and diagnostic accuracy of Tn-POCT: Summary of the evidence 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
In Settings Where No Central Laboratory is Available  
In pre-hospital or ambulance settings, limited evidence points to the potential use of [Tn-POCT] for the diagnosis 
and management of patients. [Tn-POCT] testing may  
reduce the percentage of patients referred to the emergency department from a primary health care centre.  
[Tn-POCT] was shown to be feasible and reliable for patients transported by ambulance, and can shorten the time 
from first medical contact to patient disposition (…).” 
Schols, 
2018 
[26]  
SR 2 / 545 Primary 
Care 
Moderat
e 
DTA results (range of 2 studies, results of MI / MI+unstable angina): 
SEN: 67%-83% / 21%-29% 
SPEC: 98-100% / 98-100% 
PPV: 40%-100% / 40%-100% 
NPV: 99%-99.7% / 94%-96% 
 
Clinical utility: 
Limited evidence (1 comparative cohort study) was found that Tn-POCT would reduce the referral rate, but the 
identified cohort study noted that it may be on offset of potentially missing out on patients with an acute myocardial 
infarction or unstable angina. 
No conclusion on Tn-
POCT, highlighting the 
inconclusive available 
evidence. 
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Table A16: Summary table of the results on the use of Tn-POCT in the emergency department 
The use of Tn-POCT in the emergency department: Summary of the evidence 
Evidence  Quality Results Conclusion 
Effect on patient management  
1 SR [25] High No. of hospital admission: N/A 
Treatment initiation: N/A 
RR: N/A 
DNT: N/A 
TAT (evidence base: 2 RCTs, 11 observational studies using a variety of different definitions of TAT36): 
RCTs (2 studies, cTnI or cTnT testing, 2,134 and 833 enrolled patients respectively): 
• Reduction in 2/2 studies: 43 min (median; p value not available) in one study, and 71 and 147 min in the other study37 (median; s. s., 
with p<0.001) 
Observational studies (5 prospective, 1 retrospective and 5 pre-post studies respectively, cTnI or cTnT testing, 31 to 2,386 enrolled pts) 
• Reduction in 11/11 studies: 18-93 min (p values available for 5/11 studies, with s. s. differences in these studies) 
 
TTD (evidence base: 2 RCTs, 1 observational study): 
RCTs (2 studies, cTnT or cTnI testing, 487 and 2,134 enrolled pts respectively): 
• Reduction in 2/2 studies: 5 and 7 min (mean and median respectively; s. s. with p=0.04 and p value not available respectively) 
Observational studies (1 pre-post study, multiple biomarkers 4,886 enrolled pts): 
• Reduction in 1/1 study: 26 min (p value not available) 
 
LOS: 
Emergency room stay (evidence base: 3 RCTs, 2 observational studies):  
RCTs (3 studies, cTnI or cTnT testing, 487-912 enrolled pts): 
• Reduction in 2/3 studies: 0.2 and 0.8 h (mean and median; diff. n. s. in individual studies) 
Currently, the evidence is 
insufficient indicating non-inferiority 
of using a pathway with Tn-POCT 
compared to  usual care if CL 
testing is timely available. 
                                                     
36 E.g., time from blood draw to result. 
37 When using the definitions “time from collection to physician notification” and “time from presentation to anti-ischemic therapy” respectively. 
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The use of Tn-POCT in the emergency department: Summary of the evidence 
Evidence  Quality Results Conclusion 
• Increase in 1/3 studies: 0.1 h (median; diff. n. s.) 
Observational studies (2 pre-post studies, cTnI testing, 366 and 671 enrolled pts respectively):  
• Reduction in 2/2 studies: 1.9 h (mean; p value NR) and 2-2.7 h respectively (mean; diff. s. s.) 
Hospital stay in ED (evidence base: 1 RCT) 
RCTs (1 study, cTnI testing, 2,243 enrolled pts) 
• Reduction in 1/1 study: 2.2 h (mean; diff. n. s.) 
 
Further testing: N/A 
 
TCD (evidence base: 1 RCT, 1 pre-post study): 
RCTs (1 study, cTnI testing, 2,134 enrolled pts) 
• Reduction in 1/1 study: 9 min (median; p value not available) 
Observational studies (1 pre-post study, multiple biomarker testing, 4,886 enrolled pts): 
• Reduction in 1/1 study (multiple biomarkers): 26 min (mean; p value not available) 
Effect on mortality/morbidity 
1 SR [25] 
 
High Mortality (evidence base: 2 RCTs and 3 observational studies) 
RCTs (2 studies; cTnT or cTnI testing, 487 and 2,243 enrolled pts respectively) 
POC vs. CL: 0.5 vs. 0% in one study (p value NR) and 1% vs.0.2% in another study (n. s., with p=0.142) 
Observational studies (3 prospective studies; cTnI or cTnT testing; 508-1,410 enrolled pts) 
None of the studies compared Tn-POCT with CL head-to-head (using statistical testing) 
 
Cardiac events (evidence base: 2 prospective studies, cTnI or cTnT testing) 
30 day cardiac event rate (1 prospective study, 704 enrolled pts; POCT vs. CL):  
• Low risk pts: 0% (95%CI: 0-25.9) vs. 0% (95%CI: 0-21.5), p value NR 
• High risk pts: 24.8% (95%CI: 20.1-30.1) vs. 28.6% (95%CI: 23.4-34.4), p value NR 
Cardiac events after 1 year (1 prospective study, 1,410 enrolled pts; POCT vs CL): 
• 2.1% (95%CI: 1.5-3) vs. 2.2% (95%CI: 1.6-3.1), p value NR 
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The use of Tn-POCT in the emergency department: Summary of the evidence 
Evidence  Quality Results Conclusion 
Other Adverse events (AE) and composite end points in ED (evidence base: 2 RCTs, cTnT or cTnI testing) 
Major AE after 3 m FU (1 RCT, 2,243 enrolled pts; POCT vs CL): 3% vs. 2%, diff. n. s., with p=0.313 
CEP events38 at 6 m (1 RCT, 487 enrolled pts; cTnT testing, POCT vs. CL): 10.4% vs. 5.4%, p value NR 
Effect on QoL 
1 SR [25]  QoL (evidence base: 1 RCT, cTnI testing, 2,243 enrolled pts using the EQ-5D questionnaire): 
POC vs. CL:  
• After 1 m: 0.742 vs. 0.759 (n. s., with p=0.614) 
• After 3 m: 0.752 vs. 0.759 (n. s., with p=0.638) 
  
                                                     
38 AMI, coronary revascularization, cardiac arrest, or mortality in patients with a negative first cTn test at 3 m FU 
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Table A17: Summary table of the results on the use of Tn-POCT in ambulatory (primary or community care) 
The use of Tn-POCT in primary care settings: Summary of the evidence  
Evidence 
base  
Quality Results Conclusion 
Effect on patient management 
2 SRs [25, 26] Moderate 
to High 
No. of hospital admission: N/A 
Treatment initiation: N/A 
RR (evidence base: 1 comparative cohort study identified by both SRs):  
• Reduction in 1/1 study (TnT testing, 196 enrolled pts): 32/128 pts (25%) vs. 29/68 pts (43%), p value not reported39 
DNT: N/A 
TAT: N/A 
TTD: N/A 
LOS: N/A 
Further testing: N/A 
TCD: N/A 
Currently, the evidence is insufficient 
indicating superiority of using a pathway 
with Tn-POCT compared to usual care in 
ambulatory care (primary or community 
care) if CL testing is not timely available. 
Effect on mortality/morbidity 
No evidence 
identified  
N/A - 
Effect on QoL 
No evidence 
identified 
N/A - 
  
                                                     
39 Yet, it is mentioned in the review that the authors of the primary study noted that there were some two patients that were not referred and missed cases (one AMI and one unstable angina respectively). 
It is therefore concluded that the use of Tn-POCT in pts with chest pain “may reduce emergency referrals, but probably at the cost of an increased risk to miss patients with an acute myocardial infarction 
or unstable angina”. 
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Table A18: Summary table of the results on the use of Tn-POCT in pre-hospital emergency medicine (PHEM)  
Effectiveness of implementing Tn-POCT in pre-hospital emergency medicine: Summary of the evidence 
Evidence base  Quality Results Conclusion 
Effect on patient management 
1 SR [25] High No. of hospital admission (1 RCT with 601 enrolled pts; pre-hosptial setting with no access to CL 
methods):  
• No difference between Tn-POCT and usual care (no further information provided) 
 
Treatment initiation: N/A 
RR: N/A 
DNT: N/A 
TAT (ambulance; 1 observational study; 928 pts): 83 min (median, range: 46-167) 
TTD (ambulance; evidence base: 1 RCT):  
• Reduction in 1/1 study (median time Tn-POCT vs CL): 8.8 hours (range: 6.2 h to 10.8 h) vs. 9.1 h 
(range 6.7 hours to 11.2 hours), P = 0.05. 
 
LOS: N/A 
Further testing: N/A 
TCD: N/A 
Currently, the evidence is insufficient indicating 
superiority of using a pathway with Tn-POCT compared 
to usual care in pre-hospital emergency medicine if CL 
testing is not timely available. 
Effect on mortality/morbidity 
1 SR [25] High Mortality: (ambulance; evidence base: 1 RCT, 601 enrolled pts) 
Death in the next 30 days: no difference between groups (no further information provided) 
Effect on QoL  
No evidence identified N/A N/A 
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Table A19: Summary table of the results on the use of D-dimer POCT   
Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
Schols, 
2018 [26] 
SR 2 / 892 Primary 
care 
Moderate DTA:  
SEN: stand alone D-dimer 84%; Wells ≤4 + D-dimer 94- 95%; Wells ≤2 + D-dimer 97%. 
SPEC: stand-alone D-dimer 62%; Wells ≤4 + D-dimer 38- 51%; Wells ≤2 + D-dimer 32%. 
PPV: stand alone D-dimer 24%;  Wells ≤4 + D-dimer 21- 37%; Wells ≤2 + D-dimer 20%. 
NPV: stand alone D-dimer 96%;  Wells ≤4 + D-dimer 94- 99%; Wells ≤2 + D-dimer 99%. 
Effectiveness: NR 
No studies assessed the effects of D-dimer on 
treatment initiation or referral rates. All studies 
were considered at high risk of bias. Evidence 
suggests combining D-dimer with a clinical deci-
sion rule (e.g. when GP use of a D-dimer POCT 
is combined with the Wells clinical decision rule) 
leads to more accurate diagnosis. Further  
research on clinical effectiveness is necessary. 
Geersing, 
2009 [31] 
SR & 
meta 
analy-
sis 
23 / 
13,959 
Primary or 
secondary 
care 
High DTA: 
SEN:  
0.85 (95%CI 0.78-0.90) for SimpliRED D-dimer;  
0.87 (0.81-0.91) for Clearview Simplify D-dimer; 
0.93 (0.88-0.97) for Triage D-dimer;  
0.96 (0.91-0.98) for Cardiac D-Dimer. 
SPEC:  
0.48 (95% CI 0.33-0.62) for Triage D-dimer;  
0.57 (0.52-0.62) for Cardiac D-dimer;  
0.62 (0.54-0.69) for Clearview Simplify D-dimer;  
0.74 (95%CI 0.69-0.78) for SimpliRED 
Likelihood ratio of a negative test result:  
0.07 (95%CI 0.04-0.16) for Cardiac D-dimer;  
0.18 (95%CI 0.08-0.43) for Triage D-dimer;  
0.21 (0.15-0.29) for SimpliRED D-dimer;  
0.22 (95% CI 0.15 to 0.29) for Clearview Simplify D-dimer. 
Effectiveness: NR 
The two quantitative tests (Cardiac D-dimer and 
Triage D-dimer) scored most favourably. 
In outpatients suspected of VE, D-dimer POCT 
can contribute important information and guide 
patient management, especially in low-risk 
patients (i.e. with low score on a clinical 
decision rule). 
POCT/point of care tests: D-dimer and Troponin 
Version 1.4, 26.11.2019 EUnetHTA Joint Action 3 WP4 177 
Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
Pasha, 
2010 [32] 
SR 4 / 199 Not 
specified40 
Moderate DTA: 
Incidence of VTE despite negative testing and unlikely clinical probability: 2% (95% CI: 
0.1-10.1%)? 
Effectiveness: 
In 49/199 (25%) patients with unlikely clinical probability and normal D-dimer CT scans 
could be withheld. 
Mortality/Morbidtidy: 1 person (2%) 
Overall (across POCT and lab tests) pooled 
incidence of morbidity was 0.34% (95%CI 0.036-
0.96%) and combined incidence of death 
(across POCT and lab tests) was 0.1% (95% CI 
0.0-0.5%). Combined 3-month mortality risk of 
PE (across POCT and lab tests) was 0.10% 
(95%CI 0.002-0.46%). 
1 death occurred across all studies (this was in 
the POCT study). 
Ruling our PE on basis of unlikely clinical 
probability and normal D-dimer is very safe.   
Hendriksen, 
2015 [33] 
SR 10 / 598 Primary 
care 
High Sensitivity*:  
88% (78%-94%) for simplified revised Geneva ≤2 model 
90% (81-96%) for original revised Geneva ≤5 
95% (87%-98%) for original Wells ≤4; 95% (87-98%) for modified Wells ≤2 
96% (88%-99%) for simplified Wells ≤1 
Specificity*: 48% (44%-53%) for original revised Geneva ≤5; 49% (45-53%) for the 
simplified Wells ≤1; 50% (46-55%) for the modified Wells ≤2; 51% (47-55%) for the 
original Wells ≤4; 53% (49%-57%) for simplified revised Geneva ≤2. 
PPV*: 20% (15%-24%) for original revised Geneva ≤5; 21% (17-26%) for original Wells 
≤4; 21% (17-26%) for modified Wells ≤2; 21% (17-25%) for simplified Wells ≤1; 21% (16-
26%) for simplified revised Geneva ≤2. 
NPV*: 97% (95-99%) original revised Geneva ≤5; 97% (94-99%) simplified revised 
Geneva ≤2; 99% (96-100%) original Wells ≤4; 99% (96-100%) modified Wells ≤2; 99% 
(97-100%) simplified Wells ≤1.  
*Data are ordered by values of the test accuracy rate. 
Effectiveness: 
Failure rates across all models:  
1.2% (95%CI 0.2%-3.3%) for simplified Wells ≤1 
Efficiency was comparable across all models 
but the Wells rules combined with D-dimer 
POCT gave the best performance in terms of 
lower failure rates 
                                                     
40 Only "outpatients" stated in one study in this review that used a POCT but not defined further (i.e. if primary care or ED) 
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Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
1.5% (95%CI 0.4-3.7%) for original Wells ≤4 
1.5% (95%CI 0.4-3.8%) for modified Wells ≤2 
2.7% (95%CI 1.1-5.4%) for original revised Geneva ≤5   
3.1% (95%CI 1.4%-5.9%) for simplified revised Geneva ≤2 
Efficiency across all models:  
43% (95%CI 39%-48%) for simplified Wells ≤1 
44% (95%CI 40-48%) for original revised Geneva ≤5 
45% (95%CI 41-49%) for modified Wells ≤2 
46% (95%CI 41-50%) for original Wells ≤4 
48% (95%CI 44%-52%) for simplified revised Geneva ≤2 
Lucassen, 
2011 [34] 
SR 52 / 
55,268 
Hospital 
setting 
(emergency 
department, 
outpatients 
or 
inpatients) 
High DTA: NR for D-dimer POCT 
Effectiveness: 
Failure rate (across all studies with qualitative D-dimer testing): 1.0% (95%CI 0.8-1.3%) 
combined with gestalt 0.7% (95%CI 0.4-1.2%) 
combined with Wells cutoff value ≤4: 1.7% (95%CI 1.0-2.8%) 
combined with Wells cutoff value <2: 0.9% (95%CI 0.6-1.5%) 
Efficiency (across all studies with qualitative D-dimer testing): 45% 95%CI 39-52%);  
Combined with gestalt: 52% (95%CI 40-64%) 
Combined with Wells cutoff value ≤4: 42% (95%CI 32-52%) 
Combined with Wells cutoff value <2: 40% (95%CI 33-48%) 
Combining a decision rule and gestalt can 
safely exclude PE when combined with 
sensitive D-dimer testing except when the less 
sensitive Wells rule (cutoff value ≤4) is 
combined with qualitative D-dimer POCT 
Marquardt, 
2015 [35] 
SR 7 / 3,279 ED  Moderate DTA: NR 
Effectiveness: 
No. of hospital admissions (1 before-after study, 462 pts) 
decreased by 13.8% 
TAT in ED (evidence base: 7 observational studies41, 3,279 pts): 
POC D-dimer tests can safely improve patient 
journey times 
                                                     
41 While the review reported initially on seven included studies on TAT, data are only presented for six studies. 
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Effectiveness and diagnostic accuracy of D-dimer-POCT: Summary of the evidence of SRs 
Author, 
year  
Study 
design 
Included 
studies / 
included 
pts 
Setting Quality Summary of the results Authors’ Conclusion 
Reduction in 5 studies (comparative; prospective and retrospective): 10-101.5 min (using 
different measures of central tendency; p-values and information on stat. testing not reported) 
No comparative data shown from 2 studies42  
 
 
Table A20: Summary table of the results on the use of D-dimer POCT derived from primary studies updating the overview of reviews 
Effectiveness of implementing D-dimer-POCT: identified studies updating the evidence from SRs 
Evidence  
base  
Study 
design 
Included 
pts 
Setting Risk of 
Bias 
Summary of the results Conclusion 
Effect on patient management  
2 studies 
[36, 37] 
NRCT 971 Primary 
care 
Moderate 
to severe 
TAT (1 study): <5min to 34 min  
RR (1 study): no statistically significant difference in patients referred, not 
referred between intervention and usual care group 
The evidence from updating the evidence 
found in SRs is insufficient to suggest that 
implementing D-dimer POCT is non-inferior  
in comparison to CL testing and superior in 
comparison to usual care if CL is not (timely) 
available. 
Effect on mortality/morbidity 
No studies identified - - - - - 
Effect on QoL 
No studies identified - - - - - 
 
 
                                                     
42 Non-comparative data was shown in one study (time to result: 10-38 min) and not reported at all in another study that the review described.  
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Applicability tables 
 
Table A21: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The identified evidence refers primarily to systematic reviews with limited data on patient 
characteristics. Nevertheless, no applicability concerns related to the population of interest 
are raised.  
Intervention For Tn-POCT, the algorithms when troponin is measured may vary. However, the 
systematic reviews hardly described which algorithm was used in the primary studies.  
As such, one can only speculate whether this represents a concern of applicability of the 
identified evidence. 
Secondly, there are numerous different Tn-POCT devices on the market. While one 
systematic review [26] controlled for whether there was a systematic pattern of outcomes 
dependent on specific products, there is still the chance that the diagnostic performance 
slightly changed within the past years. It may be that the Tn-POCT devices got software 
updates or changed technologically.  
For D-dimer POCT, similarly, there are also numerous devices on the market with 
differences as to whether D-dimers are measured qualitatively or quantitatively and which 
cut-off values are used. This may represent an intervention-related applicability concern 
and especially different cut-off values were noted as a factor potentially explaining 
heterogeneity found in two meta analyses [31, 34].  
Comparators For Tn-POCT, the comparators used were mostly usual care (incl. mostly CL methods as 
well). Similarly to the intervention-related applicability concerns raised, different algorithms 
that are in place may have plaid a factor. However, the systematic reviews hardly described 
which algorithm was used in the primary studies. As such, one can only speculate whether 
this represents a concern of applicability of the identified evidence.   
Besides, there were no further suspected applicability concerns in the context of the 
chosen comparators found for the reviews on Tn-POCT or D-dimer POCT.  
Outcomes For Tn-POCT, no applicability concerns were identified. Evidence was found for most  
of the outcomes of interest.  
We have considered DTA studies only if they also considered patient-important outcomes. 
In so doing, we tried to limit the applicability concern when using surrogate endpoints 
(diagnostic performance) that can be used to indirectly extrapolate on a potential effect. 
Setting There is no standard global definition of ambulatory care settings or emergency care.  
The reviews identified studies from all over the world, yet mostly in western countries. For 
both Tn-POCT and D-dimer POCT, the available evidence stems from studies conducted 
all over the world. Due to the fact that each health care system – also within the Western 
world – is structured differently, there may be significant applicability concerns when it 
comes to the evidence in the ambulatory care setting. 
Similarly, In Austria, the identified settings may not be identical to the ones to be found in 
the available evidence. For pre-hospital emergency medicine [106], for instance, voluntary 
work plays a significant role. Training for becoming a paramedic is relatively short in Austria 
when compared to international standards and, hence, one needs to reflect as to whether 
the evidence found in this setting is applicable in the Austrian context. 
In addition, one systematic review [25] especially reflected on the role of Tn-POCT in 
settings where no CL is available. Remote settings were, inter alia, listed. These settings 
may not be identical to the remote areas to be found in Austria or Romania. 
In addition, for both Tn-POCT and D-dimer POCT, the available evidence is stems from 
studies conducted all over the world. Due to the fact that each health care system – also 
within the Western world – is structured differently, there may be significant applicability 
concerns when it comes to the evidence in the ambulatory care setting.  
Abbreviations: CL – central laboratory; POCT – point of care testing. 
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APPENDIX 4: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL AND LEGAL ASPECTS 
1. Ethical  
1.1. Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new ethical issues? 
No 
1.2. Does comparing the new technology to the defined, existing comparators point to any 
differences that may be ethically relevant? 
No 
2. Organisational  
2.1. Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) require organisational changes? 
Yes 
Should the tests show benefits in terms of clinical utility or patient outcomes, it may be  
necessary to effect organisational changes to be able to realise the potential of the tests. 
2.2. Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be organisationally relevant? 
Yes 
Yes there may be organisationally relevant, contextual factors e.g. in referring practises. 
3. Social  
3.1. Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any new social issues? 
No 
3.2. Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be socially relevant? 
No 
4. Legal   
4.1. Does the introduction of the new technology and its potential use/non-use instead of the 
defined, existing comparator(s) give rise to any legal issues? 
No 
4.2. Does comparing the new technology to the defined, existing comparator(s) point to any 
differences that may be legally relevant? 
No 
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APPENDIX 5: DOCUMENTATION OF EXPERT INPUT  
Pre-defined questions: 
1. How are Tn-POCT and D-dimer POCT currently used in the Austrian context? In which set-
ting and by which type of doctors?   
2. Where would you see these two diagnostics to be placed within the clinical pathway and do 
you know of any thresholds that may apply in this context?  
3. What is your clinical experience with using these POC tests? Do you use these POCTs in 
practice? 
4. Are there settings where one of these POCTs may be used instead of a central lab test? 
(e.g., if central lab test is unavailable such as in remote areas). If so, please specify the 
specific settings and reflect on the potential utility for these two POCT in the respective set-
tings. 
5. If a central lab test is available, what clinical benefits do you think might be associated with 
using POCT in Austria?  
6. Do you know of any clinical decision rules in this area (cardiopulmonary symptoms, sus-
pected venous thromboembolism) that are routinely used in practice e.g. Wells rule?  
 
 
INTERVIEW SUMMARIES (AT) 
Interview 1 (primary care): 
1. Generally, the clinical expert highlights that he may not be able to answer the first question 
fully. Nonetheless he is willing to reflect on his thoughts how this may be in Austria: He 
highlights hereby that he does not think that these POCTs are used regularly in general 
practice. Potential reasons are hereby mentioned: The GPs might not get paid for them and 
they are more expensive than the central lab tests. In Austria, the health system is quite fo-
cused on hospital care. Patients are referred to the hospital quickly and no POCT is done. 
The problem with POCT is the lack of sensitivity. These tests are used to rule out diseases, 
not to prove that the disease is present. 
2. Please see drawing. Not aware of any thresholds.  
3. The clinical expert has no experience in using them. He used to practice in Germany, 
where the POCTs are not reimbursed. GPs apply clinical decision rules (e.g. Wells score) 
and if it is negative the physician can be quite certain that the patient does not have the 
disease.  
4. Not aware of any areas or situations when a central lab would not be available.  
5. Especially for the D-dimer POCT the expert does not see the point in using it. The main aim 
of POCT is to rule out the disease and if the physician has a strong suspect that the patient 
has the disease, the patient will be sent to the hospital, and no POCT will be done. There is 
not a high risk of treating DVT later (e.g. 3 hours) if you do not do POCT, the only risk is 
that the patient will get PE, but it is very unlikely. According to the clinical expert, Tn-POCT 
makes more sense because coronary artery syndrome is a more severe disease. Neverthe-
less, it is unlikely that a patient would have ACS and not present symptoms. In ACS, an 
ECG is done first. If the result is clear it is not necessary to do the Tn test. The clinical ex-
pert does not expect a change in the referral practice in Austria. 
6. The clinical decision rules are probably not used systematically and routinely used among 
GPs. There is the Wells score and other scores but as mentioned before, not routinely 
used.  
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Interview 2 (primary care): 
1. In General practices (randomly – not refunded everywhere: either patient or doctor pays 
testing), hospital outpatient units (emergency rooms). D-Dimer and Tn are being used, but 
no quantification possible because the costs are not refunded 
2. D-dimer is seen as exclusion test in guidelines, so it is considered most valuable in avoid-
ing further testing and/or hospital admission when negative. Helps reduce uncertainty, and 
safety-medication (LMWH till results can be obtained – which may, at week-ends, take 
days). Problem: no funding by social insurance, which in practice limits the use.  Troponin: 
not suitable for exclusion (positive after several hours, does not exclude acute coronary 
syndrome), but does help somewhat in decision making as to which pathway to choose.  
3. D-dimer: yes (s.above; (fear or symptoms of) DVT and PE rather frequent reasons for en-
counter: highly valuable in daily practice, Troponin: no – no exclusion possible, applicable 
after hours after symptom onset, so rather infrequent and good chance or expiring unused 
(no refund either). 
4. See above: D-dimer of high value for family practice and any point of first contact. Troponin 
one helpful tool in a bigger picture, for family practice and outpatient units. Lab test take 
more than few hours in any extramural setting: patient at risk of DVT/PE or CHD cannot be 
sent to labs, sending blood samples takes too much time: decisions have to be made within 
minutes. Unavailable POCT (D-dimer) means: either admission to hospital, or organisation 
of imaging: venous ultrasound also not generally refunded for outpatients, so mostly angi-
ography is performed (for: refunded): higher potential harm, no higher benefit, invasive, 
painful. 
5. S.above 
6. Wells rule, DEGAM algorithm for chest pain available and used – not widely known though. 
Suspected reasons: CME mostly provided by specialists, for whom those decision rules 
play a minor role (in-hospital, access to lab test, imaging etc. available and generally pre-
ferred), no decision aids integrated in practice software, fast and easy to access point of 
care tools not routinely used, clinical guidelines to time consuming to search and find. Cul-
ture of decision making…. 
 
Interview 3 (emergency department): 
At the beginning of the interview, the interviewee was asked what he thinks could be an adequate 
definition of POC and what could be adequate reference standards for the diagnostics under 
evaluation. 
 
Definition of POC 
The definition of POC is ambiguous, which was raised by both the interviewers and the interview-
ee. According to the expert, there is no standard definition, different experts understand it differ-
ently. “Point” in POC can be defined in terms of a time point (i.e. a fast test) or in terms of a geo-
graphical point (i.e. bedside of the patients). Many products represent a mix of these two features. 
According to the expert the location is not as important as the time factor but this is highly de-
pendent on the setting (emergency department, cardiologist office, etc.) and on the type of dis-
ease.  
So depending on the definition used and the individual perception, some tests may be classified 
as POC or no POC. The interviewee highlights that this non-standardised definition of POC may 
also be reflected in the context of marketing: a wider definition may increase the market of some 
of the available products.  
Other problems with POCT are that they are often semi-quantitative and present challenges in 
proper documentation, it they are not connected to electronic chart systems. Prints on thermal 
paper turn illegible if they get in contact with disinfectants.  
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Reference standard 
The reference standard was also discussed. In case of the troponin (Tn) POCT it is quite difficult 
to define the reference standard. Acute coronary syndrome (ACS) is a makeshift-diagnosis, coro-
nary artery occlusion is diagnosed by angiography, and the diagnosis of myocardial infarction or 
other forms of myocardial injury is even more complex.. Generally, the expert sees the POC test 
more important for the acute risk stratification than in a definitive diagnosis. Given an appropriate 
time-frame, a negative Tn is a good prognostic sign. If positive, subsequent diagnostic workup is 
mandatory. Overall, Tn level is only a part of the diagnostic means.  
For D-dimer most frequent diagnosis is pulmonary embolism (PE). PE is diagnosed by CT-scan. 
Other diagnoses include vascular complications such as aortic dissection, which is likewise diag-
nosed by CT-scan. However, D-dimer is elevated in several other conditions with a great variety 
of reference standards. Furthermore D-dimer may be increased during gravidity.  
 
Current use of the tests in Austria 
Tn test is important in the diagnosis of ACS. For example in emergency departments  Tn test is 
useful because a negative test result can facilitate an early rule-out diagnosis. Tn test is also use-
ful for specialist clinics and office-based cardiologists, they can also interpret test results in con-
text. However, in the inpatient setting POC Tn test should not be done routinely. Tn test must not 
be interpreted without at least clinical history, presentation and ECG readings. GPs well-trained in 
ECG-interpretation who perform acute medicine or emergency medicine or so-called “Gemeinde- 
and Sprengelärzte” may have access to Troponin if they are far away from hospitals or centres, 
because early risk stratification can inform decisions e.g. on admission to a hospital. 
D-dimer test has a very low specificity. In the diagnosis of PE the pre-test probability is more im-
portant than a POC D-dimer test result itself. Only if the d-dimer test is combined with the pre-test 
probability (for instance via the Wells score) a proper interpretation of the result is possible. How-
ever, teaching experience shows that it is unlikely to be the case in Austria that pre-test probability 
is routinely assessed. Also referrals to emergency department, according to the interviewee’s 
experience, rarely indicate results of a pre-test probability calculation. One consequences of false-
ly using and interpreting D-dimer tests are unnecessary CTs. Moreover, PE is a continuum rang-
ing from small or life threatening; probably each person has at least a minor PE in their lives. So if 
we really look closely, we will increase the detection rate of clinically non-significant PE. An im-
portant consequence of a PE diagnosis is therapeutic anticoagulation at least for several months 
with a particular risk/benefit ratio. However, D-dimer is a very unspecific marker, which may also 
be positive due to inflammation. Even uncomplicated infections often show positive test results  
Therefore, POC D-dimer test should have a limited availability and should be used only in select-
ed departments in hospitals, in the EDs and by selected community-based specialists. The expert 
did not know how frequently the D-dimer test is used currently in office-based practices in Austria. 
There is potentially an alternative role for d-dimer as a biomarker screening tool as it can rule out 
many things. There are different cut-off points depending on the product (technical) and popula-
tion (e.g. pregnant, older persons), which makes interpretation difficult. 
 
Place of the tests in the diagnostic pathway 
Tn test: ACS is the most frequent condition for the use of a Tn test. In case of ACS the time is 
crucial. When patients present with respective acute symptoms, ECG needs to be performed im-
mediately. In case of ST-elevation the therapy does depend on clinical signs and ECG, but not on 
Tn. There is no established role for a POC Tn test here. In case of non-ST elevation acute coro-
nary syndrome (NSTE-ACS) Tn is a very important diagnosic tool, and will influence therapy and 
management. This is an area of application for POC Tn.  
A proper interpretation the test result requires reflections about misdiagnosis and consequences 
of subsequent diagnostic and therapeutic interventions. 
In Austria the ESC guideline is in use, which describes 2 algorithms, depending on the setting.  
D-dimer test: Usual usage for D-dimer POCT is diagnosis of PE. PE diagnosis is less time critical 
than ACS workup, because usually a delay in diagnosis and treatment of several hours has no 
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relevant impact on the outcome.. D-dimer tests should be interpreted together with a pre-test 
probability. In case of increased post-test probability PE is diagnosed or ruled out by CT-scan. PE 
may be treated in the in-patient or outpatient setting, anticoagulation is usually prescribed for sev-
eral months. Other diagnoses may be found in the CT-scan, whether relevant or not, which may 
result in further diagnostic and/ therapeutic actions. In case of low post-test probabilities (D-dimer 
and clinical factors) alternative diagnoses or no further workup is performed, usually without per-
forming a CT-scan. 
Several guidelines, including a 2019 ESC guideline are available and used. 
 
Setting 
Settings for these POCT may include hospital units, such as wards, perioperative units, intensive 
care units, and emergency departments, outpatient departments, specialist offices, GP offices and 
mobile units, such as ambulance vehicles. These settings itself are heterogeneous, centralised 
and and decentralised, some very remote. Even some hospital settings do not have a central lab 
available 24/7.  
 
Clinical decision rules 
Clinical decision rules should be used but in practice their application varies greatly  
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INTERVIEW SUMMARIES (RO) 
Interview 1 (cardiologist) 
1. Are used by doctors from emergency services and cardiologists. Context: emergency 
2. These are diagnostic tests for severe myocardial ischemia and venous thromboembolism 
(including deep venous thrombosis and pulmonary embolism). The limits are related to the 
fact that there are no protocols in hospitals (maybe there are, but not respected?) for their 
interpretation in connection with clinical situations. Other limits - repeating in dynamics can 
be a problem (kits use), physicians are quick to "resolve" the problem of diagnosis more 
quickly and send the patient further. Dynamics require patient tracking time. Other limits for 
Tn: overdose of revascularization in urgency; other causes of increased Tn are not known 
(by doctors). 
3. Yes. Both.  
4. There may be screening methods in family doctors' offices and in Permanent Centers to 
help address emergencies (eg coronary arteries pathology , many do not have ECG) and to 
decide which patients are sent to the UPU and refer to elective referrals.  
5. If the correct instruction is done by those who use them, and if they are being taught what is 
the normal dynamics of these tests (for example troponin is high and many days after the 
onset of an MI) and if doctors know that there are false positives too. Not once we were 
fooled by ambulance staff on the basis of elevated troponin, addmiting patients for the 
STEMI program (that is revascularization in the first 12 hours after with ST elevation infarc-
tion). Patients who sure did not enter in surgery because they were already 2-3 days after 
their debut but occupied beds in the UTIC and when the STEMI patient actually appeared, 
it was a problem finding a place for him. 
6. Of course. But their use is relative.  
 
Interview 2 (emergency department) 
1. From my knowledge, fast tests for troponin and D dimers are available in all emergency 
units, and in county and university hospital laboratories. They are used by emergency 
doctors or other specialists who do triage in emergency rooms. 
2. These tests are useful in the rapid diagnosis of acute coronary syndrome, especially in the 
absence of electrocardiographic changes (for troponin), and for confirmation of pulmonary 
thromboembolism, dimers. There are also false positive results, especially for. D dimers, 
which have elevated values in sepsis, in neoplasia, but values increased in the clinical 
context, help a lot in supporting the diagnosis. 
3. Working in an emergency receiving unit in a university hospital, I use both tests for about 
10 years, daily. They are very useful, and for refuting the diagnosis, especially as about 
30% of patients coming up accuse chest pain. 
4. I consider it useful that these tests can be available in small hospitals, which have only an 
emergency receiving compartment, as well as in permanent centers, an early and accurate 
diagnosis of acute coronary syndrome, which causes a high mortality rate in Romania 
5. Consider the widespread use, even in ambulatory cardiology offices, for a more accurate 
diagnosis of acute coronary artery disease, and especially for not to unnecessarily crowd 
county and university hospitals with patients coming from the territory without need. 
Repeating after 6 hours of EKG and troponin at a city hospital, without surprising changes, 
would be useful in order to avoid unnecessary transfer of patients 
6. In the diagnostic guidelines of acute coronary artery disease and pulmonary thromboembo-
lism, paraclinical explorations include the dosing of troponin, CK mb, and D dimers respec-
tively. The Institute of Cardiovascular Diseases in Iasi even condition the transfer of patients 
without EKG changes by the presence of elevated troponin and CK mb values. Widespread 
use as diagnostic tools would be extremely useful, even with the limits of false positives. It's 
a useful way of diagnosing in emergency hospital rooms that do not have cardiologists or 
internists. For example. at Hirlau Town Hospital in Iasi County, triage in emergency room are 
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also provided by pediatricians, doctors of infectious diseases, pneumologists who have less 
clinical experience, in these cases they prove the usefulness of these laboratory parameters. 
 
Interview 3 (family doctor) 
1. In primary medicine, no such tests are used. They are mainly used in EDs and laboratories 
(public or hospital). 
2. These tests may fall into the positive or differential diagnosis stage (suspicion of myocardial 
infarction or thromboembolism), but also in the monitoring of at-risk patients stage  
(eg, D-dimer thrombophlebitis). 
3. I did not use it. 
4. Permanent rural centers, Ambulance substations, all ED services related to hospital units; 
Being rapid tests, they direct the diagnosis in emergency cases (myocardial infarction, 
pulmonary embolism, etc.) and consequently the necessary measures can be taken quickly. 
5. Acute cardiopulmonary symptoms are an emergency that needs to be investigated as 
quickly as possible. Ideal would be to organize and operate specialized centers on such 
symptoms (hypotension - collapse / shock, acute chest pain, arrhythmias, etc.), 
autonomous of what is happening now in ED (all urgency or all patients are seen in that 
emergency service); to these specialized centers to be directed all acute cases where there 
is suspicion of major cardiovascular event. 
6. I do not know protocols applied in practice for such clinical situations. But there are 
international guidelines on ischemic heart disease or pulmonary thromboembolism, reliable 
sources for guidance in practice. 
 
Interview 4 (family doctor) 
1. They are used both in the hospital and outpatient by cardiologists, internists and family 
doctors. 
2. D-dimer has negative predictive value for pulmonary embolism and deep vein thrombosis. 
So if it's normal, the patient does not have these diseases and you can send him home 
quietly. Troponins can confirm a myocardial infarction in case of acute coronary syndrome 
without ECG changes (Non-STEMI). 
3. I use in my ambulatory practice D-dimer in case of clinical suspicion of pulmonary 
embolism or deep vein thrombosis because I get the result in less than 2 hours. In the case 
of troponins the response comes after several hours and I do not risk to wait in case of an 
acute coronary syndrome. 
4. For isolated rural areas and Medical Permanent Centers, both tests if done quickly can 
save lives or save unnecessary travel. 
5. The benefits would be that it is specified if the patient does not have embolism, thrombosis, 
or stroke, and will not waste any more resources. If the diagnosis is confirmed, the patient 
would be guided to the appropriate medical service. Clearly, the approach of doctors who 
will have these tests available will be changed. 
6. The Romanian Cardiology Society has developed guidelines based on those of the 
European Society of Cardiology. 
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APPENDIX 6: MISCELLANEOUS 
Table A22: Documentation of queries to study authors in the assessment report 
Study Content of query Reply received  
yes / no   
Content of reply 
CADTH, 
2016 [25] 
“In table 26 (p. 128): It appears that 
there are sensitivity and specificity 
data inserted in the table dealing with 
mortality and MAE outcomes (see 
Venge). Is this a mistake?” 
Yes “You are correct – that is an error 
in Table 26. The data that should 
be included from The Venge article 
is from Table 3 of the original 
article, but the data from Table 2 
has been used in error.” 
CADTH, 
2016 [25] 
Evidence of settings where central 
lab test is not available (ref. 48, 52, 
53, 54, 55, 61, 62): We did not see 
the data in any evidence tables. Is 
there a supplement document 
available in which these data are 
presented? If so, it would be greatly 
appreciated if you could send it to us. 
Yes “For the settings where central lab 
is not available, as there was 
limited data and it’s been reported 
in text, there are no tables for this 
information.” 
 
For the purpose of transparency, a separate document with comments on the 2nd draft assess-
ment from external experts and the manufacturer(s) (fact check), as well as responses from the 
author, is available on the EUnetHTA website. 
  
 
 
